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ABSTRACT 
Therapeutic strategies for the symptomatic treatment of Alzheimer patients have 
mostly been targeted at improving the central cholinergic deficit, which is correlated 
to the degree of cognitive impairment. One such strategy which increases the 
availability of acetylcholine (ACh) has been the use of cholinesterase (ChE)- 
inhibitors, among which tacrine, has been claimed to cause substantial improvement 
in cognitive function. The present study investigated the effects of tacrine and the 
more classical ChE-inhibitors eserine, neostigmine and edrophonium in vitro. The 
KI-evoked release of [3H]ACh was measured from rat hippocampal prisms 
preloaded with [3H]choline. 
Contrary to several previous reports, each of these classical ChE-inhibitors 
potentiated K+-evoked release at 10-200piM concentrations. Tacrine caused 
comparable potentiation although concentrations exceeding 100gM gave marked 
inhibition of [3H]ACh release. Potentiation of release was observed even in the 
presence of the choline uptake-inhibitor hemicholinium-3 (HC-3), suggesting that the 
observed effects were due in part, to a mechanism additional to that of inhibition of 
cholinesterases. 
Since tacrine and the other ChE-inhibitors have been reported to have PCP-like 
activity, the benzomorphan a ligands (+)cyclazocine or (±)pentazocine were tested 
and found to oppose potentiation without affecting control K+-evoked release. 
However, negligible displacement of [3H](+)pentazocine binding from hippocampal 
membranes by the ChE-inhibitors, indicated that the potentiation is unlikely to involve 
benzomorphan-like a binding. The non benzomorphan cy ligands haloperidol and 
DTG inhibited control K+-evoked release as markedly as did tacrine, suggesting a 
role for cy binding in the inhibition of [3H]ACh release. 
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The possibilty that potentiation of [3HIACh release might involve muscarinic or 
nicotinic receptor-mediated feedback was investigated since the ChE-inhibitors, and 
cyclazocine, pentazocine and (+)NANM are also known to displace nicotinic and 
muscarinic receptor binding. The muscarinic antagonist atropine enhanced the 
potentiation caused by the ChE-inhibitors, supporting the existence of a muscarinic 
receptor mediating negative feedback. However, the nicotinic antagonist dihydro-p- 
erythroidine (DHPE) had no effect, although acting alone, it potentiated KI-evoked 
[3H]ACh release. This latter effect was similar to that of the ChE-inhibitors and was 
similarly blocked by (+)cyclazocine and (±)pentazocine. It is suggested that the ChE- 
inhibitors and DHPE block negative feedback mediated by nicotinic autoreceptors 
and unmask the cy inhibitory action of (+)cyclazocine and (±)pentazocine. However 
(+)NANM which was found to be a muscarinic autoreceptor antagonist, additionally 
required atropine to unmask its a inhibitory effect. The micromolar concentrations of 





* HC-3 increases the S2/S1 ratio of K+-evoked [3H]ACh release from rat 
hippocampal prisms by a mechanism best explained by block of choline uptake 
rather than by antagonism at muscarinic receptors. 
Tacrine and the classical ChE-inhibitors eserine, neostigmine and edrophonium 
caused a further increase in the S2/Sl ratio over and above the increase caused 
by HC-3. This implies that a mechanism exists for the potentiation of the release 
of [3H]ACh in addition to ChE inhibition. 
e Tacrine differs from the classical ChE-inhibitors however, in causing inhibition of 
[3H]ACh release at concentrations greater than 50ýLM. This cannot be the result 
of negative feedback mediated by the action of ACh at muscarinic autoreceptors. 
Neither can it be due to the influence of monoamines or 5-HT (which are also 
released by tacrine), since prior reserpinization of the slices did not change the 
dual effects of tacrine. 
* Tacrine (as well as the other ChE-inhibitors) in the concentration range affecting 
[3H]ACh release, caused appreciable displacement of [3H]QNB from 
hippocampal membrane preparations. Direct actions therefore, at muscarinic 
autoreceptors cannot be excluded at this stage. 
9 The above findings clarify the contradictory literature on the effects of tacrine and 
the classical ChE-inhibitors. 
Chapter 4 
e Since tacrine is also known to interact with PCP binding sites, the effects of the 
non-competitive NMDA antagonists PCP and MK-801 were tested. MK-801 had 
no effect on K+-evoked release or on the neostigmine-induced potentiation of 
[3H]ACh release. PCP however, (which is also known to bind a binding sites) 
caused an increase in [3H]ACh release at 100ýM concentrations. 
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* The effects were investigated of cy ligands on KI-evoked release and on the ChE- 
inhibitor-induced potentiation of [3H]ACh release. The benzomorphan cri 
selective ligands (+)cyclazocine and (±)pentazocine opposed the ChE-inhibitor- 
induced potentiation of [3H]ACh release at concentrations which alone had no 
effect on control KI-evoked release. 
e However the potentiation of release caused by neostigmine was not inhibited by 
the "prototypic" a ligand (+)NANM at concentrations comparable to that of 
(+)cyclazocine. 
* The ChE-inhibitors eserine, neostigmine and edrophonium caused only weak 
di"cement of the cyl radioligand [3H](+)pentazocine from hippocampal 
membrane preparations. This suggests that the potentiation of [3H]ACh release 
by the ChE-inhibitors is unlikely to be due to an interaction al binding sites. 
-m The non benzomorphan cy ligands haloperidol, (+)3-PPP and DTG, which act at al 
and u2 sites were also investigated. Haloperidol and DTG were shown to inhibit 
control K+-evoked [3H]ACh release in a concentration-dependent manner and 
haloperidol was also observed to cause a functional antagonism of the 
potentiation caused by the ChE-inhibitors. 
* It was provisionally considered therefore, that the inhibition of [3H]ACh release 
caused by DTG, haloperidol, and also by tacrine, might be mediated by (Y2 
binding sites. However it was noted that micromolar concentrations were 
necessary in contrast to the nanomolar IC50 and KID values previously reported 
from radioligand binding studies. 
0 The a binding properties of tacrine and the effects described above of 
benzomorphan and non benzomorphan cy ligands on [3H]ACh release and its 
potentiation, have not been reported previously. 
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* The possibilty was examined that nicotinic or muscarinic actions of the 
benzornorphan a ligands (+)cyclazocine, (±)pentazocine and (+)NANM and the 
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ChE-inhibitors are responsible for the different effects of these drugs on K1- 
evoked [3H]ACh release. 
" In agreement with previous reports of muscarinic autoreceptors, atropine enhanced 
the potentiation of release caused by tacrine and the other ChE-inhibitors. It was 
argued that the ChE-inhibitors had minimal antagonist properties, if any, at the 
muscarinic autoreceptors and that [3H]QNB displacement (Chapter 3) was not 
necessarily a reliable indicator of muscarinic autoreceptor binding. 
" It was concluded that tacrine, acts as a muscarinic autoreceptor agonist, with 
maximum inhibitory effect at 30ýM concentrations. However, an independent 
mechanism over-rides this with potentiation at this concentration (see below). At 
greater concentrations cy-mediated inhibition predominates (Chapter 4). 
" The above interpretation of the effects of tacrine have not previously been 
suggested. 
" The inhibition of KI-evoked [3H]ACh release by the muscarinic agonists 
oxotremorine or carbachol was antagonized by atropine and also by (+)NANM. 
These results support the role of muscarinic autoreceptors in the mediation of 
negative feedback and validate the superfusion release system used in this 
study. 
" Although (+)NANM alone had no effect on the potentiation caused by neostigmine 
(Chapter 4), in the presence of atropine, the potentiation was opposed. It 
appears that atropine unmasks an inhibitory effect of (+)NANM, comparable to 
the overt effect of (+)cyclazocine and (±)pentazocine. 
" The nicotinic agonists nicotine and DMPP had no effect on KI-evoked [31-11ACh 
release at 0.1-10pM concentrations. 
*Although the competitive nicotinic antagonists DHPE and d-tubocurarine increased 
control KI-evoked release of [3H]ACh, DHPE had no effect over and above the 
ChE-inhibitor induced potentiation. 
It was suggested that DHPE and the ChE-inhibitors have a common mechanism of 
action. This was further supported by the observation that (+)cyclazocine or 
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(±)pentazocine but not (+)NANM, opposed the potentiation caused by DHPE, as 
well as the potentiation caused by the ChE-inhibitors (Chapter 4). 
* It was proposed that nicotinic autoreceptors mediate negative feedback, by 
inactivating voltage operated Ca2+ channels at control K+-evoked levels of ACh 
release. The ChE-inhibitors and DHPE block these autoreceptors, reactivate the 
Ca2+ channels and potentiate control [3H]ACh release as observed. 
* On this basis nicotine or DMPP might be expected to contribute to Ca2+ channel 
inactivation and to be "self-limiting" in their effects on K+-evoked ACh release. 
* The effect described above, of nicotinic autoreceptor blockade, on control K+- 
evoked [3H]ACh release have not been described previously. 
Chapter 6 
-m The a ligands (+)cyclazocine, (±)pentazocine and (+)NANM are also known to have 
antagonist actions at nicotinic receptors. Thus their lack of effect on control K+- 
evoked release (Chapter 4), which contrasts with the marked effect of DHPE 
(Chapter 5), may be explained as the net result of potentiation mediated by the 
nicotinic autoreceptors and inhibition by the a binding sites. 
-D In the presence of the ChE-inhibitors or DHPE the inhibitory effect of (+)cyclazocine 
or (±)pentazocine acting at the cy binding sites is unmasked. Since (+)NANM also 
blocks muscarinic autoreceptors however (Chapter 4), it additionally requires the 
presence of atropine to reveal its (T activity (Chapter 5). 
9 It is suggested that the inhibition caused by the benzomorphans (+)cyclazocine, 
(±)pentazocine and (+)NANM is similar to the functional antagonism observed 
with haloperidol and is mediated by an action at the a binding sites. 
* Inhibition of [3H]ACh release was caused by micromolar concentrations of the a 
ligands (Chapter 4), in contrast to their reported nanomolar IC50 and KID values. 
It is speculated that the 'low affinity' (Y binding sites are involved and noted that 
these have been implicated in the modulation of KI channels. Further work on 
this would be useful. 
7 
It has not previously been recognized that (Y binding opposes control and 
potentiated K+-evoked [3H]ACh release. 
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"The first to present his case seems right, 
till another comes forward and questions him. " 
Proverbs 18 vs 17 
"Whatever exists has already been named, 
and what man is has been known: 
no man can contend with One Who is stronger than he. " 
Ecclesiastes 6 vs 10 
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Alzheimer's disease 'a neuroclegenerative disorder' is one of the most devastating 
diseases of the human brain that affects many lives all over the world. It is the 
commonest cause of dementia amongst the elderly and the fourth major cause of 
death in the developed world, after heart disease, cancer and stroke (Van Dujin et the 
al., 1991). Although first described in 1907 byýpsychiatrist Alois Alzheimer as an 
exclusively presenile disorder, the senile form of the condition, which has been 
shown to be pathologically similar in the majority of the cases to the young demented 
patients, is now generally accepted as senile dementia of the Alzheimer type 
(SDAT). There are a number of different types of dementia of which dementia of the 
Alzheimer's type is the most common, accounting for over 50% of the cases 
(Bondareff, 1994). 
Clinical symptoms and diagnosis of Alzheimer's disease 
Since there is no effective treatment at present to prevent or ameliorate the 
progression of Alzheimer's disease, brain biopsy is not considered justified as a 
means of diagnosis. Currently differential diagnosis of Alzheimer's disease by 
clinicians is carried out by exclusion of other known forms of dementia namely multi 
infarct dementia (MID). Moreover, there are a number of other conditions (e. g 
depressive illness, acute confusional states) from which dementia needs to be 
differentiated (Huppert & Tym, 1986). The diagnosis of dementia and a judgement 
regarding the type of dementia is based largely on clinical findings supported by 
appropriate radiological and laboratory investigations (Mc Geer, 1986). Recently 
however, preliminary studies for a non invasive diagnostic test have been reported in 
the USA. It was observed that patients diagnosed with probable Alzheimer's disease 
or potentially at risk of developing it, exhibited a marked hypersensitivity to the pupil 
dilatory effects of the cholinergic antagonist tropicamide. This test awaits 
confirmation in larger trials (Scinto et al., 1994). 
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Clinically, Alzheimer's disease is characterized by an insiduous onset which is 
gradually progressive. In the first stage, impairment of memory (short term memory) 
for recent events is usually the prominent feature. Disorientation especially in time 
and place frequently occurs (wandering). Fleeting and variable spells of impaired 
concentration, restlessness, anxiety and depression occur alongside other features 
of dementia. In the second stage all aspects of memory fail progressively, blunting of 
emotions and apathy begin to take over the mood and state. At this stage Parkinson- 
like symptoms have also been observed, psychotic syndrome with hallucinations and 
delusions may also be seen towards the latter end of this stage. In the third and final 
stage there is gross disturbance of all intellectual functions. There are marked 
neurological deficits and an increase in muscle tone appears with accompanying 
slow wide-based and unsteady gait. There is gross emotional disinhibition and the 
former personality becomes submerged - patients do not recognize relatives or even 
their own face in the mirror. Double incontinence is almost invariable at this stage. 
Progressive wasting is also seen to occur despite a voracious appetite (Huppert & 
Tym, 1986). 
Neuropathology of Alzheimer"s disease 
Macroscopically, the classical feature associated with Alzheimer's disease is brain 
atrophy. In the cerebral cortex, the frontal and temporal lobes are strikingly affected 
with concomitant ventricular enlargement. These features are distinctive, but not 
necessarily diagnostic and in presenile cases brain atrophy may not even be 
pronounced (Perry, 1986). Post mortern studies have also shown that early 
hippocampal atrophy, is related to the Alzheimer's disease process and that it could 
be of potential predictive value (De Leon et al., 1993). 
The neuropathology of the disease at the microscopic level is complex. Post mortem 
Alzheimer histology is characterized by senile amyloid plaques, neurofibrillary 
tangles and neuronal loss. Neither plaques nor neurofibrillary tangles are unique to 
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Alzheimer's disease and are present to varying degrees in normal ageing (Perry, 
1986) and other neurological diseases (e. g post encephalitic Parkinson ism) (Rowan, 
1993). There has been much debate about the relative importance of these different 
pathological features and how they relate to each other. It has been shown by Braak 
et al., (1993), that the distribution pattern of the amyloid deposits does not correlate 
to that of the neurofibrillary changes and that amyloid deposits are not necessarily a 
pre requisite for the development of neurofibrillary changes. 
In both normal ageing and Alzheimer's disease, plaques are complex extracellular 
depositions which accumulate in the cerebral cortex as round or ovoid structuyes 
many times the size of individual neurons. There are three main components in a 
typical Alzheimer plaque - degenerating neurites (abnormally enlarged distal axons, 
dendrites and nerve terminals), glial processes and reactive astrocytes and a central 
amyloid core. The relative abundance of these differing components has been used 
to subclassify plaques and relate their features to plaque development and evolution. 
The more mature or classical senile plaque is distinguished by a central core 
composed of amyloid material surrounded by a peripheral rim of dystrophic neurites 
and reactive astrocytic cells (Perry, 1986). These dystrophic neurites surrounding the 
amyloid core of a mature senile plaque also contain paired helical filaments (PHF) - 
the main structural constituent of the neurofibrillary tangles (Hardy & Allsop, 1991). 
Microglia are also observed in the centre of the plaque (Rowan, 1993). Senile 
plaques are found to occur primarily in the neocortex and also in subcortical areas 
such as the hippocampus. It is believed that some factor or a lack of protection must 
make the cells in these areas more sensitive to the formation of senile plaques 
(Rowan, 1993). Heparin sulphate, other proteoglycans, inorganic compounds and 
other proteins such as al antichymotrypsin (an inflammation associated anti 
protease), apolipoprotein, acety1cholinesterase (AChE), complement, ubiquitin, and 
tyrosine hydroxylase have all been found closely associated with senile plaques 
(Mesulam & Geula, 1991; Rowan, 1993; Selkoe, 1991; Wilmot et al., 1995). 
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Diffuse deposits of amyloid are also detectable in many brain regions of clinically 
unaffected individuals and it has been suggested that these deposits are precursors 
of the senile plaques (Rowan, 1993). Most diffuse plaques show no association with 
abnormal neurites or reactive glial cells and few or no amyloid fibrils. These are often 
the only form of amyloid plaque found in cases of Down syndrome below the age of 
35 and are also found abundantly in the brains of ex boxers with dementia pugilistica 
(Hardy & Allsop, 1991; Roberts et al., 1990). In Alzheimer's disease diffuse plaques 
are usually more numerous and widespread throughout the CNS than senile plaques 
(e. g often in the spinal chord and cerebellum) appearing as though they evolve into 
neuritic plaques in only specific brain regions (Hardy & Allsop, 1991). 
A variety of neurotransmitters and neuropeptides have been shown to be present in 
plaque neurites. There is immunohistochemical evidence indicating that plaque 
neurites are derived from a variety of neuron types. Thus, of the classical 
neurotransmitter systems investigated, fluorescent studies have demonstrated 
catecholaminergic varicosities in plaques and both AChE histochemical reactivity 
and ChAT immunocytochemistry implicating cholinergic processes in aged human 
and monkey brain (Perry, 1986). 
The neurofibrillary tangles first described by Alois Alzheimer are characterized by an 
abnormal filamentous accumulation of paired helical filaments in the cytoplasm of 
dying neurons. It is one of the major histological hallmarks of Alzheimer's disease 
and is essential for the pathological diagnosis of the disease. In contrast to plaque 
formation, tangles are not found to any significant extent in the neocortex of 
nonclemented elderly brains, although in Alzheimer's disease tangles form to the 
greatest extent in the neocortex (Perry, 1986). Tangles are abundant in the 
pyramidal cells of the hippocampal formation and in the medial temporal cortex. 
They are also found in the association cortex and in certain subcortical nuclei in 
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particular the magnocellular nucleus of Meynert (cholinergic), the locus coeruleus 
(noradrenergic) and the raphe nucleus of the brain stem (serotonergic) (Price, 1986). 
Abnormalities in the cholinergic neurotransmitter sYStem in Alzheimer's 
disease 
Neurons of the basal forebrain cholinergic system (i. e the medial septum, diagonal 
band of Broca and nucleus basalis of Meynert (nbM)), provide the major cholinergic 
innervation of the amygdala, hippocampus and neocortex (Price et al., 1993). In 
Alzheimer's disease many nbM nerve cells have been found to develop 
neurofibrillary tangles and some neurons are reduced in size. Attempts have been 
made to link the deposition of P amyloid in Alzheimer's disease, with cholinergic 
involvement although the question of whether basal forebrain lesions induce plaques 
remains controversial. It has however been reported that increased synthesis of the 
P amyloid precursor protein occurs after nucleus basalis lesions and that the plaques 
found, are jointly reactive for the P amyloid peptide and acetylch ol i neste rase 
(Wallace et aL, 1991; Ulrich et al., 1990). 
There is a large body of evidence that abnormalities of the basal forebrain are 
related to memory loss and other symptoms of dementia (Perry et al., 1988). Among 
the most characteristic changes in Alzheimer's disease is the early loss of basal 
forebrain cholinergic neurons in the nucleus basalis of Meynert - up to 90% in some 
cases (Giacobini, 1990). A loss of ACh content and the enzyme responsible for ACh 
synthesis - choline acetyltransfe rase (ChAT) has also been reported. Release of 
[3H]ACh as measured in frontal cortex slices from human autopsy after short post 
mortern delay and also from biopsies have demonstrated a significant reduction (50- 
70%) in the evoked release of [3H]ACh (Giacobini, 1990). Reports on the loss of 
ChAT from the brain cortex of Alzheimer patients resulting from the degeneration of 
basal forebrain cholinergic neurons have been amply confirmed and reductions of up 
to 90% are known to occur in the same areas known to contain high levels of 
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amyloid protein. Reductions in ChAT activity have also been shown to correlate well 
with the severity of cognitive deficits and density of plaques (Perry et al., 1978). On 
the other hand it appears that normal ageing is not associated with such dramatic 
changes of ACh content and ChAT activity in the brain cortex or changes in the 
number of cholinergic neurons in the basal forebrain (Decker et aL, 1987; Henke & 
Lang, 1983). The derangement of cholinergic function seen in other forms of 
dementia rules out a primary involvement of ACh in Alzheimer's disease (Perry, 
1994). 
The great majority of cortical cholinesterase activity in the brain is expressed in the 
form of axonal and perikaryal AChE. However in Alzheimer's disease it has been 
found that AChE within normal cells and axons of the cerebral cortex is relatively low 
whereas intense AChE activity appears in the neuritic plaques, and neurofibrillary 
tangles. Electron microscopic histochemistry shows that this cholinesterase activity is 
ass ociated with amyloid deposits, abnormal neurites and paired helical filaments. 
Moreover in some areas of the Alzheimer brain, plaques and tangles appear to 
contain virtually all of the cortical AChE. Thus the cholinesterase positivity of cortical 
plaques and tangles is not an occasional event, but a widespread phenomenon and 
can therefore be considered to be one of the markers present in all the 
neuropathological structures associated with Alzheimer's disease (Mesulam & 
Geula, 1991). 
Although the total number of muscarinic ACh receptors is not substantially changed 
in the brain cortex of patients with Alzheimer's disease, the number of M2 receptors 
has been shown to be diminished (Mash et al., 1985). However, the largely 
postsynaptic M1 receptors appear to be increased and an increased level of M1 
mRNA has also been isolated from the temporal cortex of patients suffering with 
Alzheimer's disease (Warpman et al., 1993). 
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Numerous studies have also shown that the number of nicotinic ACh receptors is 
clearly decreased (30-50%) in post mortern Alzheimer brain tissue as well as in other 
forms of dementia as measured by the binding of radiolabelled ACh, nicotine and 
methylcarbamylcholine (Perry, 1994). It is thought that the M2 muscarinic and 
nicotinic ACh receptors that have been lost are those located presynaptically on the 
nerve terminals of basal forebrain cholinergic neurons. Furthermore, the loss of 
nicotinic receptors has been correlated to presynaptic changes including ChAT 
activity and loss of cells in the nbM which projects to the cortex (Giacobini, 1990). 
Despite the preserved number of muscarinic receptors, a possible explanation for 
the poor effects seen with muscarinic agonists is thought to be due to disturbances 
in the receptor-mediated signal transduction in Alzheimer brain. It has been 
observed that the preservation of a neurotransmitter recognition site in a disease 
state is not necessarily an indication that the receptor is functionally intact - the 
functional integrity of a neurotransmiter receptor depends on its coupling to intact, 
associated signal transduction mechanisms. Thus, it has been suggested that these 
muscarinic receptors may be functionally impaired in Alzheimer's disease and is 
consistent with evidence of a degree of receptor uncoupling in the disease, which 
may account for some of the therapeutic inefficacy of the muscarinic agonists 
(Warpman, 1993). 
Pearce and Potter (1991) however have shown that human cortical M1 muscarinic 
receptors labelled with 1 nM [3H]pirenzepine are not significantly changed in number, 
high and low affinity binding states, or GppNHp (a non hydrolysable analogue of 
GTP)-sensitive high affinity agonist binding, in Alzheimer's disease. The major 
postsynaptic muscarinic receptor associated with cerebral excitation belong to the 
M1 subtype, which is coupled to G proteins to activate phospholipase C. Further 
studies by these workers showed equal levels of M1 receptors in control and 
denervated rat hippocampi and also unchanged high and low affinity agonist binding 
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states, unchanged GppNHp-sensitive high affinity agonist binding and effectively 
normal agonist activated phospholipase C activity, 1 year after denervation. These 
observations are thought to support the idea that denervated Ml receptors remain 
fully capable of responding to agonists (Pearce & Potter, 1991). 
Abnormalities in non cholinergic n euro transmitter systems 
It has been shown that neurotransmitter systems other than the cholinergic system 
are also affected in Alzheimer's disease - namely the monoaminergic system in 
which 5-HT (5-hydroxytryptamine) and catechokmines act as neurotransmitters. 
Nerve bundles containing 5-HT originate in the raphe nuclei of the mid brain and 
innervate structures of the brain such as the striatum, limbic system and neocortex. 
Reduced cell counts and the presence of tangles in the raphe nuclei have been 
described in Alzheimer's disease and the maximum binding values have been 
reported to be 50% of the controls in the putamen and cingulate cortex (Regland, 
1993). Reduced [3H]5-HT binding has also been observed in post mortem samples 
of temporal cortex, but not in biopsy samples, suggesting that 5-HT receptor losses 
are most likely to be a feature of the latter stages of the disease. It has also been 
suggested that the loss of 5-HT receptors may be a reflection of the loss of 
cholinergic terminals on which they are thought to be localised (Bowen et al., 1983). 
It has been shown that noradrenergic deficits contribute to the pathogenesis of 
Alzheimer's disease in at least a subpopulation of patients, who suffer from 
considerable cortical noradrenergic depletion, decreased NA turnover, decreased 
levels of NA and neuron loss in the locus ceruleus (Adolfsson et al., 1979; Bondareff, 
1982). It has been observed that the severity of neuronal degeneration in the locus 
ceruleus is more evident in younger Alzheimer patients (Bonclareff, 1994). A 
decrease in al and a2 and an increase in Pl and P2 adrenergic receptors has been 
reported (Kalaria et al., 1989 & 1991). Nevertheless a2 and 5HT1A sites in 
Alzheimer's disease have been shown to be capable of undergoing guanine 
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nucleotide-induced (cGMP) conversion from low to high affinity agonist states and 
are thought to be effectively coupled to G proteins (Cowburn et aL, 1993). 
Evidence that noradrenergic dysfunction influences the cognitive deficits of 
Alzheimer patients is not well established, but a significant correlation between brain 
NA markers and performance on cognitive tests have been reported (Adolfsson et 
al., 1979; Mann et aL, 1980). Evidence of a dysfunction of dopaminergic neurons has 
been less conclusive, although reports on the loss of DA in areas like the thalamus, 
hypothalamus, striatum and pons also exist (Regland, 1993). 
The disturbances in neurotransmitter functions are obviously widespread in 
Alzheimer's disease not only affecting the cholinergic and monoaminergic systems 
but other neurotransmitter systems as well. Studies on the levels of the excitatory 
amino acid glutamate, the major neurotransmitter utilized by pyramidal cells of both 
the cerebral cortex and hippocampus, range from reduced glutamate levels, to no 
change at post mortem in Alzheimer patients (Dewar & Mc Culloch, 1994). Moreover 
in biopsy material, the K+-stimulated release of glutamate, as well as the excitatory 
amino acid aspartate, has been shown to be unchanged in Alzheimer patients 
compared to controls (Smith et al., 1983). However the biosynthetic enzyme of 
glutamate, glutaminase, was found to be depleted as were neurons stained with 
antibodies raised against this enzyme (Akiyama et al., 1989). Depletion of [3H]D- 
aspartate binding in cerebral cortex and hippocampus also suggest marked loss of 
glutaminergic terminals, although the use of this ligand as a specific marker of 
glutaminergic terminals has been questioned following the observation that lesions of 
glutarnatergic pathways such as cortico-striatal and retino-collicular projections, 
failed to reduce [3H]D-aspartate binding (cited in Dewar & Mc Culloch, 1994). 
Perhaps the most convincing evidence for the role of glutamate in Alzheimer's 
disease comes from the reduced number of pyramidal cell perikarya, which is 
reported to correlate with the severity of dementia (Palmer & Gershon, 1990). 
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A role for glutamate-mediated neurotoxicity has been supported by several lines of 
evidence. The demonstration that increased levels of glutamate in hippocampal 
cultures cause cytoskeletal changes similar to those observed in tangles, supports 
the notion that glutamate may be involved in excitotoxic processes in Alzheimer's 
disease (Mattson, 1990). However it is thought unlikely that excessive glutamate 
receptor activation is the primary event in the neurodegenerative process, although it 
is known that cells with compromised metabolic function exhibit increased 
susceptibility to N-methyl-D-aspartate receptor-mediated neurotoxicity (Novelli et aL, 
1988). 
Short intrinsic neurons in the cerebral cortex are thought to utilize GABA and a 
variety of neuropeptides such as neuropeptide Y, somatostatin and substance P. A 
0 11 r, Cý I loss of GABAergic innervation is indicated by reduced levels of GABA recept r 
markers (Simpson et al., 1988) and reduced somatostatin immunoreactivity (Rossor 
et al., 1980), which is co-localised with GABA in these non pyramidal neurons 
(Heridry et al., 1984). Correlations have been noted between cortical somatostatin 
deficits and plaque and tangle densities. There is also evidence for some loss of 
neuropeptide Y, which also coexists with somatostatin in some cortical and 
hippocampal interneurons. Immunohistochemistry has also revealed a profound 
depletion of substance P reactive perikarya in a number of cortical regions (Dewar & 
Mc Culloch, 1994). There is also evidence for a loss of (y binding sites in the 
hippocampus in Alzheimer's disease which is consistent with pyramidal cell loss in 
the same region (Jansen et al., 1993) 
The discovery that specific growth (trophic) factors govern the survival, maintenance 
and response to injury, of key neurons led to an interest in determining the status of 
these growth factors and their receptors in Alzheimer's disease. Of special interest 
amongst these agents is nerve growth factor (NGF), which is now known to be 
associated with the basal forebrain cholinergic system (Wilcock & Dawbarn, 1994). 
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Research in the area of growth factors is two-fold; firstly to establish whether basal 
forebrain cholinergic pathology is due to disturbances in trophic factors and 
secondly, whether they may be a rationale for therapeutic approaches based on 
increasing the levels, synthesis and release of select growth factors such as nerve 
growth factor (Perry, 1994). However to date, no convincing evidence for a primary 
disturbance in nerve growth factor, or its receptor, or related factors, has been 
shown although the degeneration of nerve growth factor producing neurons such as 
those in the hippocampal pyramidal layer, suggest that some abnormality in the 
production of the respective growth factors is likely (Wilcock & Dawbarn, 1994). 
Molecular pathology 
The central amyloid core of senile plaques is composed of mainly highly insoluble P- 
pleated, unbranched proteinaceous fibrils which are unusually resistant to many 
solvents and proteolytic enzymes (Rowan, 1993). Eventually in 1984, a pepticle 
consisting of about 39-42 amino acid residues was identified - now known as P/A4 
peptide, P amyloid or amyloid P protein (AP)(Glenner & Wong, 1986). The source of 
P amyloid is now known to be P amyloid precursor protein (APP). This protein has at 
least three isoforms which contain the P amyloid sequence. They all have a single 
membrane spanning region, with a long extracellular N-terminal segment and a short 
intracellular C-terminal tail. The P amyloid sequence forms part of this 
transmembrane component (up to 14 amino acids) and extends to include some 
(approximately 28) extracellular amino acids. Two isoforms (APP751 and APP770) 
contain inserts of Kunitz-type serine protease inhibitor domains, which have been 
found to be identical to protease nexin 11. APP695 is the dominant form in the CNS 
(Rowan, 1993). 
The endogenous APP gene is expressed in virtually every cell type both neuronal 
(astrocytes and microglia) as well as non neuronal (blood platelets, endothelial cells) 
tissues (Regland & Gottfries, 1992). The cellular source of P amyloid deposited in 
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Alzheimer's disease remains yet unclear, although the balance of opinion appears to 
be in favour of a neuronal origin (Murphy, 1992). 
Neurofibrillary tangles, neurites of senile plaques and neuropil threads are composed 
of relatively insoluble paired helical filaments (Selkoe, 1991). Chemical and 
immunohistochernical studies of neurofibrillary tangles have identified ubiquitin, P 
amyloid and the microtubule associated protein - tau (Hardy & Allsop, 1991). Tau 
from Alzheimer brain is abnormally phosphorylated, consisting of three tau isoforms 
with molecular weights of 60,64 and 68 (A68) Kd (Rowan, 1993). It has been 
claimed that this protein can only account for about 10% of the mass of paired helical 
filaments; the remainder is unknown (Hardy & Allsop, 1991). 
The main role of tau, as a microtubule associated protein is thought to be to stabilise 
axonal microtubules in their polymerised state. Microtubules play an essential role in 
neurons in the maintenance of structure and also in providing the framework for 
orthograde and retrograde axonal transport. Evidence suggests that the abnormally 
phosphorylated forms of tau found in Alzheimer's disease, interacts abnormally with 
microtubules (Hanger et al., 1991). Many antibodies have been shown to react with 
tau in the normal, as well as the phosporylated form of tau. AIZ50, a monoclonal 
antibody reacts specifically with the A68 isoform of tau and displays tangles, plaque 
neurites and neuropil threads very clearly (Osmand & Switzer, 1991). 
It is still unclear how P amyloid is formed from APP. One of the major pathways for 
APP involves the cleavage of the molecule in the middle of the P amyloid sequence 
by proteolysis. Since this secreted form of APP contains only a part of the P amyloid 
sequence, neither this nor the remaining membrane bound fragment is likely to be 
the source of P amyloid in Alzheimer's disease (Rowan, 1993). However abnormal 
degradation of APP has been shown to result in the formation of fragments with 
intact p amyloid and its subsequent deposition. At present the identity of the 
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proteolytic enzymes involved in the normal and abnormal APP processing pathways 
are unknown, although it has been proposed that the enclosomal-lysosomal pathway 
may be responsible for the abnormal degradation of APP (Hardy & Higgins, 1992). 
It has been suggested that cholinesterases also have protease activity 
(Balasubramanian, 1984). Such proteolytic action could transform a circulating or 
neuronally formed APP, into the soluble P amyloid found within the plaques and 
could also contribute to the degenerative transformation of cytoskeletal proteins into 
the PHF of the neurofibrillary tangles. In this way the putative proteolytic activity of 
the plaque and tangle bound cholinesterase like substances would be expected to 
further contribute to abnormal protein processing (Mesulam & Geula, 1991). 
Aetiology of Alzheimer's disease 
Considerable progress has been made over the past decade in determining the 
identity of the protein and molecular events which are involved in the molecular 
pathology of Alzheimer's disease. The discovery that the gene coding for APP is 
located on chromosome 21, opened the way to establishing a genetic basis for the 
disease (Rosenberg, 1993). However it is now clear, that the underlying disease 
process does not have a single cause, but can be triggered by a number of genetic 
and/or environmental factors. Thus Alzheimer's disease is presently described as a 
heterogenous group of disorders; some being transmitted genetically and the 
majority being sporadic. Nevertheless the pathological sequence of events is 
believed to be the same in all cases. 
The hypothesis that abnormal APP processing and the deposition of P amyloid, the 
main component of the neuritic plaque, is the central event in the aetiology of 
Alzheimer's disease has been widely debated and derives from several 
observations. 
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* Humans with Down syndrome (trisomy 21) are known to develop neuropathological 
features indistinguishable from those of Alzheimer's disease. They are known to 
develop typical P arnyloid-bearing plaques and neurofibrillary tangles and a 
decline in cognitive functioning by their fourth decade. It is generally assumed 
that the invariant occurence of these P amyloid lesions, is related to the over 
expression of the APP gene caused by the extra copy of chromosome 21 
(Masters et al., 1985). The predictability with which persons with Downs 
syndrome develop the typical characteristics of Alzheimer's disease, has made it 
possible to investigate the time course of such degenerative events, as well as 
the chronological and pathological relationships between the the amyloid 
formation and neurofibrillary tangles. 
* It has been found that APP processing is altered in Alzheimer patients having 
mutations in the chromosome containing the APP gene, located on chromosome 
21. Recent identification of mutations in the APP gene on chromosome 21, in 
several different families in which Alzheimer's disease is inherited (familial), have 
provided further evidence for a causative role for P amyloid as well as a genetic 
basis for Alzheimer's disease (Ashall & Goate, 1994; Rosenberg, 1993). 
However it has been found that mutations in chromosome 21 are not present in 
all familial cases and evidence linking familial and sporadic Alzheimer's disease 
with other genes located on chromosomes 14 and 19, the gene for apolipoprotein 
E (apoE4) have also been reported (Ashall & Goate, 1994; Scott, 1993). 
Individuals that inherit 2 alleles of apoE4 are thought to be more likely (8 times) 
to have Alzheimer's disease compared to normal individuals. It appears that the 
genetic causes of Alzheimer's disease are themselves heterogenous. 
* The possibilty that P amyloid-neu rotoxi city may be a prominent cause of neuronal 
degeneration has been widely debated over the last few years. Initial studies in 
which in vivo hippocampal and cortical infusions of synthetic P amyloid or SDS- 
extracted P amyloid derived from Alzheimer brain were tested, suggested a 
neurotoxic effect in rat. Results of subsequent studies conflicted with these and it 
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is now thought that the discrepancies observed may be due to the aggregation 
status of the peptide and the concentration used (Rosenberg, 1993). The 
aggregated form is considered to be more toxic, although the mechanism by 
which it exerts toxicity remains unclear - apoptosis (where cell death occurs in 
response to internal metabolic cues that trigger a molecular programme of self- 
destruction) and destabilization of Ca2+ homeostasis have been proposed 
(Cotman et aL, 1993). ApoE4, a plasma lipoprotein, ' which is synthesized in the 
brain and has been shown to be localized in the senile plaques and neurofibrillary 
tangles in Alzheimer's disease, is thought to play a role in P amyloid aggregation 
(Wilmot et aL, 1995). 
9 Studies with transgenic mice, genetically programmed for neuronal over expression 
of human mutant APP, have shown that these mice express high levels of human 
mutant APP and also develop progressively some of the pathological hallmarks 
of Alzheimer's disease such as neuritic plaques, synaptic loss, astrocytosis and 
microgliosis (Games et aL, 1995). 
Nevertheless, the majority of cases of Alzheimer's disease appear to be sporadic 
with only a small proportion of cases having a genetic basis. It has been proposed 
that sporadic cases may be either directly due to environmental factors, or have an 
inherited susceptibilty to environmental factors. Of the various environmental factors 
put forward as potential risk factors for Alzheimer's disease, one of the most 
significant is a previous history of head injury. Epidemiological studies have provided 
evidence for a link between head injury and the subsequent development of 
Alzheimer-type pathology - an apparent association in 2-20% of Alzheimer cases. 
Repeated blows to the head experienced by boxers are known to result in a 
dementing syndrome called dementia pugilistica, where widespread neurofibrillary 
tangle formation in the cortex has been observed (Roberts et a/., 1990). The 
presence of large numbers of diffuse P amyloid has also been observed, although no 
appreciable neuritic plaque formation has been seen to occur (Roberts et al., 199o). 
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It has been suggested that the neuronal trauma and ischaemia which accompany 
head injury causes a cascade of molecular events resulting in APP over expression, 
which in certain susceptible individuals leads to mismetabolism and subsequent 
deposition of 0 amyloid protein (Gentleman et al., 1993). 
The involvement of aluminium (Al) in Alzheimer's disease has been implicated and is 
also considered to be a risk factor following a number of epidemiological studies. It 
has been observed that the incidence of Alzheimer's disease is significantly 
increased in areas where there are high residual levels of Al from the treatment of 
water supplies. Progressive cognitive decline has also been reported in miners 
chronically exposed to Al powder to prevent silicotic lung disease (Rifat & Eastwood, 
1994). The brain content of Al is not found to be raised in neuropathologically 
assessed cases of severe Alzheimer's disease compared with pathology free 
controls, but focal deposits of aluminosilicate are present in the central core region of 
senile plaques and studies in vitro indicate that aluminosilicates can influence the 
fibrillary aggregation of P amyloid. It has been suggested that if Al contributes to the 
pathogenesis of sporadic Alzheimer's disease, it does so indirectly in susceptible 
individuals, possibly via effects on the biosynthesis or proteolytic processing of APP, 
or the processing of tau (Edwardson & Candy, 1992). 
The herpes simplex virus type 1 (HSV1) which is known to be latent in the trigeminal 
ganglia of sufferers of cold sores has also been highly implicated in the pathogenesis 
of Alzheimer's disease. In population studies, HSV1 has also been shown to be 
prevalent in 85% by the age of 60. Furthermore the regions of the brain affected in 
herpes encephalitis are also those which show the main neuropathological features - 
plaques and neurofibrillary tangles in Alzheimer's disease (Itzhaki et al., 1993). 
A number of criticisms have been put forward concerning the amyloid hypothesis. 
First sporadic (non familial) cases of Alzheimer's disease which are undoubtedly the 
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majority, are unlikely to be explained by an over expression of the APP gene or a 
mutational defect. Moreover recent genetic studies have clearly shown that 
hereditary Alzheimer's disease has several aetiologies - in some cases defined 
mutations in the P amyloid gene on chromosome 21 have been shown to occur, 
whereas in other cases such mutations are absent (Scott, 1993; Ashall & Goate, 
1994). Also recent transgenic mouse models of Alzheimer's disease which have 
been able to express high levels of human mutant APP do not develop neurofibrillary 
tangles, characteristic of Alzheimer's disease (Duff & Hardy, 1995). Furthermore 
amyloid plaques which are common in the cortex in normal ageing and are present in 
high density in cognitively normal elderly patients are accompanied by little neuronal 
alteration or mental dysfunction, possibly because the P amyloid deposition is not the 
central event in the pathogenesis of Alzheimer's disease. An alternative hypothesis 
suggests a protective role for APP rather than a toxic one, whereby Alzheimer's 
disease is most likely to develop when APP is insufficient either because of a genetic 
effect, or because of intense exposure to causal factors in the environment which 
produces APP which is both protective and amyloidogenic (Regland & Gottfries, 
1992). 
Alzheimer's disease models 
Whereas the classical neuropathological features - the senile plaques and the 
neurofibrillary tangles provide the keystone for post mortem diagnosis of Alzheimer's 
disease, changes in the functional activity of a wide variety of identified 
neurotransmitters; have also been established as discussed previously. So far it has 
proved difficult to ascertain which neuropathological and neurochernical changes are 
primary in the aetiology and development of the disease, or which might be 
responsible for the different psychopathological features. 
The discovery that Alzheimer's disease is associated with a loss of basal cholinergic 
neurons, as well as the correlation of cholinergic abnormalities with the severity of 
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memory loss and other symptoms of dementia (Perry et al., 1978), stimulated 
research on the role of cholinergic mechanisms in learning and memory with a view 
to developing more efficient cholinergic pharmacotherapy. 
The importance of central cholinergic systems in learning, memory and cognition has 
been suggested from the pharmacological studies accumulated from both animals 
and humans. Many studies, for example have demonstrated that antimuscarinic 
agents such as atropine and scopolamine, can disrupt both the acquisition and 
performance of a variety of learned behaviours. In rodents, primates and man there 
have been numerous reports that scopolamine produces memory impairments 
similar to that seen in Alzheimer's disease (Dunnett, 1994). However subsequent 
studies have shown that the memory deficits produced by scopolamine, produce a 
non specific disruption of performance which are substantially different to those seen 
in Alzheimer's disease (Fibiger, 1991). To some extent these differences, are not 
surprising because muscarinic antagonists produce an acute, short-lasting blockade 
of cholinergic receptors that are primarily postsynaptic and anatomically non specific, 
while Alzheimer's disease is a chronic, irreversible disorder which involves 
anatomically specific changes in presynaptic cholinergic function. 
An alternative to studying the role of cholinergic systems in learning and memory has 
been to lesion selected populations of cholinergic neurons. The identification of an 
affected population of cortically projecting cholinergic neurons that are degenerated 
in dementia, has stimulated researchers to reproduce this deficit in animals by 
experimental lesions using a variety of techniques - surgical, electrolytic, neurotoxin 
methods. However problems have arisen concerning the specificity of the lesions 
produced, particularly those that are surgically induced. Nevertheless neurotoxins 
such as cholinotoxins and excitotoxins which are used regularly in lesioning studies 
and have often demonstrated improved selectivity (Cutler et al., 1994). 
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Administered in appropriate concentrations, neurotoxins are capable of destroying 
cell bodies at the site of injection in the basal forebrain. In both rodents and primates, 
lesions of the nucleus basalis and or medial septum produce deficits in learning, 
although the nature of the deficit is not completely the same for each area. 
Impairment produced by these lesions can be reversed using a cholinesterase 
inhibitor or a directly acting agonists (Dunnett, 1994). 
Of the cholinotoxins available, the strongest claims have been made for ethylcholine 
mustard aziridiniurn (AF64A or ECMA), a nitrogen mustard analog of choline which is 
an irreversible choline uptake inhibitor. Lesions of the nucleus basalis of Meynert by 
AF64A have shown significant decreases in hippocampal ChAT activity, as well as 
presynaptic cholinergic dysfunction similar to Alzheimer's disease and also marked 
and long lasting impairments in memory and other cognitive behaviour (Cutler et al., 
1994). However the neurochemical specificity of AF64A appears to depend on the 
route of administration - intraventricular infusion being the favoured route (Fisher et 
al., 1982; Walsh et al., 1984) rather than intraparenchymal infusion, which appears 
to induce extensive nonspecific, gross cellular toxicity (Allen et aL, 1988) thus limiting 
the usefulness AF64A. 
Lesions of terminal regions have also been simulated with the direct injection of 
hemicholinium (HC-3), a reversible choline uptake blocker, into the hippocampus or 
into the ventricles. This produces an impairment in memory on both passive 
avoidance and spatial tasks, although this effect is not consistently found in all 
studies (Colhoun & Rylett, 1986). 
Many groups have used excitatory amino acid neurotoxins such as kainic acid or 
ibotenic acid, to lesion the nucleus basalis of magnocellularis Which provides 
cholinergic projections to the neocortex. However it has been shown that the effects 
of such lesions indicate a disturbance of some form of conditional discrimination 
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learning, or attentional process, rather than mnemonic basis for learning (Dunnett et 
a/., 1991). Furthermore detailed anatomical analyses of the effects of ibotenic acid 
infusion into the basal forebrain have indicated that the magnitude of the behavioural 
deficits correlated not so much with the degree of reduction in cortical ChAT activity, 
as with the magnitude of the lesions, in terms of general cellular destruction in the 
dorsal and ventral globus palliclus (Everitt et al., 1987), rendering the cholinergic 
interpretation of the behavioural deficit somewhat problematic. 
Alternative toxins such as quisqualic acid and the excitotoxic amino acid receptor 
agonist cc amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) have been 
found to be effective in destroying the nucleus basalis of magnocellularis cell bodies 
leading to reductions in neocortical ChAT activity in excess of 70%, while sparing 
most noncholinergic neurons (cited in Dunnett et al., 1991). However with AMPA 
lesions there were no effects on acquisition or retention in the spatial water maze, 
thus making the interpretation of excitotoxin lesions difficult (Page et aL, 1991). 
Thus the evidence supporting the role of cholinergic mechanisms in learning and 
memory is vast. Recently however, the role of NMDA receptors in memory has been 
investigated following the proposal that long-term potentiation (LTP) may be a 
mechanism of memory. The phenomenon of LTP, an enduring change in synaptic 
efficiency, has been extensively demonstrated in the hippocampus and also 
described in the amygdala and cortex (Brown et al., 1990). Lesion data suggest that 
memories are not stored either in the hippocampus or in the amygdala, since 
animals with bilateral ablation of the hippocampus and amygdala do not lose 
memories but become incapable of learning new ones (cited in lzguierdo, 1991). 
Evidence to implicate glutamatergic neurotransmission both in LTP and in learning 
and memory come from the observations that NMDA antagonists such as MK-801 
(dizocilpine), AP5 (2-amino-5-phosphonopentanoic acid) and AP7 (2-amino-7- 
phosphonoheptanoic acid), prevent the development of LTP and impair the 
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performance of experimental animals in tasks that require learning and memory 
(Izguierdo, 1991). Thus glutamatergic dysfunction may play a significant role in the 
memory impairments that characterize Alzheimer's disease. 
An immunotoxic approach has been recently described using the nerve growth factor 
(NGF) receptors located on the cholinergic neurons in the basal forebrain. The toxin 
saporin has been conjugated to NGF receptor antibodies, in order to target its toxic 
action and has been shown to be effective in destructing the septal and nucleus 
basalis of magnocellularis cholinergic neurons. This novel approach awaits re 
evaluation. Thus it is evident that the choice of neurotoxin is important, as some of 
the deficits observed may not be related to decreases in ACh (Wiley et al., 1991). 
Behavioural models and behavioural testing have been a successful approach in 
developing anxiolytics, anti-parkinsons and also neuroleptic drugs, although they 
have failed to screen and predict clinical efficacy of potential anti Alzheimer drugs to 
a similar extent for many reasons. One of the major reasons for this failure is likely to 
be the difficulty of addressing the complexicity of symptoms present in the Alzheimer 
patient. Disturbances of the higher cortical function characteristic of cognitive 
impairment in Alzheimer's disease such as aphasia, apraxia and agnosia are difficult 
to study in animals. A further complication is that the irreversible progression seen in 
Alzheimer's disease cannot be mimicked in experimental lesions. However most of 
the cholinomimetic drugs being developed and used in the treatment of Alzheimer's 
disease today, have been screened and tested using many or most of the animal 
models described above and will continue to do so until animal models more relevant 
to the Alzheimer pathology as well as the symptoms are developed. 
Recently however, two novel animal models have been developed which display 
many of the neuropathological characteristics of Alzheimer's disease. These are the 
transgenic mouse model and the animal model of Down's syndrome - the trisomy 16 
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mouse (Cutler et aL, 1994). The transgenic mouse model uses the human APP gene 
encoding mutations associated with familial Alzheimer's disease and via 
transgenesis introduces extra copies into newly fertilized mouse eggs. Over 
expression of the APP gene in these transgenic mice has been reported to show 
neuropathology strikingly similar to that of Alzheimer's disease, although there is no 
evidence of neurofibrillary tangles (Duff & Hardy, 1995). However the reproducibilty 
of this model has been questioned and as these mice have not yet been assessed 
for cognitive dysfunction, it remains to be seen whether the mice will be useful for 
testing therapeutic compounds. 
As mentioned previously Down's syndrome subjects develop Alzheimer-like 
characteristics such as basal forebrain degeneration, neuritic plaques and 
neurofibrillary tangles. Some researchers have investigated the possibility of an 
animal model of Downs syndrome - the trisomy 16 mouse. Because trisomy fetuses 
die in utero or shortly after birth, trisomy 16 basal forebrain transplants are used to 
study the molecular pathogenesis of neuronal deficits in both Alzheimer's disease 
and Downs syndrome. Immunocytochemical staining techniques have suggested the 
presence of proteins associated with Alzheimer's disease in hippocampal grafts of 
trisomy 16 mice, thus suggesting another possible model of Alzheimer 
neuropathology (Richards et aL, 1991). 
Therapy 
Although pathological events such as amyloid plaques and tangle formation are 
currently viewed as the primary target in the development of therapeutic strategies, 
the need for further treatment of the neuronal damage and related clinical symptoms 
has also been recognized. Irrespective of the aetiology, the strong evidence 
correlating the loss of cholinergic markers with memory loss and cognitive 
dysfunction in Alzheimer's disease has suggested cholinergic therapy, as a means of 
reducing the symptoms and improving cognitive function. Although there is no 
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incontrovertible evidence that the cholinergic deficit in Alzheimer's disease is the 
central specific cause of cognitive losses, there has been adequate support for a role 
for cholinergic activity in cognition and for this reason, considerable effort has been 
turned to the development of therapies that compensate the cholinergic loss in 
Alzheimer patients. Thus even with the theoretical advent of antiamyloidogenic 
agents, other drugs aimed at improving the transmitter deficits are also thought to be 
a likely and necessary adjunct. 
A variety of other substances such as the nootropics, NMDA antagonists and 
benzodiazepines have also been shown to enhance learning and memory functions 
(Schindler, 1992; lzquierdo, 1991). Therapeutic agents have also been aimed at 
restoring NMDA receptor function by activating its glycine modulatory site. 
Milacemide, which is converted to glycine in the CNS, has been shown to facilitate 
memory retrieval in young and aged healthy adults (Dewar& McCulloch, 1994). 
The strategies aimed at enhancing cholinergic activity which have been clinically 
explored so far are - the use of the precursor (choline), cholinesterase inhibitors 
(ChE-inhibitors) and cholinoceptor agonists. None of these approaches however, has 
achieved the degree of benefit to Alzheimer patients anywhere near that which is 
achieved with drugs like L-dopa for the treatment of Parkinson's disease, possibly 
because the degenerating nerve cells include cholinergic as well as non cholinergic. 
The two most promising approaches so far have been cholinesterase inhibition and 
cholinoceptor stimulation. K+ channel blockers such as the aminopyridines (4- 
aminopyridine and 3,4-di aminopyridine) which are known to augment cholinergic 
transmission (both basal and depolarization induced ACh release), have also been 
tested. The more recently investigated K' channel blocker linopiridine (Du 996) is 
thought to be more favourable as it has been shown to specifically enhance K+ 
evoked ACh release (De Souza, 1993). 
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9 Precursor loading - An increase in ACh synthesis was attempted by means of 
providing an excess of the precursors involved. At first choline itself was used, but it 
was found that in a high proportion of Alzheimer patients it was broken down by 
intestinal bacteria to trimethylamine, which smells of rotten fish. Choline was 
therefore substituted by phosphotidy1choline (lecithin), which when given in highly 
pure doses for 4 months showed favourable results in one control trial, among a 
subgroup of older patients, whose plasma choline levels rose to twice the baseline 
level (Little et aL, 1985). However the drug group as a whole showed no 
improvement in memory and moreover other workers were unable to replicate this 
improvement, using high purity lecithin albeit in a younger group of patients (Levy, 
1994). 
9 Cholinoceptor agonists - Five muscarinic receptor agonists have been tested in 
Alzheimer's disease; these are RS-86, pilocarpine, oxotremorine, arecoline and 
bethanechol. The most widely reported in this category is RS-86, which has shown 
some improvements in a few patients, but has now been discontinued due to its 
ineffectiveness and high toxicity. Arecoline has also been investigated by introducing 
it into the cerebral ventricle (intrathecally), although the invasive nature of this 
procedure has resulted in numerous serious unwanted effects such as meningitis 
and severe extrapyramidal symptoms (Spiegal, 1989). These first generation 
agonists were unsuccessful due to their poor oral bioavailability, short duration of 
action and poor selectivity for postsynaptic (Ml) receptors. Moreover the peripheral 
side effects associated with non selectivity, also make these drugs dose limiting 
(Giacobini, 1993). 
Recent advances in the development of muscarinic receptor agonists have been 
aimed at specific subtypes, following the identification of at least five muscarinic 
receptor subtypes (Ml-M5) in the brain. As mentioned above, most of the muscarinic 
agonists which have been evaluated in Alzheimer's disease show adverse peripheral 
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side effects and are either non selective (such as RS-86 which is a mixed M1/M2 
agonist), or M2>M1 selective (Fisher et al., 1991). These may also activate M2 
autoreceptors resulting in a decrease of ACh release. Therefore M1 agonist, M2 
antagonist or Ml agonist/M2 antagonist compounds have been suggested to be 
likely prospects for the treatment of Alzheimer's disease (Fisher et al., 1991; Potter, 
1987), although M2 antagonists would be expected to have major peripheral side 
effects on cardiac and smooth muscles. 
However, the most important fact considered to be relevant to the development of a 
specific muscarinic agent for treatment of Alzheimer's disease is that most of the 
mRNA in the cerebral cortex and hippocampus is for M1 and M3 receptors. 
Therefore activation in the cerebral cortex and hippocampus in Alzheimer's disease 
is most likely to be enhanced with selective agonists for for these receptors. Since 
Ml receptors (which cause excitation in the cortex and hippocampus) are so far 
known to exist only in the brain, whereas M3 receptors are also prevalent 
peripherally, the best single choice for further development is considered to be an 
Ml agonist (Potter, 1992). 
The choice of an Ml specific agonist is further supported by reports that Ml 
receptors are unchanged or increased in Alzheimer's disease. Furthermore 
experimental lesions of the fimbria/fornix (which produces total cholinergic 
denervation) were also shown to cause no loss of M1 receptors in the rat 
hippocampus, 1 year after lesioning (Pearce & Potter, 1991). The same study also 
showed no change in the high affinity binding of M1 agonists, or the ability of these 
agonists to activate phosphoinositide hydrolysis (Pearce & Potter, 1991). 
Recently structurally novel muscarinic agonists have been synthesized with the 
anticipation of overcoming limited oral activity, short duration of action and peripheral 
side effects seen with the classical agonists. Included in this "new generation 
49 
VIA 
agonists" are, arecoline oximes, oxadiazoles, compounds of the AF series, 
spiromides related to RS-86, pilocarpine and oxotremorine analogues (Schwarz et 
al., 1991). AF102B, a rigid analog of ACh has been shown to have a relatively high 
selectivity for M1 receptors (Fisher et al., 1991). It is reported to improve learning 
and memory defects in animal models and is thought to be a promising drug for the 
treatment of Alzheimer's disease (Fisher et al., 1991). Release of ACh in rat brain by 
muscarinic agonists has also been reported - the prototype of such compounds 
being BM5, an oxotremorine analogue which is reported as having presynaptic 
antagonistic and postsynaptic agonistic properties (Nordstr6m et al., 1983). SDZ 
ENS 163, a pilocarpine derivative, is also thought to be highly specific for the M1 
muscarinic receptors and is also known for its ACh releasing properties, which have 
been attributed to its M2 antagonist effect, similar to BM5 (Enz et aL, 1992). Despite 
its pronounced M2 antagonist activity, in vivo studies have shown that it has no 
effect on blood pressure and heart rate after intraperitoneal administration of this 
compound - clinical studies continue. More recently xanomelonine, also a specific 
M1 agonist, is currently in Phase 11 of clinical development for mid moderate 
Alzheimer's disease patients (Bodick et al., 1994). In vivo studies have shown that 
xanomelonine does not produce hypothermia, salivation or tremor at doses up to 
100mg/kg, although dose-dependent increases in heart rate were observed (Bodick 
et aL, 1994). 
The development of nicotinic agonists for the treatment of Alzheimer's disease has 
not been pursued as actively, possibly due to the rapid desensitization of nicotinic 
receptors. An interesting aspect of the nicotinic receptor is that unlike most 
transmitter receptors, it is upregulated by its agonist (thought to be due to its rapid 
desensitization) and this increase in receptor number is evident for example in the 
brain of smokers, which may reflect enhanced function. Thus the observation that 
smoking protects against Alzheimer's disease could be explained on the basis of 
nicotine off setting the disease-related receptor decrement (Wonnacott, 1990). 
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A broader class of agents called cholinergic channel activators have been used to 
describe agents which are nicotinic receptor agonists as well as allosteric 
modulators. These agents are thought to interact selectively with neuronal nicotinic 
receptor subtypes at a site distinct from the ACh binding site (an allosteric site), 
which is not subject to the same desensitization mechanisms. ABT-418 ((S)-3- 
methyl-5-(l-methyl-2-pyrrolidinyl)isoxazole), is a prototype of this class which 
selectively activates neuronal nicotinic receptors, without eliciting the dose limiting 
side effects typically observed with (-)nicotine (Arneric et al., 1994). 
Cholinesterase inhibitors - these are aimed at increasing the duration of released 
ACh, which in turn prolongs stimulation of post synaptic receptors which are largely 
intact in Alzheimer's disease. Eserine (physostigmine), a reversible carbamate 
cholinesterase inhibitor was the first ChE-inhibitor used in the treatment of 
Alzheimer's disease and has also been used in the treatment of atropine poisoning 
and also in ophthalmologic practices as a mi otic agent. Several investigators have 
reported improvement only with moderate doses of intravenous (i. v) eserine and 
failure to induce improvement at both high and low doses, giving rise to an inverted 
U-shaped dose response curve of improvement. The bulk of evidence suggests that 
the administration of i. v eserine can transiently improve memory and other 
psychological functions to a small extent. Oral eserine, despite being poorly and 
irregularly absorbed by the gastrointestinal tract also gives significant improvement 
when given repeatedly every 2-3 hours. This improment has been shown to be 
restricted to particular tasks and only a subgroup of patients have been shown to be 
"clinically significant". The degree of dementia and the dose are thought to be major 
determinants of response. Doses of 9-15mg eserine produce peak plasma levels 
ranging from 0.5-2.4ng/ml; the plasma and brain half life being short - 15-30 min 
(Thal, 1991). 
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The limitations of eserine as a treatment for Alzheimer's disease is its short acting 
effect and also its side effects - the most common being nausea, vomitting, diarrhoea 
and sweating. Clinical studies of a novel form of slow releasing eserine derivative 
called eptastigmine (heptyl-physostigmine or MF-201), have shown that it has a 
longer duration of action and lower hepatotoxicity compared to other ChE-inhibitors 
(eserine and tacrine)(Imbimbo & Lucchelli, 1994), although high doses have revealed 
neutropenia in certain studies (Canal et al., 1994). 
In 1986, Summersý et aL reported marked therapeutic improvement with a long 
lasting cholinesterase inhibitor called tetrahyd roam i noacrid i ne (THA/tacrine), in 17 
patients in a double blind crossover trial. These workers also claimed that tacrine not 
only caused an improvement in test scores, but additionally caused worthwhile 
changes in activities of daily living. However Summers trial was subject to severe 
criticism on methodological grounds, although major efforts to replicate the study in 
better designed trials still continued. Promising results were reported in open studies 
(Gauthier et al. 1989), followed by disappointing results from a double blind placebo 
controlled trial (Gauthier, 1990). 
Two other reports however still stand as obtaining positive benefits. Tacrine was 
shown to produce statistically significant and clinically important improvement 
compared to placebo in the performance of patients with Alzheimer's disease in the 
studies performed by Warner Lambert-Parke Davis in the US and independently by 
Eagger et al., in the UK (Eagger et al., 1991, Wallace, 1992). However these studies 
showed that while improvement correlated with plasma tacrine levels, there were 
also significant unwanted side effects. The most commonly seen side effects of 
tacrine are nausea, vornitting, diarrhoea, sweating and hepatotoxicity. Tacrine was 
discontinued for a while because of these side effects, namely an elevation of liver 
enzymes and hepatotoxicity but was recently introduced in Europe and reintroduced 
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in the US following favourable reports from two independent groups (Farlow et aL, 
1992; Knapp et a/., 1994). 
The mechanism of action of tacrine is varied as well as complex and it is thought that 
the improvement in cognitive function may not be entirely due to inhibition of ChE. 
Tacrine is a reversible inhibitor of ChEs, more potent on butyryl-cholinesterase than 
on AChE and its binding site is thought to be a hydrophobic area, close to the active 
site (Freeman & Dawson, 1991). It is not as potent as eserine, but has a longer half- 
life of 2.5h (Ahlin et al., 1991), which adds to its therapeutic efficacy. The therapeutic 
plasma concentrations range from 0.2-0.6ýM (Baldwin et al., 1991; Summers et al., 
1986). 
A second possible mechanism of action may be a direct effect on cholinoceptors. 
Tacrine has also been found to interact with muscarinic and nicotinic receptors (De 
Sarno et aL, 1989; Nilsson et al., 1987) and is also reported to inhibit carbachol 
stimulated phosphoinositide (PI) hydrolysis at concentrations (Freeman & Dawson, 
1991) which agree closely with its ability to displace muscarinic ligand binding. 
Tacrine has also been reported to release DA from the striatum and 5-HT and NA 
from the cortex (Baldwin et al., 1991; Drukarch et aL, 1988; Robinson et al., 1989) 
and also to inhibit the enzyme responsible for the breakdown of the monoamines - 
monoamine oxidase (MAO)(Nordberg et al., 1989; Adern, 1992). It has been 
speculated that these effects may also play a significant role in some of the 
improvements seen in Alzheimer's disease. Several studies have also shown that 
tacrine directly affects Na', K+ and Ca2+ channels (Marsh et al., 1990; Halliwell & 
Grove, 1989; Griffith & Sim, 1990; Osterrieder, 1987; Drukarch et al., 1987; Chaki et 
al., 1991). 
A number of other cholinesterase inhibitors are currently under investigation. These 
include velnacrine (a hydroxyl derivative of tacrine), galanthamine a cholinesterase 
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inhibitor extracted from the caucasian snowdrop, the antimalarial metriphonate, 
heptylphysostigmine (now withdrawn) and also the novel piperidine based 
cholinesterase inhibitor E 2020 (Levy, 1994). E 2020 which is chemically unique, has 
been shown to be an effective and relatively specific inhibitor of AChE, with dose- 
dependent activity that has greater selectivity for AChE and a longer duration of 
inhibitory action than either eserine or tacrine. Moreover toxicology studies as well as 
initial clinical studies have indicated that E 2020 is devoid of toxicity (Rogers et al., 
1991). 
The use of ChE-inhibitors is thought to be the more favourable cholinornimetic 
approach and probably the most promising so far. Whereas agonists stimulate 
cholinoceptors on cholinergic neurons which improve the modulatory effect of ACh 
on these cells, ChE-inhibitors aim to preserve and enhance the physiological action 
of the neurotransmitter by increasing its level close to normal concentrations in the 
surviving neurons (Giacobini, 1993). 
The balance of opinion is that the ChE-inhibitors tacrine and eserine improve 
cognitive function for a variable length of time in at least a proportion of patients with 
Alzheimer's disease. However attempts are being directed at widening the 
therapeutic scope and developing a more advantageous risk-benefit profile with 
fewer peripheral side effects and a lower likelihood of hepatotoxicity. 
ChE-inhibitors are also important in view of the fact that AChE may play an important 
role in the pathogenesis of Alzheimer's disease. As mentioned previously, amyloid 
plaques and tangles are known to have high AChE activity. It is thought that AChE 
may have a direct or indirect proteolytic mechanism, thus participating in the 
formation of plaques and tangles by means of amyloid processing and accumulation. 
Histochernical studies have shown that tacrine and eserine not only inhibit the AChE 
of normal axons and perikarya, but also the AChE of plaques and tangles (Mesulam 
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& Geula, 1991). However biochemical studies have shown that AChE extracted from 
senile plaques are less sensitive to the ChE-inhibitors tacrine, eserine and E-2020. It 
was suggested that the intrinsic properties of AChE present in senile plaques might 
be altered (due to a conformational change in structure) compared to normal brain 
AChE, or that the accessibilty of the ChE-inhibitors is impeded in plaques (Nakamura 
et al., 1993). However it must be noted that the extraction of AChE in this study with 
Triton X-1 00 and other salts may have contributed to the altered properties of the 
enzyme. 
It is suggested that the correlations between the cognitive deficits, typical 
pathological changes and neurochemical markers all support the notion that loss of 
cortical neurons, synapses and decrease of ChAT are more supportive of 
pathogenetic mechanisms, than concentration of plaques and amyloid or density of 
tangles (Giacobini, 1993). However the success of the ChE-inhibitors in the 
treatment of Alzheimer's disease has not been that remarkable and does not support 
these claims. It has been postulated that steady state extensive inhibition of ChE, 
(measurable in plasma BuChE and CNS ACh levels) but not drug concentration, 
relates to a favourable clinical reponse (Becker & Giacobini, 1988). Clinical 
observations are apparently in agreement and it has been argued according to this 
hypothesis that the adverse and toxic effects of ChE-inhibitors are unlikely to be 
related to their plasma levels of ChE inhibition but to the intrinsic properties of the 
compound (Giacobini, 1993). Futhermore it has been reported by Hallak & Giacobini 
(1989), that although a direct correlation between the inhibition of AChE and 
extracellular ACh levels have been observed with most ChE-inhibitors, several 
discrepancies are also noted, where this relationship is not apparent (in rat brain). It 
was concluded that the change in AChE activity in the CNS is not the only factor 
regulating extracellular ACh concentration - ACh release is also regulated by 
cholinergic autoreceptors, as well as by other neurotransmitters (Giacobini, 1993). De 
Sarno et al., (1989) showed that tacrine, eserine and eptastigmine are also ligands 
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for both muscarinic and nicotinic cholinoceptors. Thus receptor interaction (as well as 
ChE inhibition) may be an important determinant of ACh levels, since it is well 
established that release of ACh is modulated by both muscarinic and nicotinic 
receptors. 
Aims and objectives 
Tacrine and eserine are the most clinically investigated ChE-inhibitors in Alzheimer's 
disease (Becker & Giacobini, 1991), even though eserine (oral or i. v) or tacrine (oral) 
in humans cause a maximum inhibition of 25-30%, at doses minimising side effects 
(Giacobini et al., 1991). It is suggested that the encouraging clinical effects reported 
with the administration of tacrine and eserine might also be a reflection of inhibition 
of plaque and tangle AChE activity (Mesulam & Geula, 1991) and also an action at 
the cholinoceptors and other receptors. From the present account it is clear that in 
addition to its potency for inhibiting ChE, measurements of brain ACh levels in vivo 
and in vitro are also considered important in determining the overall efficacy of a 
ChE-inhibitor as a cholinomimetic. For this reason the present work investigates the 
mechanisms by which ChE-inhibitors affect the availability of ACh by studying the 
effect of tacrine, eserine, neostigmine and edrophonium on the release of K+-evoked 
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INTRODUCTION 
A variety of methods have been developed for the measurement of in vivo and in 
vitro neurotransmitter release in the CNS. In vivo methods of the past have included 
the cortical cup method used for superficial areas, the push pull cannula for deeper 
lying structures and the ventricular perfusion technique. Recently however, it 
appears that these techniques have largely been replaced by in vivo microdialysis, 
which has the advantage of measuring direct and regional transmitter release in the 
conscious animal. 
Static and dynamic methods are used in the measurement of neurotransmiter 
release in vitro. The static method examines release by incubating the tissue 
preparation in a fixed volume of an appropriate medium for a specified period of 
time, after which the preparation is either rapidly cooled, filtered or centrifuged. The 
supernatant is then assayed for the neurotransmitter under investigation. The major 
limitations to this method are that released transmitter may be re-accumulated by the 
tissue, or build up in extracellular concentration so as to exaggerate feedback or 
feedforward mechanisms. Furthermore rapid cooling may shock the tissue resulting 
in artifactual release, or may terminate release completely. Another drawback with 
this method is that it is not suitable for investigating time phenomena. These 
problems decrease the sensitivity to small changes in release produced by a 
particular treatment (Minnema & Michaelson, 1985). 
The dynamic approach uses superfused synaptosome, slice or prism preparations 
and overcomes many of the limitations of the above mentioned method. Continuous 
superfusion when optimized, obviates problems associated with the accumulation of 
neurotransmitters and permits the establishment of a baseline rate of release for 
each tissue sample, from which effects of treatment can be compared (Minnema & 
Michaelson, 1985). 
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Superfusion of brain slices or prisms has been used to examine the release of a 
variety of neurotransmitters - eg. catecholamines, GABA, 5-HT and ACh. Many 
studies investigating ACh release, have used the radiochemical method which 
measures the release of radiolabel after preloading with [3H]choline (or 
[14C]choline). Such isotopic methods of estimating ACh release do not necessarily 
reflect the actual amount released, since unlabelled ACh pre-existing in the tissue 
may also contribute (Beani et al., 1984; Richter, 1976). It has also been reported that 
the synthesis of labelled ACh accounts for only 50-60% of the total amount of ACh 
synthesized during preloading and before release (Molenaar et al., 1973). Thus the 
radiolabel released is inevitably diluted by the concominant release of unlabelled 
ACh. 
The alternative method does not preload the tissue with a radiolabel, but simply 
measures the unlabelled ACh released. Beani et al. (1984), compared these 
methods using electrically stimulated cortical slices. They concluded that the method 
based on [3H]choline preloading allowed drug-induced inhibition of release to be 
detected more readily than potentiation. However the radiochemical method used 
throughout the work reported in this thesis was clearly capable of detecting the 
potentiation as well as inhibition of release - as will be seen in the following chapters. 
Although these methods have been well established they require the use of ChE- 
inhibitors to overcome the difficulty of measuring small amounts ACh. The use of 
ChE-inhibitors however, may lead to unrequired pharmacological effects such the 
activation of autoreceptors that modulate ACh release. Recently Umeda and Sumi 
(1990), introduced a highly sensitive method for assaying unlabelled ACh release, 
which does not require the use of ChE-inhibitors. This static method measures basal 
and KI-evoked release of unlabelled ACh, albeit in the presence of hemicholinium 
(HC-3). ACh released was hydrolyzed and phosphorylated with [32P]ATP. 
Significantly, potentiations of [3H]ACh release described in this present thesis were 
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no less readily detectable than those of unlabelled ACh release reported by Umeda 
and Sumi (1990) (Chapter 3). 
Further studies by Hadhazy and Szerb (1977) have compared the release of 
[3H]ACh evoked by electrical stimulation and 25 mM K+. It was observed that high 
K+ caused a greater and a more prolonged release of the label than did electrical 
stimulation. It is thought that one of the reasons for this might be that high K+ 
concentrations would affect all terminals and cause release from a larger pool than 
would electrical stimulation unless stimulated maximally (Hadhazy & Szerb, 1977). It 
was also observed that the quantity of [3H]ACh which could be released by K+ was 
larger (about double in the case of cortical and hippocampal and triple in striatal 
slices) than that which could be released by electrical stimulation. Although it is 
possible that K+ stimulation might additionally release ACh from cell bodies and 
dendrites while electrical stimulation may not, it is unlikely that this would cause a 
significant contribution to the total amount of ACh released from the axon nerve 
terminal. 
A variety of tissue preparations are used for the study of neurotransmitter release in 
the mammalian nervous system. Amongst these preparations, the hierarchy of 
complexity is from ganglia in vitro, tissue slices or prisms, and finally to 
synaptosomes. The most commonly used tissue preparations for the measurement 
of neurotransmitter release in vitro are synaptosomes and slices or prisms. 
Synaptosomes are thought to have the advantage of synaptic accessibility in that 
they avoid the confounding influences of non neural tissue, membrane barriers and 
neuronal loops. However factors limiting their use are transmitter heterogeneity, 
contamination with gliosomes and lack of integrity and intactness (Minnema & 
Michaelson, 1985). In contrast to synaptosomes, slice or prism preparations may 
retain neuronal cell bodies and axonal processes. This may be useful when it is 
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required to determine whether exogenous ligands modify release by an action on the 
cell body or on the nerve terminals. However the hippocampus which receives more 
than 85% of its cholinergic innervation extrinsically from the medial septum, the slice 
or prism preparation would be expected to retain these cholinergic nerve terminals 
intact making it useful in the investigation of the presynaptic modulation of ACh 
release. 
Slices or prisms have been used widely in the CNS, in the study of ACh - its 
synthesis and release, and the regulation and regional differences of these 
processes including interactions with other neurotransmitters. The nomenclature for 
prisms and slices is quite often interchanged in the literature. Prisms are defined as 
tissue cut by means of a mechanical tissue chopper at fixed intervals in two 
directions at a defined angle. Slices are defined as tissue cut either mechanically in 
single or consecutive sections at designated intervals, with a tissue chopper or by a 
hand razor (Weiler et al., 1982). 
When prepared and maintained properly, hippocampal slices or prisms retain 
electrical activity and neuronal integrity for several hours (Weiler et al. 1982). 
Intracellular recordings made from CA1 pyramidal cells in the hippocampal slice 
preparation have been shown to display those characteristics previously described 
for the intact preparation including EPSPs (excitatory post synaptic potentials), 
IPSPs (inhibitory post synaptic potentials), depolarising after potentials, frequency 
potentiation, double pulse facilitation and probable dendritic spikes (Scwartzkroin, 
1975). Furthermore it has been shown that the quantitative measure of some 
passive membrane properties (for example cell resistance and rheobase level, 
important for establishing criteria by which to evaluate cell 'health' and electrode 
impalement) of CA1 pyramidal cells recorded from slices of guinea pig and rabbit 
hippocampus are in substantial agreement with measurements taken in intact 
preparations (Scwartzkroin, 1977). These studies thus demonstrate that cells in the 
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slices are not abnormal following the trauma suffered during its preparation and 
maintenance of the tissue in vitro. It would seem reasonable to conclude therefore, 
that the axon terminals of projection within the hippocampus retain their function and 
that hippocampal slices and prisms represent a feasible means of studying 
presynaptic mechanisms in this pathway. 
Evidence from lesioning studies indicate that the cholinergic innervation of the 
hippocampus is almost entirely extrinsic. It was reported that septal lesions (made 
approximately 10-12 days prior to the experiments) destroyed cholinergic afferents to 
the hippocampus causing a significant reduction (>85%) of evoked ACh release 
(Mulder et aL, 1974) and according to Szerb's study completely abolished it (Szerb, 
1977). Furthermore ChAT and AChE activity were also observed to be greatly 
reduced (75% and 60% respectively) (Mulder et al., 1974). These results suggest 
that the release of ACh from intrinsic cholinergic neurons would account for only 
15% at the most, of the total ACh release evoked in slices or prisms from the 
hippocampus. These results are supported by immunohistochemical staining for 
ChAT which revealed only a small incidence of cholinergic interneurones in the 
hippocampus (Sofroniew et aL, 1985). 
Mechanisms of synthesis of ACh in brain slices or prisms 
The biosynthetic enzyme choline acetyltransferase (ChAT), is not rate limiting and 
the rate of synthesis of ACh depends on the the availability of the precursors - 
choline and acetylcoenzyme A (acetylCoA). The source of acetylCoA for ACh 
synthesis is glucose or pyruvate. The supply of acetyl groups for ACh synthesis in 
the cytoplasm requires the translocation of acetylCoA from mitochondria to the 
cytoplasmic site where ChAT is available for ACh synthesis. The source of choline 
for ACh synthesis is partly extracellular since neurones do not synthesize choline 
de novo (Browning & Schulman, 1968) and also the synthesis of ACh is inhibited by 
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compounds such as hernicholinium-3 (HC-3) which inhibits high affinity choline 
transport. 
Many studies have been concerned with the source and availability of choline and 
acetylCoA and their role in the regulation of ACh synthesis. There is evidence that 
synthesis and release of ACh in vitro can proceed without the addition of choline 
(Budai & Kasa, 1988, Weiler et aL, 1979; O'Regan & Collier, 1981). However there 
are also reports that the release of ACh is dependent on choline in the incubation 
medium, particularly during prolonged depolarization (Millington & Goldberg, 1982). 
Although radioactive choline added to the incubating medium is incorporated into 
ACh in brain slices, a total dependence on extracellular choline for ACh synthesis 
has not been demonstrated. It has been suggested that in brain tissue in vitro, a net 
production of free choline occurs by release from its chemically bound form (lipid 
choline). Collier et aL (1972) showed, in brain slices, that bound choline can be 
utilized for ACh synthesis. ACh concentrations depleted by incubation in Nal-free 
medium were restored without the addition of exogenous choline (Collier et al., 
1972). Furthermore it has been estimated from in vivo studies in the rat, that 12% of 
the brain choline originates from free choline in the plasma and 88% comes to the 
brain as lipid choline. It was concluded from this that the lipid choline which enters 
the brain pool from the plasma then contributes to the free choline available for ACh 
synthesis (Schuberth & Jenden, 1975). Nevertheless labelled choline in the medium 
successfully competes with unlabelled choline for ACh synthesis and it has been 
shown that 50-60% of the total ACh synthesized during a 60 min incubation is 
labelled (Molenaar et al., 1973). 
Subcellular fractionation of brain tissue has shown evidence of at least two 
compartments of ACh in the nerve endings; one contained in the vesicles and the 
other free in the cytoplasm and described as the cytoplasmic pool (Richter 
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Marchbanks, 1971a). Isotopic labelling techniques have shown that slices or 
synatosomes when depolarized for prolonged periods of time, release newly 
synthesized ACh, from a rapidly turning over store in the tissue, which does not 
resemble the vesicular or cytoplasmic pools. 
The subcellular localization of this store was investigated by measuring the ratios of 
labelled to total released ACh ('labelling ratio') in different subcellular fractions 
prepared from slices of brain (cortex) immediately after incubation with [3H]choline. 
These ratios were compared with the values obtained for the ACh released during 
incubation in high KCI medium. Both in the synaptic vesicles and in the nerve ending 
cytoplasm, the labelling ratio of the ACh was much lower than that of the ACh 
released from the slices (Molenaar et al., 1973). However the vesicle fraction has 
been reported to be heterogenous and it has been suggested that a small pool of 
vesicles highly labelled with [3H]ACh is preferentially released (relative to the 
remaining larger vesicles found in the resting terminals) (Richter & Marchbanks, 
1971 a). The fact that such a pool of active vesicles has not yet been identified by 
subcellular fractionation methods described above, is thought to be due to either its 
lability, or the similarity of its physical properties to those vesicular or cytoplasmic 
fractions isolated (Molenaar et aL, 1973). It would seem unlikely that gross 
techniques like subcellular fractionation would reveal details at this resolution. 
However it is generally accepted that transmitter released by depolarization 
(electrical or high K+) is of vesicular origin although it has been suggested that 
transmitters can be quantally released even from the cytoplasm in a Ca2+- 
dependent manner (Tauc, 1982). 
The relative contribution of newly synthesized ACh and longer-term (preformed) 
stores to evoked release has been investigated. Richter (1976) showed that during 
prolonged periods of depolarization (-90 min) the release of ACh was clearly 
biphasic. The peak rate of release gradually declined to a plateau level after about 
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10 min and was maintained for at least 60 min. It was observed that the peak release 
had a lower sensitivity to HC-3 (when added with the depolarizing K+) and was also 
unaffected by added choline suggesting that the peak and plateau phases of release 
may be different. Richter put forward the idea that a larger portion of the peak than 
plateau phase might represent release of preformed ACh thus explaining its lower 
sensitivity to HC-3 during this period. 
It was therefore decided to measure release of [3H]ACh evoked by KI depolarization 
for 2 min. From the evidence above it was concluded that shorter periods of 
stimulation would be more likely to reflect preformed [3H]ACh without a contribution 
from newly synthesized unlabelled ACh. K+ depolarization was chosen as an 
alternative to electrical stimulation to exclude the effects of propagated action 
potentials in hippocampal interneurons and to localize the depolarization to nerve 
terminals. K+ stimulated release of ACh has been shown to be insensitive to TTX 
(Benishin, 1990; Weiler et al., 1984; Nordstrom & Bartfai, 1980) indicating that ACh 
release mediated by propagated action potentials does not occur during K+ 
depolarization. The following experiments characterize the release system by 
examining the effect of varying concentrations of KCI as a depolarizing stimulus and 
also the effect of Ca2+ on evoked release of radiolabel. 
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METHODS 
Preparation of tissue 
Male Sprague Dawley rats (200-300g) were stunned and killed by cervical 
dislocation, followed by decapitation. The brain was removed and dissected on ice 
for the hippocampus. Hippocampal prisms were prepared by chopping the tissue at 
0.2mm intervals in two planes at 450 angle, using a McIlwain tissue chopper. The 
prisms were added to ice cold superfusion medium (Krebs' solution) gassed with 5% 
C02195% 02 and thoroughly mixed with a vortex mixer in order to form a 
homogenous suspension. The tissue suspension was then centrifuged at 2400 rpm 
for 2 min and resuspended in superfusion medium. This procedure was repeated in 
order to eliminate any excess extracellular choline and finally resuspended in 3.5mls 
of gassed superfusion medium containing 20gl of [3H]choline solution (giving a final 
concentration of 0.37ýM; 1.268xlO7 DPM/ml) and incubated at 370C for 40-45 min. 
Following centrifugation and resuspension as described above the prisms were then 
ready for superfusion. 
Superfusion of the hippocampal prisms 
The superfusion chambers were fitted with jackets through which water was 
circulated by a pump to maintain the chambers at 370C. Each superfusion chamber 
contained a 7.5mm Swinnex Millipore filter (Millipore Corporation). An aliquot of 
0.3ml of hippocampal prisms was then pipetted onto a disc of filter paper (Whatman 
4) placed directly on the Swinnex Millipore filter bed. The hippocampal prisms were 
superfused with medium (Krebs' solution, continuously gassed with 95% 02/5% C02, 
see Materials) at a rate of 0.25ml per min, using a Watson Marlow peristaltic pump. 
After an initial 60 min washout period, release experiments were initiated (t=O) and 
superfusate from each chamber was collected for successive 5 min intervals, in 
scintillation vials. 
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At the required times the superfusion medium was changed by transferring the input 
lines without stopping the pump, to superfusion medium containing the required 
concentration of KCI, drug or combination of drugs in Krebs' solution. [3H]ACh 
release was initiated by superfusing the hippocampal prisms for two 2 min periods 
(S1 and S2 at t=9 and 34 min) with Krebs' solution containing high KCI 
concentrations. When a high KCI concentration (eg 30mM) was used, a 
corresponding reduction in NaCl concentration was made to maintain osmolarity. 
The experiments with Ca2l-free media were carried out in two different ways. Ca2+ 
was either excluded throughout the duration of the experiment (i. e after the initial 
washout period) or during the S1 and S2 stimulation only. 
Determination of radiolabel in release experiments 
The superfusion apparatus consisted of 12 chambers, accommodating 12 samples 
of hippocampal prisms (from a single rat), from which efflux of tritium was measured. 
The radioactivity in each 5 min sample was counted by adding 4ml of the water 
tolerant scintillation fluid 'Liquiscint' (see Materials) to each of the scintillation vials 
containing superfusate. After the second stimulation (S2), radioactivity remaining in 
the tissue was also determined. Each of the tissue samples was added separately to 
4ml of NE260 scintillation fluid (which solubilizes tissue prisms) in scintillation vials. 
All vials were left to stand overnight and then counted (5 min) for tritium in a 
Beckman LS 233 scintillation counter, wide window for tritium, counting efficiency 
35%. In preliminary experiments it was shown that the counting efficiency in the two 
scintillation fluids is the same and that there were no variations in quenching caused 
by volumes of superfusion medium ranging from 0.5-1.5ml. 
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Release in each 5 min superfusate was expressed graphically as CPM eg. Figure 
3.1 a. It was also normalized as fractional release (%, eg. Figure 3.1b), calculated 
according to the following formula. 
CPM released per fraction xi 00% 
Total CIPM released + CIPM remaining on filter after superfusion 
After the 2 min K+ stimulation (S1 or S2), radioactivity increased in the 3 subsequent 
5 min superfusates eg. Figure 2.1 b. The corresponding fractional releases for each 
tissue sample separately were corrrected for baseline fractional release and then 
summed to give total fractional release for that particular stimulation (S1 or S2). This 
was done by subtracting the value of the fractional release calculated for the 5 min 
superfusate immediately prior to the KI stimulus. The corrected total fractional 
releases in the S2 and S1 stimulations were then calculated for each sample 
separately. 
Thus the result of any typical experiment is four separate and invariate control S2/S1 
ratios and four separate and invariate ratios for drug superfused tissue. From these 
control and drug-treated groups, the mean and standard error of the mean (SEM) 
ratio was then calculated and displayed graphically. Thus the SEMs of the S2/S1 
ratios displayed throughout this thesis represent variations between tissue samples 
and also between rats where experiments were repeated on different occasions 
(usually N=4, see statistical analysis), eg. Figure 3.3. 
It should be noted that where fractional release plots are shown (Figures 2.1b, 2.2b, 
2.3b, 3.1b, 3.2b, 3.4b, 3.6b, 3.9b & 4.13b), fractional releases at each time point for 
the replicate tissue samples involved (from 1 rat, i. e 1 experiment), are represented 
for convenience as mean ± SEM, even though the individual values were kept 
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segregated for the calculation of individual S2/S1 ratios. The fractional release plots 
therefore cannot be used to calculate the final S2/S1 ratios and their SEMs, and are 
displayed simply to show the "signal to noise" ratio in typical experiments. The SEMs 
for the fractional release plots indicate the variations between quadruplicate aliquots 
of a single tissue sample (from 1 rat, i. e 1 experiment) and largely reflect variations 
in the sampling of suspensions of prisms in superfusion medium. These suspensions 
sediment rapidly after mixing with a vortex mixer so that good aliquot reproducibilty is 
difficult to achieve. Nonetheless individual S2/S1 ratios calculated as described 
above, will be independent of between-aliquot variations since S1 and S2 in each 
ratio refer to the same aliquot. 
Experimental design 
The 12 superfusion chambers were divided into 3 groups for comparison - i. e a 
control group and 2 test groups, each comprising 4 superfusion chambers, thus 
giving 4 replicate S2/S1 ratios for each group. Each experiment was repeated 4 
times (N=4) unless otherwise stated. 
Statistical analysis 
Analysis of variance (ANOVA) 
Data (S2/S1 ratios) from control and the two drug-treated groups from experiments 
done on different occasions (N=4 rats, i. e 4 experiments) were analyzed as a two- 
way analysis of variance (MINITAB, statistical package, IBM pc). In situations where 
significant differences in variances were noted between control and drug-treated 
groups (P<0.05) probability levels were assigned using a subsidiary Mest 
(MINITAB). Throughout, there was no interaction between drug treatments and 
experiments (rats). 
The mean S2/S1 ratios and their SEMs, eg. Table 3.1 and Figure 3.3 were 
calculated in one of two ways depending on the results of the two-way analysis of 
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variance. Where there was no difference in variance between experiments (rats) Le 
P>0.05, the overall mean ± SEM was calculated from the total number of replicates 
(n=16 or less) pooled from all 4 experiments. Where P<0.05, the overall mean 
SEM was calculated from the individual means for each separate experiment (N=4). 
It was only possible to test 2 drug (test) groups and a control in any one experiment 
(i. e 3x4 superfusion chambers). Therefore in order to present all the data on a single 
concentration-effect graph (eg. Figure 3.3), the mean S2/S1 values from each of the 
separate control groups were used to calculate the overall mean control value and 
the associated standard error (N>4). 
t-tests 
It is known that Mests when used for small samples require that the two population 
standard deviations be approximately equal. Therefore in situations where the 
sample standard deviations differ appreciably (i. e when one is twice the other or 
more) an alternative method using adjusted means and standard errors must be 
used to calculate the t value. 
Adjusted means provide a mean that is unaffected by the differing number of 
observations in the different experiments and also adjusts for the possibility of 
interactions. Thus the adjusted mean is the main response to that treatment, 
independent of any possible experimental differences either directly or in interaction 
and is essentially a mean of means rather than a grand mean. Therefore the means 
compared are not simple unweighted means of the observations. Instead, the mean 
of each treatment in each experiment was found and the average of those means for 
a particular treatment was taken. 
However in order to estimate the standard error (SEM) an estimation of the 
population variance is required. The more data available, the more sensitive the t- 
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test will be - i. e better able to detect differences. In the standard two sample Mest, 
the data from both samples are used to estimate the variance ((Y'). In this case 
however, even though the comparison is between two groups, the data from all 3 
groups are used to estimate Cy2. In fact the estimate Of Cy2 used, is the error mean 
square from the ANOVA table calculated by Minitab. This value a', is used by 
Minitab to give the standard deviation (SD) = standard error of each mean. 
The following equation was used to calculate t values, which were then compared 
with calculated values tabulated in t-distribution tables for significance. The error 
degrees of freedom as shown from the analysis of variance of unweighted means 
(MINITAB) was used to assign probability levels - P>0.05 or P<0.05,0.01,0.001 or 
0.0001. 
t= 
V(SDA)' + (SDB)' 




Male rats of the Sprague-Dawley species weighing 200-300g were used for all the 
experiments described throughout the thesis. These were obtained from the colonies 
bred and maintained by the Biological Services Unit at King's College London, 
Kensington Campus. 
Radiochemicals 
From Amersham International p1c, Buckinghamshire, England. 
[Methyl-3H]choline chloride in ethanol solution; specific activity 555GBq/mmol 
(1 5Ci/mmol). 
Solutions 
Superfusion medium (Krebs' solution) 
NaCl 121 mM; KCI 1.85mM; KH2PO4 1.17mM; MgS04 1.17mM; glucose 11.1 mM; 
NaHC03 25mM; CaC12 1.22mM, pre-equilibrated with 950,16 02/5% C02 gas mixture. 
High K+ Krebs'solution 
NaCl 98mM; KCI 30mM; KH2PO4 1.17mM; MgS04 1.17mM; glucose 11.1mM; 
NaHC03 25mM; CaC12 1.22mM, pre-equilibrated with 95% 02/5% C02 gas mixture. 
Scintillants 
From National Diagnostics, Hessle, Hull. 
'Liquiscint'. 
From NE technology, Sighthill, Edinburgh. 
General purpose scintillator for internal counting of aqueous and non aqueous 
samples- NE 260. 
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RESULTS 
Preliminary studies showed no difference in the counts for tritium observed between 
radiolabel (a fixed volume) counted in 4ml of Liquiscint or 4ml of NE260. 
Furthermore, varying the volume of Krebs' solution (0.5,1.0 and 1.5ml) containing 
fixed amounts of radiolabel also did not affect the counts, indicating that quenching 
does not vary in the volume of superfusate collected in 5 min at a flow rate of 0.25ml 
per min. 
1. The effect of varying the depolarizing concentration of K"" 
The collection of 5 min fractions began after a washout period of 60 min with 
superfusion medium (Krebs' solution), following preliminary experiments which 
showed that approximately 60 min of pre-superfusion was neccesary to wash out the 
excess radiolabel and to reduce the resting release of radioactivity to a steady level. 
When the prisms were superfused (stimulated) with high K+ Krebs' solution 
containing normal Ca2+ concentrations (1.22mM) for 2 min, a marked increase in 
the release of radioactivity relative to spontaneous/basal levels was observed (Figure 
2.1). The appearance of increased radioactivity began approximately 5 min after KI 
stimulation. Counts of succesive 5 min samples showed that radiolabel collected in 
the superfusion medium reached maximum after 5 to 10 min. 
As Figure 2.1 shows the amount of radioactivity released was dependent on the 
concentration of K' used. The release of radioactivity was appreciably greater with 
50mM KCI during the S1 stimulation than with 10 or 30mM. However the peak 
release observed during the S2 stimulation (with 50mM) was comparable to that of 
the S2 stimulation observed with 30mM K+. The mean ± SEM S2/S1 ratios 
corresponding to the data shown in Figure 2.1 are lOmM K+ S2/Sl 0.910 ± 0.213, 
30mM K+ S2/Sl 0.750 ± 0.032 and 50mM K+ S2/Sl 0.657 ± 0.048. It is noted that 
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the trend is for the S2/S1 ratio to decline with increasing K+ concentration although 
this did not prove statistically significant. 
2. The effect of varying the stimulation time 
The effect of varying stimulation times (2 min versus 3 min) is shown in Figure 2.2 
where 30mM KI was used. The mean ± SEM of the S2/Sl ratios corresponding to 
the data shown in this Figure are, 2 min stimulation S2/S1 0.731 ± 0.069 and 3 min 
stimulation S2/S1 0.579 ± 0.048. The mean S2/S1 ratio observed when K+ 
stimulation was 2 min (S2/S1 0.727 ± 0.018, N=1 1) was significantly greater 
(P<0.001) than that for 3 min stimulations (S2/S1 0.587 ± 0.016, N=5). 
3. The effect of Ca2+ on release of radiolabel 
Superfusion with Ca2l-free medium began after the initial washout period. This 
caused a gradual decrease in spontaneous/basal release - Figure 2.3. Under these 
conditions, stimulation with Ca2+-free high KI solution showed no release of 
radioactivity during S1 or S2 stimulations. However as Figure 2.3 shows, omission of 
Ca2+ only in the high K+ superfusing medium caused a marked decrease in 






































05 10 15 20 A ýo A4 ý5 90 515 
f 
Time (min) t 
Figure 2.1 The release of radiolabel from rat hippocampal prisms evoked by high K+ concentrations. 
The prisms were preloaded with [3H]choline (see Methods for details) and stimulated twice (S1 and S2) 
for 2 min with different concentrations of K+ (10,30,50mM). The point of application of K+ is indicated 
by arrows on the X-axis. Each point represents the mean ± SEM of replicate samples obtained from a 
typical experiment expressed as: 
a) CIPM 



































2 min stimulation 
3 min stimulation 




Figure 2.2 The release of radiolabel from rat hippocampal prisms evoked by high K+ concentrations - 
the effect of varying stimulation times. 
The prisms were preloaded with [3H]choline (see Methods for details) and stimulated twice (S1 and S2) 
for 2 min or 3 min with 30mM K+. The point of application of K+ is indicated by arrows on the X-axis. 
Each point represents the mean ± SEM of replicate samples obtained from a typical experiment 
expressed as: 
a) CPM 
b) fractional release 
76 
2 min stimulation 
3 min stimulation 
1600 
1400. 

































-A- Ca-free throughout 
Control 
Ca-free stimulation 
-A- Ca-free throughout 




Figure 2.3 The release of radiolabel from rat hippocampal prisms evoked by high K+ concentrations - 
the effect of Ca2+. 
The prisms were preloaded with [3H]choline (see Methods for details) and stimulated twice (S1 and S2) 
for 2 min with 30mM K+. The point of application of K+ is indicated by arrows on the X-axis. Ca2+ was 
omitted either throughout the experiment (i. e in the superfusion medium and high K+ Krebs' solution), 
OR only in high K+ Krebs' solution (i. e in S1 and S2 only). Each point represents the mean ± SEM of 
replicate samples obtained from a typical experiment expressed as: 
CPM 
b) fractional release 
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DISCUSSION 
As was noted in the Introduction to this chapter, the cholinergic neuronal content of 
the septo-hippocampal projections makes the hippocampus a favourable area of 
brain for studying cholinergic synaptic transmission. It was concluded that less than 
15% of cholinergic nerve terminals in the hippocampus belong to intrinsic neurons. 
Thus [3H]ACh release evoked is assumed to be largely from the single population of 
the terminals of the septal projections, and drug effects to result from discrete 
actions modifying release from these terminals. 
The use of thick prisms was avoided as the majority (98%) of cells in thick slices 
(-0.7mm) were found to be swollen with only small patches of cells intact (Bak et aL, 
1980). It has been suggested that the swelling of neurons occurs when maintenance 
conditions for the slices are inadequate - the oxygen and glucose supply being the 
most important factors (Bak et aL, 1980). Prisms of 0.2mm (200ýtm) thickness were 
used therefore, as previous morphological and electrophysiological studies have 
shown thin slices (striatal) to be fairly well preserved even after 5 hours incubation. 
There was a trend towards increased release of radiolabel with increasing 
concentrations of the KCI solution (10-50mM), with which the hippocampal prisms 
were superfused (Figure 2.1). Changes in ionic strength are not responsible for this 
effect as it has been shown that 33mM Tris-HCI did not have any effect on [3H]ACh 
release when compared with an identical concentration of KI. This concentration of 
K' also does not affect the activity of lactate dehydrogenase released into the 
superfusate, which is an indicator of the integrity of the tissue (Richter & Marchbanks 
1971b). Changes in KI concentration are however responsible for depolarization of 
nerve terminals in the prisms and cause neurotransmitter release. According to the 
Nernst equation, a K' concentration of 30mM would be expected to cause a 55- 
60mV depolarization. This would be sufficient to activate voltage-o pe rated calcium 
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channels and to initiate [31-11ACh release from cholinergic nerve terminals in the 
slices. The relationship between nerve terminal depolarization, Ca2+ channel 
activation and ACh release is considered further in Chapter 5 
It is notable that while the S1 release evoked by 50mM KI is appreciably greater 
than that evoked by 30mM K+ the S2 releases are comparable. An interpretation of 
this observation is that depletion or dilution of releasable pool is greater after the 
stronger S1 stimulus, thus reducing the availability of radioactivity for release in the 
S2 stimulus. If this is so drug-induced potentiation of release (Chapters 3-6) could 
well be underestimated, particularly at 50mM concentrations of K+. Furthermore 
drug-induced inhibition of release would be difficult to observe with 1 OmM K+ (Figure 
2.1). It seemed therefore, that 30mM K+ was the most favourable concentration for 
observing inhibition and facilitation of [3H]ACh release. 
It can be argued as above, that the decline in S2/S1 ratio with increasing K+ (Figure 
2.1) is due to increased release during the S1 stimulation, which causes a greater 
depletion of the releasable pool of [3H]ACh. Thus there remains progressively less to 
drive release in the S2 stimulation. Furthermore an increasing S1 release would lead 
to an increase in uptake of unlabelled choline. This unlabelled choline would be 
acetylated and dilute the pool of releasable [3H]ACh. Thus dilution and depletion 
together may account for the fractional S2/S1 ratio (0.6-0.85) observed with the 
radiolabelling technique used throughout the work described in this thesis. 
From the above argument it would appear that the measurement of unlabelled ACh 
release would reflect only depletion of the releasable pool of ACh. Indeed it was 
observed by Richter (1976) that KI (50mM) evoked release (from prisms) of 
unlabelled ACh during the S2 stimulus was - 70% of S1. However Beani et al., 
(1984) reported an S2/S1 ratio of 1 for electrically evoked release of unlabelled ACh. 
As mentioned in the Introduction to this chapter, high K+ has been shown to cause a 
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greater, more prolonged release of ACh than electrical stimulation (Hadhazy & 
Szerb, 1977). This may be likely to cause a greater depletion, thus explaining the 
discrepancy between these two studies. 
Previous accounts of the superfusion technique specified flow rates of 0.25 to 0.6 ml 
per min (Murrin et aL, 1977; Raiteri, 1974; Hadhazy & Szerb, 1977; Marchi et aL, 
1981; Mulder et aL, 1974). From preliminary experiments (data not shown) it was 
concluded that potentiation of release by tacrine (30ýM) (Chapter 3) was not 
significantly changed by flow rates of 0.25 or 0.4ml per min or by KI concentrations 
in the range 20 - 30mM. However it was found that 3 min stimulation of the prisms 
with 30mM K+ gave a significantly smaller control S2/S1 ratio than did 2 min 
stimulations (see Results and Figure 2.2). Thus a stimulation time of 2 min exposure 
to 30mM K+, at a superfusion rate of 0.25ml per min was employed throughout the 
course of the work described in this thesis, where evoked release is described. 
It is well known that Ca2+ is essential for the release of neurotransmitter from nerve 
terminals and as Figure 2.3 shows, its omission from the superfusion and high KI 
medium abolished the K+-evoked release of radiolabel. These results confirm the 
Ca2'-dependence of [3H]ACh release in these experiments. Excluding Ca2+ from 
only the high K+ medium did not have such a dramatic effect. This is possibly due to 
residual Ca2+ within the nerve terminals and tissue interstices since it is unlikely that 
a Ca2+-free environment could have been attained in a period of 2 min. The use of 
Ca2+ chelators such as EGTA however was avoided in this study. 
Electrophoretic separation of [3H]choline from [3H]ACh was not possible at the low 
levels of release at which the experiments were carried out (approximately 1000cpm, 
0.1pmol). There is however substantial evidence that the increase in efflux of 
radiolabel evoked by electrical or KI stimulation is in fact due to [3H]ACh (Pohorecki 
et al., 1988; Mulder et al., 1974; Beani et al., 1984; Richardson & Szerb, 1974; 
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Szerb, 1977). Moreover [3H]choline release has been shown to be unaffected by K+ 
(Richter, 1976; Weiler, 1989; Wonnacott & Marchbanks, 1976) which suggests that 
the increased radioactivity observed must be the result of [3H]ACh release. 
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CHAPTER 3 
Potentiation of [3H]ACh release by ChE-inhibitors and HC-3 
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INTRODUCTION 
The discovery of reduced concentrations of markers for cholinergic neurones, in the 
cortex and hippocampus from patients with Alzheimer's disease (Davies & Maloney, 
1976) led to the use of cholinomimetic agents as a therapy for these patients. Oral 
loading of precursors such as choline (Etienne et al., 1978) and phosphatidy1choline 
(lecithin)(Etienne et aL, 1981) however, did not have appreciable effects. Agonist 
therapy too, proved to be unsatisfactory (Spiegal, 1989). Enhancement of the action 
of the naturally released agonist from the surviving cholinergic neurones by a 
cholinesterase inhibitor appears to be the most favourable strategy so far, in the 
treatment of Alzheimer's disease, although it would not discriminate between the 
variety of cholinoceptor subtypes now known to exist in the CNS. 
Eserine, a carbamate inhibitor of cholinesterases (ChE), was the first of its kind to be 
used in the treatment of patients with Alzheimer's disease. Given orally, its effect was 
found to be too brief and irregular. It is not therefore considered an effective 
therapeutic agent because of its unfavourable pharmacokinetic profile and the 
insufficient inhibition of ChE allowed by its narrow therapeutic window (Thal et a/., 
1988). More recently, Summers et aL, (1986) re-introduced tacrine (1,2,3,4- 
tetrahydro-9-aminoacridine or THA), a potent and reversible inhibitor of butyryl- and 
acetyl-ChEs, as an agent likely to be of therapeutic benefit to some patients with 
Alzheimer's disease. Tacrine has been shown to be a longer acting ChE-inhibitor with 
a wider therapeutic window than eserine. Despite numerous criticisms about 
Summer's trial, tacrine recently won unanimous approval from the FDA following the 
data presented by Farlow et al., (1992) which showed that it was superior to placebo 
in alleviating the symptoms of Alzheimers disease. It was therefore thought 
worthwhile by many clinicians, to investigate tacrine more rigorously. 
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Tacrine has featured in a number of studies using brain slices or synaptosomes. 
There have been some reports that it inhibits the release of [3H]ACh from electrically 
stimulated slices of rat striatum, cortex and hippocampus (Drukarch et al., 1987; 
Loiacono & Mitchelson, 1990; Potter et al., 1989) and also that it increases release 
(Loiacono & Mitchelson, 1990; Potter et al., 1989), although this effect was not 
always supported by the statistical data. It was speculated that inhibition involved 
muscarinic receptors and increase of release involved nicotinic receptors, both types 
being located presynaptically. More recently Umeda & Sumi (1990), using a fixed 
volume (non-superfusion) technique, have provided clearer evidence that tacrine as 
well as eserine (Ishi & Surni, 1992) increases basal and K+-evoked release of 
unlabelled ACh from hippocampal and striatal slices. 
The effects of tacrine and eserine have also been studied using human brain slices 
obtained at post mortem (Nilsson et al., 1987; Nordberg et al., 1989) with delays of 
less than 22 h. In non-Alzheimer cortical tissue (control), tacrine (1 00ptM) or eserine 
(100ýi! Vl) significantly decreased the K+-stimulated release of [3H]ACh. In Alzheimer 
samples, the evoked [3H]ACh release was intrinsically less than in the control tissue, 
but it was enhanced to control values in the presence of tacrine or eserine at 1 00ýM. 
The nicotinic antagonists dihydro-Verythroidine (DHPE) or mecamylamine, were 
shown to counteract the enhancement of release caused by tacrine in the Alzheimer 
samples whereas in non-Alzheimer samples, these antagonists were unable to 
change the tacrine effect (Nordberg et al., 1989). Atropine, which increased the 
evoked release of [3H]ACh from the Alzheimer samples, was also shown to abolish 
the effect of tacrine in the same tissue. This study indicates a complex mechanism of 
action for tacrine, involving both muscarinic and nicotinic receptors and this is indeed 
supported by receptor competition studies, where tacrine is shown to displace 
[3H]nicotine and [3H]QNB binding (Nilsson et al., 1987). 
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Investigations of the action of tacrine on peripheral ACh release, however, seem to 
be more supportive of its role as a cholinomimetic, compared to the observations 
made with CNS tissue. Tacrine has been shown to increase the spontaneous quantal 
release of ACh at the neuromuscular junction (Thesleff et al., 1990), as well as the 
quantal release evoked by K+ depolarisation (Provan & Miyamato, 1990) and by 
nerve stimulation (Harvey & Rowan, 1990). Tacrine was also shown to be effective in 
the chicken heart (Lindmar & Loffelholz, 1990), where it enhanced the ACh release 
caused by field stimulation. As discussed above, evidence of its effectiveness as a 
cholinomimetic in the CNS has not been widely reported, especially in the absence of 
other drugs. 
In addition to the inhibition of AChE, tacrine has also been shown to have multiple 
actions in the CNS. In rat brain, it has been reported to increase the basal release of 
[3H]NA (noradrenaline) and [3H]5HT (5-hydroxytryptamine) from cortical slices and 
[3H]DA (dopamine) from striatal slices (Drukarch et al., 1988; Robinson et al., 1989; 
Baldwin et al., 1991) and also to inhibit both forms of monoamine oxiclase (MAO) 
(Nordberg et aL, 1989; Adern, 1992). It has also been shown to inhibit the KI-evoked 
release of [14C]GABA (y-aminobutyric acid), from cortical slices (De Belleroche & 
Gardiner, 1988). Tacrine displays affinity for muscarinic and nicotinic cholinoceptors 
(Drukarch et al., 1988; Nilsson et al., 1987; Nordberg et al., 1989) and shows about a 
10 fold greater affinity for muscarinic cholinoceptors compared to nicotinic 
cholinoceptors (De Sarno et al., 1989; Nilsson et al., 1987). It also interacts with other 
receptors such as those for phencyclidine (Albin et al., 1988) and at high 
concentrations, adenosine receptors (Freeman et a/., 1988). Furthermore, tacrine has 
a structural similarity to 4-aminopyridine, and similar to this compound, blocks K+ 
channels in a variety of tissues (Osterrieder, 1987; Halliwell & Grove, 1989; 
Rogawski, 1987; Griffith & Sim, 1990; Drukarch et al., 1987; Chaki et al., 1991). it 
also blocks Na+ and Ca2+ currents in rat dorsal root (Kelly et al., 1991) and superior 
cervical sympathetic ganglia (Marsh et al., 1990). 
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Following renewed claims supporting the clinical usefulness of tacrine in Alzheimer's 
disease, the aim of the study described in this chapter was to clarify the effect of the 
drug, on K+-evoked release of [3H]ACh from rat hippocampal prisms and to 
compare its effects with three other classical, ChE inhibitors - eserine, neostigmine 
and edrophonium. Eserine, a carbamate ester was chosen because of its previous 
trials in the treatment of Alzheimer's disease. It has also been used in the treatment 
of myasthenia gravis and glaucoma and also experimentally in the measurement of 
ACh release in vitro, where ChE inhibitors are frequently added to protect the ACh 
released, from hydrolysis. Eserine is predominantly positively charged at 
physiological pH (approximately 76%) and combines with the anionic site of the ChE 
in a similar way to neostigmine. 
Neostigmine, also a carbarnate ester is completely ionized in aqueous solution, 
because it is a quaternary ammonium compound. Since the blood-brain barrier is 
largely impermeable to quaternary ammonium compounds, neostigmine and related 
compounds are without significant effect on the CNS. These carbamyl esters 
resemble ACh and react with the esteratic site of ChE in a similar way, except that 
hydrolysis occurs at a much slower rate. Edrophonium however, a quaternary 
ammonium compound lacks the carbamyl ester group and cannot be hydrolyzed by 
ChE. Instead it slows down the rate of hydrolysis of ACh by combining very rapidly at 
the anionic site of the ChE. It has a very rapid dissociation rate on dilution which limits 
its use clinically. Like edrophonium, tacrine also lacks a carbamyl group and binds to 
the anionic site of the ChE. Neostigmine and edrophonium were chosen in the 
present study because of their selective extracellular actions, due to the positively 
charged nitrogen atom in these molecules. It was anticipated that tacrine and eserine 
might have additional intracellular actions. 
The hippocampus was chosen for study because it is known to receive cholinergic 
innervation and is one of the major areas affected in Alzheimer's disease (see 
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Chapter 1). Although a few cholinergic neurones may be intrinsic to the hippocampus, 
greater than 85% of cholinergic hippocampal fibers arise from areas outside the 
hippocampus which include the medial septum and the basal forebrain nuclei. It was 
therefore considered reasonable to assume that drug effects, on ACh release from 
hippocampal prism preparations, would reflect predominantly actions at the level of 
the nerve terminal, rather than actions requiring propagated nerve action potentials. 
Furthermore DNA cloning techniques have revealed the existence of five different 
genes coding for the muscarinic receptors ml, m2, m3, m4 and m5 which are 
expressed in the brain. Studies with complementary nucleic acid sequences which 
are able to hybridize with parts of muscarinic receptor mRNA, either with Northern 
blots of mRNA from tissues, or in situ hybridization, along with immunoreactivity 
studies have broadened existing knowledge regarding the anatomical localization of 
muscarinic receptors. The hippocampus has been shown to contain mRNA for all five 
(ml-m5) muscarinic receptors and also shows immunoreactivity for the 
corresponding antireceptor antibodies (Brann et aL, 1993; Ladinsky, 1993; Vilaro et 
aL, 1993). 
Immunohistochemical studies have also localized brain nicotinic cholinoceptors using 
specific antibodies. It was observed that the distribution for CNS nicotinic 
cholinoceptors was very similar to that of radiolabelled nicotinic agonist binding sites 
(Lukas & Bencherif 1992). There is evidence for the existence of multiple types of 
nicotinic cholinoceptors in the CNS on the basis of the identification of a variety of 
subunit-encoding genes and messenger RNAs in brain tissue and also on the basis 
of long recognized complexities in the pharmacological/physiological characteristics 
of receptors mediating nicotinic cholinergic responses in the brain. Seven (x-subunit 
genes (cc2 to cc9) and four P-subunit genes (p2-p4) have been identified. While cc7 
(and rodent a4) subunits are the only subunits that are apparently capable of forming 
functional homo-oligomeric channels, any pairwise combination of (x2, (x3 or (A with 
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P2 or [A have been shown to generate ion channel activity when expressed in the 
xenopus oocyte system (Lukas & Bencherif 1992; Role, 1992). From the foregoing, it 
is clear that the hippocampus is equipped to display a full range of cholinergic 
mechanisms and is also anatomically relevent to Alzheimer's disease. 
The presence of monoaminergic innervation of the hippocampus has also been 
established (Lindvall & Bjorklund, 1974) and evidence exists that manipulations of the 
dopaminergic, noradrenergic and serotonergic systems innervating the forebrain have 
pronounced effects on in vivo ACh release in the hippocampal formation (Robinson & 
Vanderwolf, 1978; Nilsson et al., 1992). Hippocampal ACh is known to be tightly 
linked to the behavioural state of the animal and these observations indicate that the 
monoaminergic afferents to the septum and the hippocampal formation may play an 
important role in the mediation of these brain stem regulatory influences. 
As tacrine is also known to affect the release of monoamines in the CNS (Drukarch 
et al., 1988; Robinson et al., 1989), a part of the study described in this chapter was 
also to investigate the extent to which monoamines are implicated in the effects of 
tacrine on [3H]ACh release. 
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METHODS 
1. Release experiments 
Preparation of tissue 
Hippocampal prisms were prepared and preloaded with [3H]choline as described in 
Chapter 2- General Methods and Materials. When preloading the prisms with the 
radioactive monoamines [3H]NA, [3H]DA or [3H]5-HT, a monoarnine oxidase 
inhibitor (MAO-inhibitor) was added in order to prevent the breakdown of these 
neurotransmitters. The prisms were incubated with 5ptM pargyline 5 min prior to to 
the addition of the radiolabelled [3H]NA or [3H]5-HT and then incubated for a further 
30 min at 370C. The final concentration of [3H]NA and [3H]5-HT in the hippocampal 
prism preparation was 0.21ýM (1.86x1O7 DIPM/ml) and 0.61ýM (2.46x107 DPM/ml). 
When [3H]DA was used at a final concentration of 0.07gM (6.5x1O6 DPM/ml), 10ýM 
nialamide was also included in the incubation medium, which was otherwise the 
same as the superfusion medium (see Chapter 2). 
Reserpinization of the prisms 
In some experiments the prisms were also treated with reserpine to deplete 
monoamine stores. Reserpine (300nM) was added with the radiolabelled amine (or 
[3H]choline) and the procedure continued as described above. Superfusion of the 
prisms was carried out as described in Chapter 2. 
2. [3H]QNB binding experiments 
Preparation of tissue 
Whole membrane preparations were used in radioligand binding experiments. Male 
Sprague-Dawley rats (250-300g) were stunned, cervically dislocated and 
decapitated. Their brains were rapidly removed and dissected on ice for the 
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hippocampus. The hippocampi thus obtained were added to 39 volumes (w/v) of ice- 
cold 0.32M sucrose to give a final concentration of 2.5% w/v and then homogenized 
in a glass homogenizer fitted with a teflon pestle, at 850 r. p. m., 10 strokes. The 
whole homogenate was centrifuged for 10 minutes at 1000g. The pellet (crude 
nuclear fraction) was discarded and the resultant supernatant fluid was thoroughly 
mixed using a vortex mixer and left on ice until used. 
Receptor binding assay 
A modified version of the receptor binding assay of Yamamura and Snyder (1974) 
was employed using tritiated quinucliclinylbenzilate ([3H]QNB) as the radioligand. To 
assay specific binding of [3H]QNB, 0.2ml (200ýfl) of the membrane preparation was 
pre-incubated at 250C with 2.25ml of 0.05M sodium phosphate buffer, pH 7.4 for 5 
min. The pre-incubation period was 15 min when ChE inhibitors were used in order 
to allow any remaining ACh to be hydrolysed. A 25gl volume of [3H]QNB solution 
was added together with a 25gl aliquot (giving the required final concentration) of the 
competing drug and incubated for 60 min. The final concentration of [3H]QNB in 
each assay vial was 0.9nM (9.4x107 DPM/ml). After the 60 min incubation, 3ml of 
the ice-cold sodium phosphate buffer solution were added and the content of the vial 
was passed through a glass fibre filter (GF/B) positioned in a vacuum-filtration 
manifold. The filters were washed three times under vacuum with 3ml of the ice-cold 
sodium phosphate buffer solution. Every determination of binding was done in 
quadruplicate, together with quadruplicate samples containing 10ýtM atropine to 
determine nonspecific [3H]QNB binding. The filters were placed in vials, into which 
4ml of the scintillant NE260 was added, left overnight and then counted for tritium 




From Sigma Chemical Co. Ltd, Poole, Dorset, England: 
Tacrine hydrochloride hydrate (9-amino-1,2,3,4-tetrahydroacridine), eserine 
hemisulphate, neostigmine bromide, edrophonium chloride, hemicholinium-3 
chloride, reserpine. 
From Burroughs Wellcome & Co., London: 
Atropine sulphate 
Radiochemicals 
From Amersham International pIc, Buckinghamshire, England: 
1) 1-[7,8-3H]Noradrenaline in 0.02M acetic acid: ethanol 9: 1 v/v; specific radioactivity 
1.48 TBq/mmol (40 Ci/mmol) 
2) 5-Hydroxy[G-3H]tryptamine creatinine sulphate in aqueous solution containing 2% 
ethanol; specific radioactivity 673 GBq/mmol (18.2 Ci/mmol) 
3) [7,8-3H]Dopamine in 0.02M acetic acid; ethanol 1: 1 v/v; specific radioactivity 
1.55TBq/mmol (42Ci/mmol) 
4) 1-Quinuclidinyl [phenyl-4-3 H] benzi late in ethanol solution; specific radioacivity 
1.74 TBq/mmol (47Ci/mmol). 
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RESULTS 
1. The effect of ChE inhibitors on KI-evoked [3H]ACh release from rat 
hippocampal prisms. 
Tacrine 
Shown in Figures 3.1 and 3.2 is the time course of the K+-stimulated release of 
radiolabel and the effects of tacrine at the given concentrations in typical 
experiments. The mean ± SEM S2/Sl ratios in these experiments are 0.632 ± 0.045 
and 1.177 ± 0.016 for the controls and 30ýM tacrine respectively in Figure 3.1 and 
0.712 ± 0.047,0.473 ± 0.062 and 0.196 ± 0.005 for controls, 100ýi! Vl and 200ýM 
tacrine respectively, in Figure 3.2. 
CONCENTRATION S2/Sl RATIO 
TACRINE CONTROL TACRINE 
lopm 0.698 ± 0.024 (n=14) 0.891 ± 0.039* (n=14) 
30pM 0.671 ± 0.027 (n=16) 1.138±0.056** (n=19) 
5opm 0.698 ± 0.024 (n=14) 0.921 0.043* (n=16) 
loopm 0.713 ± 0.034 (N=4) 0.562 0.086* (N=4) 
200ýW 0.713 ± 0.034 (N=4) 0.245 0.033** (N=4) 
TABLE 3.1 
The effect of tacrine on K+-evoked [3H]ACh release. The test samples were superfused with tacrine 
10 min prior to and during the S2 stimulation. The S2/S1 values are represented as the mean ± SEM of 
the means (N) or the mean ± SEM of the total number of replicate samples (n) observed from four 
experiments, depending on the analysis of variance; see Methods (Chapter 2) for details. Significant 
differences with respect to the controls are denoted by * P<0.001 and ** P<0.0001. 
As shown in Figure 3.3 and Table 3.1 above, tacrine in the concentration range of 
10-50ýt! Vl significantly increased the S2/S1 ratio of evoked [3H]ACh release. The 
maximal effect was observed at 30ýM tacrine which produced a 70% increase of 
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V 
[3H]ACh release above control levels. The concentrations of tacrine above 50ýM 
tested in this study, produced a marked reduction in [3H]ACh release. At 1 00ýM and 
20ORM tacrine, release was inhibited by 21% (P<0.001) and 66% (P<0.0001) of the 
control value. These results are shown in the bell-shaped concentration-effect curve 
in Figure 3.3. Tacrine did not alter the basal release of [3H]ACh at the concentrations 
tested (Figures 3.1 & 3.2). 
Eserine 
A typical effect of 100gM eserine on K+-stimulated [3H]ACh release compared with 
the controls is shown in Figure 3.4. The mean ± SEM S2/S1 ratios corresponding to 
the data plotted in Figure 3.4 are 0.727 ± 0.013 and 0.997 ± 0.065 for controls and 
1 00ýM eserine respectively. 
The S2/Sl ratios in the presence of eserine at concentrations ranging from 10- 
200ýLM are shown in Figure 3.5 and Table 3.2 below. Although all of the four 
concentrations tested increased [3H]ACh release significantly, a concentration- 
CONCENTRATION S2/Sl RATIO 
ESERINE CONTROL ESERINE 
lopm 0.734 ± 0.030 (n=15) 0.965±0.039* (n=15) 
30pM 0.734 ± 0.030 (n=15) 0.997 ± 0.026** (n=16) 
loopm 0.725 ± 0.029 (n=13) 1.042±0.039** (n=15) 
200pM 0.725 ± 0.029 (n=13) 1.026 ± 0.036** (n=16) 
TABLE 3.2 
The effect of eserine on K+-evoked [3H]ACh release. The test samples were superfused with 
eserine 10 min prior to and during the S2 stimulation. The S2/S1 values are represented as the mean ± 
SEM of the total number of replicate samples (n) observed from four experiments; see Methods 
(Chapter 2) for details. Significant differences with respect to the controls are denoted by * P<0.001 
and **P<0.0001. 
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related effect is not apparent. Eserine at 1 OptM concentrations showed a 36% 
increase in SM 1 ratio whereas at 1 OOpLM and 200ptM, a 44% and 42% increase was 
observed. Eserine did not affect the basal release of [3H]ACh at any of the 
concentrations tested. 
Neostigmine. 
Typical effects of neostigmine at concentrations of 30 and 100ýM on K+-stimulated 
[3H]ACh release are shown in Figure 3.6. The corresponding mean ± SEM of the 
S2/S1 ratios are 0.673 ± 0.037,0.903 ± 0.069 and 1.393 ± 0.121 for the control, 
30ýtM and 100ýt! Vl neostigmine groups respectively. 
The effect of neostigmine in the concentration range 10-200ýtM is shown in Figure 
3.7 and Table 3.3 below. Neostigmine significantly increased release in a 
concentration-dependent manner with a maximal effect at 1 00ýM. At this 
concentration neostigmine produced an increase of 115%, and also at the lowest 
concentration of 1 OýM, an increase of 20%, which was still statistically significant. 
CONCENTRATION S2/Sl RATIO 
NEOSTIGMINE CONTROL NEOSTIGMINE 
lopm 0.734 ± 0.029 (n=14) 0.882 ± 0.026* (n=16) 
30pLM 0.653 ± 0.024 (n=13) 1.082 ± 0.083* (n=16) 
loopm 0.653 ± 0.024 (n=l 3) 1.405 ± 0.079** (n-1 6) 
200pM 0.734 ± 0.029 (n=14) 1.133±0.059** (n=14) 
TABLE 3.3 
The effect of neostigmine on K+-evoked [3H]ACh release. The test samples were superfused with 
neostigmine 10 min prior to and during the S2 stimulation. The S2/S1 values are represented as the 
mean ± SEM of the total number of replicate samples (n) observed from four experiments; see Methods 
(Chapter 2) for details. Significant differences with respect to the controls are denoted by 
* P<0.001 and ** P<0.0001. 
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Neostigmine did not affect the basal release of [3H]ACh at any of the concentrations 
tested. 
Figure 3.7 shows an apparent decrease in [3H]ACh release at 200ý11V! concentrations 
of neostigmine. However, since the effects of 100 and 200ýM neostigmine were not 
compared within the same experiment, the relative effects of 100 and 200ýW 
concentrations were compared in a further group of experiments. As shown in Figure 
3.8a, no difference in the S2/Sl ratio was observed at 100 and 200ýM neostigmine 
(control S2/S1 0.706 ± 0.042 (n=15), 100ýt! Vl neostigmine S2/S1 1.607 ± 0.086 
(n=15), 200ýM neostigmine S2/S1 1.513 ± 0.076 (n=16). Figure 3.8b also shows the 
effect of superfusing the prisms with neostigmine only during the S2 stimulation 
rather than 10 minutes prior to as well as during S2 stimulation. The S2/S 1 ratio was 
slightly greater when neostigmine was present only during the S2 stimulation - S2/S1 
(S2 only) 1.171 ± 0.047 (n=7) compared with 1.019 ± 0.050 (n=8); P<0.05. 
Edrophonium 
CONCENTRATION S2/Sl RATIO 
EDROPHONIUM CONTROL EDROPHONIUM 
lopm 0.601 ± 0.027 (n=15) 0.799 0.042** (n=l 6) 
30ýW 0.601 ± 0.027 (n=15) 0.829 0.037** (n=15) 
1 00PLIVI 0.627 ± 0.063 (N=4) 1.00 ± 0.074* (N=4) 
200ýM 0.627 ± 0.063 (N=4) 1.13 ± 0.071 (N=4) 
TABLE 3.4 
The effect of edrophonium on K+-evoked [3HIACh release. The test samples were superfused with 
edrophonium 10 min prior to and during the S2 stimulation. The S2/S1 values are represented as the 
mean ± SEM of the means (N) or the mean ± SEM of the total number of replicate samples (n) 
observed from four experiments, depending on the analysis of variance; see Methods (Chapter 2) for 
details. Significant differences with respect to the controls are denoted by * P<0.05 and ** P<0.01. 
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Figure 3.9 shows the profile of K'-stimulated release and the typical effect of 100ýM 
edrophonium. The mean ± SEM S2/Sl ratios corresponding to the data shown in 
Figure 3.9 are 0.798 ± 0.029 and 1 . 304 ± 0.103 
for controls and 1 00ýLM edrophonium 
respectively. 
Edrophonium increases [3H]ACh release and the S2/S1 ratios (Figure 3.10 and 
Table 3.4) in a con centration-dependent manner in the range 10-200ýM. At the 
lowest concentration of 1 OýM edrophonium, there was a 33% increase and at 
200ýM an 81% increase was observed. The S2/Sl ratios for 100ýM and 200ptM 
edrophonium are not significantly different from each other (P>0.05) and therefore 
these concentrations appear to be maximally effective. Edrophonium did not affect 
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Figure 3.1 The release of radiolabel from rat hippocampal prisms evoked by 30mM K+ - the effect of 
tacrine (30pM). 
The prisms were preloaded with [3H]choline (see Chapter 2 for experimental details) and stimulated 
twice, (S1 and S2) for 2 min. Tacrine was added to the superfusion medium 10 min prior to and during 
the S2 stimulation, in the test group. Each point represents release as the mean ± SEM of the replicate 
samples (per group) from one typical experiment expressed as: 
a) CPM 
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Figure 3.2 The release of radiolabel from rat hippocampal prisms evoked by 30mM K+ - the effect of 
tacrine (100,200pM). 
The prisms were preloaded with [3H]choline (see Chapter 2 for experimental details) and stimulated 
twice, (S1 and S2) for 2 min. Tacrine was added to the superfusion medium 10 min prior to and during 
the S2 stimulation, in the test group. Each point represents release as the mean ± SEM of the replicate 
samples (per group) from one typical experiment, expressed as: 
a) CPM 
b) fractional release. 
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Figure 3.3 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippcampal prisms - the effect 
of tacrine (10-200ýM)- 
The prisms were stimulated twice (S1 and S2) for 2 min and tacrine was added to the superfusion 
medium 10 min prior to and during the S2 stimulation. Each point represents the S2/S1 ratio as the 
mean ± SEM of the means (N) or the mean ± SEM of the total number of replicate samples (n) 
observed from 4 experiments; see Table 3.1 for details. The control represents the mean ± SEM of 
means obtained from all the experiments. Significant differences in the S2/S1 ratio compared to the 
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Figure 3.4 The release of radiolabel from rat hippocampal prisms evoked by 30mM K+ - the effect of 
eserine. 
The prisms were preloaded with [3H]choline (see Chapter 2 for experimental details) and stimulated 
twice, (Sl and S2) for 2 min. Eserine was added to the superfusion medium 10 min prior to and during 
the S2 stimulation, in the test group. Each point represents release as the mean ± SEM of the replicate 
samples (per group) from one typical experiment, expressed as: 
CPM 
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Figure 3.5 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippcampal prisms - the effect 
of eserine (10-200pM); 
The prisms were stimulated twice (S1 and S2) for 2 min and eserine was added to the superfusion 
medium 10 min prior to and during the S2 stimulation. Each point represents the S2/S1 ratio as the 
mean ± SEM of the total number of replicate samples (n) observed from 4 experiments; see Table 3.2 
for details. The control represents the mean ± SEM of all the replicate samples obtained from all the 
experiments. Significant differences in the S2/S1 ratio compared to the control group are denoted by 
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Figure 3.6 The release of radiolabel from rat hippocampal prisms evoked by 30mM K+ - the effect of 
neostigmine. 
The prisms were preloaded with [3H]choline (see Chapter 2 for experimental details) and stimulated 
twice, (S1 and S2) for 2 min. Neostigmine was added to the superfusion medium 10 min prior to and 
during the S2 stimulation, in the test group. Each point represents release as the mean ± SEM of the 
replicate samples (per group) from one typical experiment, expressed as: 
a) CIPM 
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Figure 3.7 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippcampal prisms - the effect 
of neostigmine (10-200pM). 
The prisms were stimulated twice (S1 and S2) for 2 min and neostigmine was added to the superfusion 
medium 10 min prior to and during the S2 stimulation. Each point represents the S2/S1 ratio as the 
mean ± SEM of the total number of replicate samples (n) observed from 4 experiments; see Table 3.3 
for details. The control represents the mean ± SEM of means from all the experiments. Significant 
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Figure 3.8 Comparison of the effects of neostigmine on the S2/S1 ratio for K+-evoked release of 
[3H]ACh from rat hippocampal prisms. 
a) 100 and 200pM neostigmine, 10 min prior to and during the 2 min S2 stimulation 
b) comparison of the effect of neostigmine on the S2 release in 12 and 2 minute treatments. 
Each column represents the S2/S1 ratio as the mean ± SEM of the total number of replicate samples 
(n) obtained from 3 (a) and 2 (b) experiments. Significant differences in the S2/S1 ratios compared to a) 
control group b) 100pM neostigmine added 10 min prior to and during the 2 min S2 stimulation, are 
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Figure 3.9 The release of radiolabel from rat hippocampal prisms evoked by 30mM K+ - the effect of 
edrophonium. 
The prisms were preloaded with [3H]choline (see Chapter 2 for experimental details) and stimulated 
twice, (S1 and S2) for 2 min. Edrophonium was added to the superfusion medium 10 min prior to and 
during the S2 stimulation, in the test group. Each point represents release as the mean ± SEM of the 
replicate samples (per group) from one typical experiment, expressed as: 
a) CPM 
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Figure 3.10 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippcampal prisms - the 
effect of edrophoniurn (10-200pM). 
The prisms were stimulated twice (S1 and S2) for 2 min and edrophoniurn was added to the 
superfusion medium 10 min prior to and during the S2 stimulation. Each point represents the S2/S1 
ratio as the mean ± SEM of means (N) or the mean ± SEM of the total number of replicate samples (n) 
observed from 4 experiments; see Table 3.4 for details. The control represents the mean ± SEM of 
means from all the experiments. Significant differences in the S2/S1 ratio compared to the control group 
are denoted by *P<0.05 and ** P<0.01. 
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2. The effect of hemicholinium-3, a choline uptake blocker on K+-evoked 
[3H]ACh release from rat hippocampal prisms. 
CONCENTRATION S2/Sl RATIO 
HC-3 CONTROL HC-3 
lopm 0.711 0.024 (n=14) 0.897 ± 0.032** (n=16) 
30gM 0.729 0.022 (N=4) 0.820 ± 0.040* (N=4) 
loogm 0.729 0.022 (N=4) 0.990 ± 0.084** (N=4) 
TABLE 3.5 
The effect of HC-3 on K+-evoked [3H]A Ch release. The test samples were superfused with HC-3 10 
min prior to and during the S2 stimulation. The S2/S1 values are represented as the mean ± SEM of the 
means (N) or the mean ± SEM of the total number of replicate samples (n) observed from four 
experiments, depending on the analysis of variance; see Methods (Chapter 2) for details. Significant 
differences with respect to the controls are denoted by * P<0.05 and ** P<0.001. 
Hernicholinium was tested at three concentrations - 10ýM, 30ýM, and 100ýM as 
shown in Figure 3.11 and Table 3.5 above. All three concentrations show a 
significant increase in the S2/S1 ratio, although there is no evidence of a 
concentration-dependent effect. Concentrations 1 OýLM, 30ýM and 1 00ýM showed 
increases of 26%, 13% and 36% and no significant difference was observed 
between 30ý" (13%) and 1 00ýM (36%) HC-3 (P>0.05). 
3. Combination of the effects of hemicholinium and ChE inhibitors on K+- 
stimulated PHIACh release from rat hippocampal prisms. 
In the following Figures, significant differences are indicated with respect to release 
in the presence of HC-3 (1 OOVtM) or the ChE inhibitors alone, although these are 
statistically different from the controls as demonstrated previously (Tables 3.1-3.5 
and Figures 3.3,3.5,3.7,3.10 and 3.11). 
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Tacrine and HC-3 
As shown in Figure 3.12a, the effect of the combination of 30ýM tacrine and 100ýM 
HC-3 together is significantly greater (P<0.001) than that of 100ýM HC-3 alone. 
However when compared with 30ýM tacrine alone as in Figure 3.12b, the effect of 
the combination was not significantly different; P>0.05. See also Table 3.6. 
Eserine and HC-3 
Similar results for eserine are shown in Figures 3.13a and 3.13b. The S2/S1 ratios 
for 100ýM HC-3 alone compared with 100ýt! Vl HC-3 and 100ýM eserine together are 
significantly different (P<0.05) whereas no difference was observed between 1 00[tM 
eserine alone and 100ýtM HC3 and 100ýV eserine together (P>0.05). See also 
Table 3.6. 
Neostigmine and HC-3 
Neostigmine (100ýM) was also shown to have a significant effect on [3H]ACh 
release over and above the effect of 100ýM HC-3 as shown in Figure 3.14a 
(P<0.001) although 100ýM HC-3 was not seen to have an effect additional to that of 
100ýtM neostigmine (P>0.05) (Figure 3.14b). See also Table 3.6. 
Edrophonium and HC-3 
Similar to the ChE inhibitors mentioned above, the effect of 100ýM edrophonium 
together with 100ýM HC-3 was shown (Figure 3.15a) to be significantly greater than 
100ýM HC-3 alone (P<0.0001) although not significantly different when compared 
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Figure 3.11 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippcampal prisms - the 
effect of hernicholinium (HC-3) (10-1 OOpM). 
The prisms were stimulated twice (S1 and S2) for 2 min and HC-3 was added to the superfusion 
medium 10 min prior to and during the S2 stimulation. Each point represents the S2/S1 ratio as the 
mean ± SEM of means (N) or the mean ± SEM of the total number of replicate samples (n) observed 
from 4 experiments; see Table 3.5 for details. The control represents the mean ± SEM of means from 
all the experiments. Significant differences in the S2/S1 ratio compared to the control group are 



























[2] 100ýtM HC-3 
F7ý 1 MiM HC-3 + 30ýW tacrine 
Control 
30ýt! Vl tacrine 
30ýtM tacrine +1 MtM HC-3 
Figure 3.12 The S2/S1 ratios for K+-evoked release of [31-11ACh from rat hippocampal prisms - the 
effects of tacrine and HC-3, individually and in combination. 
a) HC-3 compared with HC-3 and tacrine together 
b) tacrine compared with HC-3 and tacrine together 
Each column represents the S2/S1 ratio as the mean ± SEM of means (N) obtained from 4 
experiments; see Table 3.6 for details. Significant differences in the S2/S1 ratio compared to HC-3 or 
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FI-71 100ýtM eserine 
F/5<71 1 00ýW eserine + 1004M HC-3 
Figure 3.13 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effects of eserine and HC-3, individually and in combination. 
a) HC-3 compared with HC-3 and eserine together 
b) eserine compared with HC-3 and eserine together. 
Each column represents the S2/S1 ratio as the mean ± SEM of means (N) obtained from 4 
experiments, - see Table 3.6 for details. Significant differences in the S2/S1 ratio compared to HC-3 or 



























P71 1 OOpM HC-3 +1 OOpM neostigmine 
Control 
100ýtM neostigmine 
1 00ýLM neostigmine +1 00ýLM HC-3 
Figure 3.14 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effects of neostigmine and HC-3, individually and in combination. 
a) HC-3 compared with HC-3 and neostigmine together 
b) neostigmine compared with HC-3 and neostigmine together. 
Each column represents the S2/S1 ratio as the mean ± SEM of the total number of replicate samples 
(n) obtained from 4 experiments; see Table 3.6 for details. Significant differences in the S2/Sj ratio 






















1 00ýLM HC-3 
1 00ýLM HC-3 +1 00ýW edrophonium 
ý Control 
F/-71 100ýLM edrophonium 
EZ] 1 00[tM edrophonium +1 00ýW HC-3 
Figure 3.15 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effects of edrophonium and HC-3, individually and in combination. 
a) HC-3 compared with HC-3 and edrophoniurn together 
b) edrophonium compared with HC-3 and edrophoniurn together. 
Each column represents the S2/S1 ratio as the mean ± SEM of the total number of replicate samples 
(n) obtained from 4 experiments; see Table 3.6 for details. Significant differences in the S2/S1 ratio 
compared to HC-3 or edrophonium alone are denoted by *P< 0.0001. 
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4. The effect of tacrine on [3H]A Ch release in reserpinized prisms. 
As shown in Figure 3.16a, the comparison of the S2/Sl ratios in reserpinised and 
untreated prisms - reserpinisation of the prisms has no effect on the S2/Sl ratio of 
[3H]ACh release (untreated S2/S1 0.706 ± 0.024 (n=18) and reserpinized S2/S1 
0.661 ± 0.034 (n=17); P>0.05). Furthermore Figure 3.16b shows that 30ýLM tacrine 
and 100ýM neostigmine potentiated [3H]ACh release in reserpinized prisms in a 
similar manner to that in untreated prisms. Tacrine and neostigmine increased the 
S2/S1 ratios by 45 and 67% (control S2/S1 0.712 ± 0.040 (n=1 1), 30ýM tacrine 
S2/Sl 1.035 ± 0.100 (n=14), P<0.001 and 100ýM neostigmine 1.191 ± 0.071 (n=15); 
P<0.001). 
The concentration-effect curve for the effect of tacrine on [3H]ACh release in 
reserpinised prisms is shown in Figure 3.17 and Table 3.7. In contrast to its effect in 
untreated prisms, 1 00ýM tacrine had no significant effect on [3H]ACh release in 
reserpinized prisms (P>0.05). An inhibition of 55% was observed with 200ýM tacrine 
- reserpinization had no effect on the inhibition of [3H]ACh release by tacrine at this 
concentration (P<0.0001), compare Figure 3.3. 
CONCENTRATION S2/Sl RATIO 
TACRINE CONTROL TACRINE 
30pM 0.712 ± 0.040 (N=4) 1.035 ± 0.100* (N=4) 
1 oopm 0.665 ± 0.013 (N=4) 0.614 ± 0.062 (N=4) 
200pM 0.655 ± 0.013 (N=4) 0.301 ± 0.021 ** (N=4) 
TABLE 3.7 
The effect of tacrine on K+-evoked PHIACh release from reserpinized hippocampal prisms. The 
test samples were superfused with tacrine 10 min prior to and during the S2 stimulation. The S2/S1 
values are represented as the mean ± SEM of means (N) observed from four experiments; see 
Methods (Chapter 2) for details. Significant differences with respect to the controls are denoted by 
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Reserpinised slices-control 
Reserpinised slices-100ý, M neostigmine 
Reserpinised slices-30pLM tacrine 
Figure 3.16 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of reserpinization. 
a) reserpinized prisms (see Chapter 2 for experimental details) compared with untreated (non 
reserpinized) prisms 
b) the effect of neostigmine and tacrine in reserpinized prisms. 
Each column represents the S2/S1 ratio as mean ± SEM of the total number of replicate samples (n) 
obtained from 3 to 4 experiments; see Results for details. Significant differences in the S2/S1 ratio 
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Control Tacrine concentration (ýM) 
Figure 3.17 The S2/S1 ratios of K+-evoked release of [3H]ACh from reserpinized rat hippocampal 
prisms (see Chapter 2 for experimental details) - the effect of tacrine. 
The prisms were stimulated twice (S1 and S2) for 2 min and tacrine was added to the superfusion 
medium 10 min prior to and during the S2 stimulation. Each point represents the S2/S1 ratio as the 
mean ± SEM of means (N) obtained from 4 experiments; see Table 3.7 for details. The control 
represents the mean ± SEM of means from all the experiments. Significant differences in the S2/S1 
ratio compared to the control group are denoted by *P<0.001 and ** P<0.0001. 
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5. The effect of tacrine on monoamine and 5-HT release and the effect of 
reserpinising the hippocampal prisms. 
The effect of tacrine on [3H]5-HT release. 
As shown in Figure 3.18, tacrine evoked a very marked increase in basal release of 
[3H]5-HT. At 100 and 200ýM concentrations tacrine caused 302 and 374% 
increases in basal [3H]5-HT release which were significantly greater than that 
evoked by 30mM KI. Tacrine-evoked release was completely abolished in 
reserpinized prisms. Similarly, the unstimulated basal release of [3H]5-HT was 
greatly reduced in the reserpinized prisms and K+-evoked release was also 
completely abolished (Figure 3.18). 
The effect of tacrine on PHINA release. 
At 100ptM concentrations, tacrine produced a 87% increase in basal release. This 
effect was completely abolished in the reserpinized prisms. Furthermore, the 
unstimulated basal release of the untreated (non reserpinized) prisms is significantly 
greater than in the reserpinized prisms. The K+-stimulated release of [3H]NA from 
the reserpinized prisms was completely abolished (Figure 3.19). 
The effect of tacrine on PHIDA release 
Tacrine at 100ýiM produced a 96% increase in the basal release of [3H]DA, which 
was totally abolished in the reserpinized prisms. As with [3H]NA, basal release from 
these prisms was markedly lower than that of the untreated prisms. The K+-evoked 
release was also greatly reduced if not abolished from the reserpinized prisms 
(Figure 3.20). 
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-m- Untreated slices-100ýM tacrine 
-*-Untreated slices-200ýW tacrine 
-A- Reserpinised slices-100ýW tacrine 
-v- Untreated slices- K+ stimulation 
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Figure 3.18 The effect of tacrine and 30mM K+ on [3H]5-HT release from reserpinized (see Chapter 
2, Methods for experimental details) and untreated (non reserpinized) rat hippocampal prisms. 
The prisms were stimulated twice (S1 and S2) for 2 min with tacrine (Sl) and K+ (S2). Each point 
represents release as the mean ± SEM of 6 replicate samples obtained from a typical experiment and 
expressed as CPM. 
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-m- Untreated slices -1 OOpM tacrine 
-e- Reserpinised slices -1 OOpM tacrine 
-A- Untreated slices - K' stimulation 
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Figure 3.19 The effect of tacrine and 30mM K+ on [3H]NA release from reserpinized (see Chapter 2, 
Methods for experimental details) and untreated (non reserpinized) rat hippocampal prisms. 
The prisms were stimulated twice (S1 and S2) for 2 min with tacrine (Sl) and K+ (S2). Each point 
represents release as the mean ± SEM of 6 replicate samples obtained from a typical experiment, 
expressed as CPM. 
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-m- Untreated slices -1 00kiM tacrine 
-e- Reserpinised slices - 100ýt! Vl tacrine 
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Figure 3.20 The effect of tacrine and 30mM K+ on [3H]DA release from reserpinized (see Chapter 2, 
Methods for experimental details) and untreated (non reserpinized) rat hippocampal prisms. 
The prisms were stimulated twice (S1 and S2) for 2 min with tacrine (Sl) and K+ (S2). Each point 
represents release as the mean ± SEM of 6 replicate samples obtained from a typical experiment, 
expressed as CPM- 
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6. The effect of the ChE-inhibitors eserine., neostigmine and edrophonium on 
monoamine and 5-HT release. 
[3H]5-HT release 
Again, concentrations of 100ýM were tested for all three ChE-inhibitors. While 
esenne had no significant effect, neostigmine and edrophonium produced increases 
of 58% and 45% of the basal release of [3H]5-HT (Figure 3.21). These increases 
were small compared to that of 302%, seen with tacrine at similar concentration 
(Figure 3.18). 
PH]NA release. 
All three ChE-inhibitors were tested at their maximum effective concentration of 
I 00ýM. Eserine and neostigmine had no effect on basal [3H]NA release. 
Edrophonium however, caused a 39% increase (Figure 3.22). 
7. The effect of the ChE-inhibitors and HC-3 on [3H]QNB binding in whole 
membrane preparations from rat hippocampus. 
The ChE-inhibitors tacrine, e serine, neostigmine and edrophonium showed a 
concentration-dependent inhibition of [3H]QNB binding (Figure 3.23). From the data 
presented tacrine appears to have the highest affinity for the muscarinic receptor 
binding sites. The affinity of HC-3 to these binding sites is comparable to the ChE- 
inhibitors eserine, neostigmine and edrophonium. Atropine was used to define 
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100ýtM neostigmine 
100ýtM edrophonium 
Figure 3.21 The effect of the ChE-inhibitors eserine, neostigmine and edrophonium on [3H]5-HT 
release from rat hippocampal prisms. 
The tissue prisms were superfused with each of the ChE-inihibtors for 2 min. Each point represents 
release as the mean ± SEM of replicate samples obtained from a typical experiment, represented as: 
a) CPM 
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Figure 3.22 The effect of the ChE-inhibitors eserine, neostigmine and edrophonium on [3HINA 
release from rat hippocampal prisms. 
The tissue prisms were superfused with each of the ChE-inihibtors for 2 min. Each point represents 
release as the mean ± SEM of replicate samples obtained from a typical experiment, represented as: 
a) CPM 
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Figure 3.23 Displacement of [3H]QNB binding in rat hippocampal membrane preparations by ChE- 
inhibitors and HC-3. 




The potentiation of [3H]ACh release by the ChE inhibitors 
The results presented in this chapter represent the first systematic comparison of the 
concentration-effect relationship for structurally different ChE-inhibitors acting to 
potentiate the K+-evoked release of ACh in rat hippocampal prisms. The ChE- 
inhibitors tacrine, eserine, neostigmine and edrophonium all produce clear increases 
in KI-evoked [3H]ACh release from hippocampal prisms (Figures 3.1 - 3.10) despite 
previous conflicting reports (see Introduction to this chapter). 
These increases were concentration dependent with neostigmine and edrophonium in 
the range 10-200ýM. Eserine however, gave no further increase in effect at 
concentrations above 10ýM. Taken together, the S2/Sl ratios obtained (Figures 3.3 - 
3.15) show no clear distinction in potency between the ChE-inhibitors in promoting 
[3H]ACh release. Their potencies as enzyme inhibitors however have been reported 
to differ widely. Thus the IC50 of neostigmine in 30 min incubations with human brain 
ChE, is smaller, by one and two orders of magnitude than that of tacrine and 
edrophonium respectively. The IC50s for tacrine, eserine, neostigmine and 
edrophonium are 0.24ýM, 72nM, 35nm and 3.7ýN respectively. (Atack et al., 1989). 
It would appear therefore, that the concentrations of the ChE-inhibitors and reaction 
times employed in the present release experiments, are sufficient to cause full 
inhibition of ChE during the 12-min exposure to the tissue. More interestingly however 
these release experiments show no clear difference between the effects of the two 
ChE-inhibitors likely to be restricted to extracellular actions and the two likely to have 
additional intracellular actions. 
In comparison with the other three ChE-inhibitors, tacrine at concentrations above 
50VtM showed clear inhibition of [3H]ACh release, as shown in Table 3.1 and Figures 
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3.2 & 3.3. Interestingly, bell-shaped dose-response curves for the memory-enhancing 
effects of tacrine have also been observed in animal studies (Nielsen et al., 1999). 
The inhibition of release observed with tacrine is in agreement with many previous 
observations where tacrine inhibited the electrically stimulated release of [3H]ACh in 
cortical (Drukarch et al., 1987; Loiacono & Mitchelson, 1990), striatal (Drukarch et al., 
1987; Buyukuysal & Wurtman, 1989) and hippocampal (Buyukuysal & Wurtman, 
1989; Potter et al., 1989) tissue. It has been proposed that ChE-inhibitors such as 
eserine and tacrine might inhibit the release of [3H]ACh from brain slices by activating 
presynaptic autoreceptors in response to increased concentrations of ACh in the 
synaptic cleft (Nilsson et al., 1987; Szerb & Somogyi, 1973). However all four ChE- 
inhibitors clearly increased [3H]ACh release in the present experiments and to 
approximately the same extent. It is difficult therefore to see how increased 
concentrations of extracellular ACh, caused by tacrine could activate autoreceptors 
sufficiently to cause overt inhibition of release, while similar increases in extracellular 
ACh caused by the other inhibitors did not cause similar inhibition. The present 
results therefore make it clear that tacrine exerts some additional effect not caused 
by the other ChE-inhibitors. 
The increase in K+-evoked release caused by these ChE inhibitors may be thought to 
be due to the accumulation of [3H]ACh in the synaptic cleft as a result of the inhibition 
of its hydrolysis, since extracellular [3H]ACh is not transported by choline carriers 
(Simon et al., 1975). It would therefore be available for collection in the tissue 
superfusates, unlike the [3H]choline formed as a result of its hydrolysis, in the 
absence of ChE inhibitors. An appreciable percentage of [3H]choline formed in this 
way in the synapse would be expected to be less susceptible to collection because it 
would be transported into the intact cells in the tissue prisms. Bearing this in mind, it 
was considered that hemicholinium-3 (HC-3) might have a comparable or even 
greater effect on the S2/Sl ratio than did the ChE inhibitors. 
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As expected HC-3 alone at concentrations of 10-100ýM gave significant increases in 
the S2/S1 ratio, although perhaps surprisingly these increases were not as marked 
as those caused by the ChE inhibitors alone (Figure 3.11). It is likely that this 
increase in S2/S1 ratio reflects the [3H]choline accumulated, as a result of the 
hydrolysis of the released [3H]ACh, and the inhibition of its transport, since it has 
been shown that [3H]choline efflux does not increase during stimulation (see Chapter 
2, General Methods and Materials). Interestingly the inclusion of a ChE-inhibitor with 
HC-3 gave a further significant increase over and above that caused by HC-3 alone 
(Figures 3.12a-3.15a). This effect was consistently observed with all four ChE- 
inhibitors. In contrast, each combination of HC-3 and ChE inhibitor gave no greater 
increase in S2/Sl ratio than was obtained with the corresponding ChE inhibitors 
acting alone (Figures 3.12b-3.15b). These results indicate that the observed effect of 
the ChE-inhibitors is not entirely due to the inhibition of cholinesterase and the 
resulting accumulation of [3H]ACh in the tissue extracellular space. It would appear 
therefore that the ChE-inhibitors have an additio nal direct effect in promoting [3H]ACh 
release. 
A previous study by Umeda and Sumi (1990), similarly examined the effects of HC-3 
and eserine on basal and K+-stimulated release of unlabelled ACh from striatal and 
hippocampal slices. Release was evoked into a fixed volume of K+-enriched 
incubation medium, rather than into medium superfusing slices. It was shown that 
HC-3 (100ýM) and eserine (20ýM) independently increased the basal and K+- 
stimulated release of ACh although together, they caused an additive effect on the 
stimulated release of ACh. This is partly similar to the results reported here with the 
superfusion method, where the effect of HC-3 (100ýM) and eserine (10OVtM) in 
combination was clearly and significantly greater than HC-3 (100[tM) alone but not 
greater than 100ýM eserine. A point of difference is that the present experiments 
show no effect of HC-3 or ChE-inhibitor on basal release. 
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HC-3 is a well known, potent inhibitor of high affinity choline uptake into nerve 
terminals and has been shown to decrease ACh release gradually by attenuating 
synthesis, which depends predominantly, if not entirely on the choline uptake from 
extracellular fluid (Kuhar & Murrin, 1978; Tedford et aL, 1986). The present results 
show no evidence that the brief incubations (12 min) with HC-3 reduce the availability 
of [3H]ACh for release. It is important to remember that the prisms are preloaded with 
[3H]choline some 2h before release is initiated. HC-3 added after these 2h will be 
unable therefore, to cause a significant reduction in the quantity of [3H]ACh available 
for release. 
To the contrary, it can be argued that the HC-3 eventually added to the superfusing 
medium, will reduce ongoing ACh synthesis from largely unlabelled choline. In the 
absence of HC-3, choline will continue to be released and reuptaken into the prisms 
after excess [3H]choline has been removed by washing the tissue (Chapter 2). HC-3 
could be seen therefore, as increasing the availability of [3H]ACh for release by 
reducing its gradual dilution with unlabelled ACh. It could be that prevention of 
'radiolabel-dilution' contributes to the potentiation by HC-3 of the [3H]ACh release 
actually observed, and more conventionally ascribed to block of the reuptake of 
[3H]choline. However the contribution of this second mechanism is likely to be small, 
since in the present experiments HC-3 is only in contact with the tissue for 12 min, 
after 84 min (see Chapter 2) of release and uptake of predominantly unlabelled 
choline. 
HC-3 is also known to have muscarinic receptor blocking properties (Bieger et al., 
1968; Bertolini et al., 1967; Madden & Mitchelson, 1975). It is possible therefore that 
it promotes ACh release by direct block of presynaptic muscarinic autoreceptors, 
which are believed to cause feedback inhibition of ACh release upon activation. 
However this seems unlikely since atropine (10ýM), which alone has no effect on K+- 
evoked [3H]ACh release, is demonstrated in Chapter 5 to increase further, the 
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release of [3H]ACh in the presence of ChE-inhibitors. As discussed previously HC-3 
did not increase the S2/Sl ratio in the presence of any of the ChE-inhibitors tested 
(Figures 3.12b - 3.15b). 
ChE-inhibitors (e. g eserine and soman) acting in peripheral synapses such as those 
in the skeletal muscle for a prolonged period of time (usually over 1 h), have been 
shown not only to preserve the release of ACh but also to cause a gradual rise of the 
ACh content in the tissue (Molenaar et aL, 1987) in resting or stimulated conditions, 
by penetrating the nerve terminal. The extra amount of ACh accumulating after ChE 
inhibition is referred to as 'surplus ACh', to be differentiated from the 'depot ACh' 
(ACh store) normally involved in synaptic transmission. Molenaar et al., (1987), 
concluded from their studies that the surplus ACh is synthesized and stored in the 
motor nerve endings and is the main source of the resting (basal) release of ACh. In 
agreement with previous observations they were also able to demonstrate that 
surplus ACh was not released by nervous impulses but was partially released by high 
concentrations of KCI applied for long periods of time (50mM, for 60 min), in a Ca2+ 
dependent way. Similar findings have also been shown by Collier and Katz (1971) for 
the superior cervical ganglion although in the brain, surplus ACh has not been 
demonstrated (Bourclois & Szerb, 1972). The possibility that 'surplus ACh' may 
contribute to the increased KI-evoked [3H]ACh release following the action of the 
cholinesterases, was however still considered. 
A number of observations argue against the above interpretation. First, there was no 
evidence of an increase in basal or resting release following the addition of the ChE- 
inhibitors 10 min before the S2 stimulation. Second, the ChE-inhibitors neostigmine 
and edrophonium also increased [3H]ACh release. These ChE-inhibitors being 
quaternary ammonium compounds are permanent cations and are likely to have 
limited access if any, into nerve terminals especially during short periods of 
superfusion. They would therefore be expected to act predominantly extracellularly, 
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rather than on the intracellular stores. Moreover the time period for such an 
accumulation of 'surplus ACh' might be expected to be greater than 12 min, as 
previous reports suggest. It was also observed (Figure 3.8b) that superfusion of the 
slices with neostigmine for only 2 min during the S2 stimulation, still increased the 
release of [3H]ACh. It appears unlikely therefore, that surplus ACh contributes to the 
increase in release caused by the ChE-inhibitors reported in this chapter. 
Another possibility which may contribute to the increase observed in the S2/S1 
release ratio is an increase in [3H]choline efflux either by a direct action of the ChE 
inhibitor itself or indirectly, by elevated synaptic [3H]ACh concentrations activating 
presynaptic muscarinic receptors. Ladinsky et al. (1974) demonstrated that 
oxotremorine and eserine increased tissue choline levels not only in ACh rich areas in 
mouse brain, but also in tissues such as spleen and cerebellum which contain no 
ACh, or very low levels. They concluded that feedback inhibition was not a necessary 
requirement for raising choline levels, since DFP (dyflos) was without effect. It was 
also argued that decreased turnover of ACh (retarded incorporation of choline into 
ACh following inhibition of release) was unlikely to be the cause as oxotremorine 
increased choline levels even in the spleen which contains no ACh as far as is known 
(Ladinsky et al., 1974). Similar observations have been made using rat striatal slices, 
treated with high concentrations of oxotremorine (1,5mM) or ACh (lmM, after 
treatment with ChE inhibitors) for prolonged incubation times (20 min) (Dolezal & 
Tucek, 1984). It was concluded by these investigators that stimulation of muscarinic 
receptors increased extracellular choline concentrations by an effect on intracellular 
phospholipid metabolism. 
In contrast to the above, studies by Weiler (1989) on the release of endogenous ACh 
from striatal slices pretreated with ChE inhibitors have demonstrated that choline 
release during ChE inhibition was unchanged during K+ depolarisation when 
compared to that released spontaneously. Furthermore, it was shown that choline 
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efflux actually decreased in the presence of the muscarinic agonist oxotremorine-M at 
concentrations in the micromolar range. The discrepancy between Weiler's results 
and those described above has been attributed to the experimental conditions 
(Weiler, 1989). The stimulation time was longer where increased choline efflux was 
observed, (Brown et aL, 1988; Lindmar et aL, 1986; Dolezal & Tucek, 1984) and the 
concentrations of the muscarinic agonists were also much larger than those used in 
Weilert study. The conditions used in this present study and described in Chapter 2 
are more comparable to Weiler's, where the exposure to high K+ was only for a 
period of 5 min. 
Furthermore, the data presented in this chapter are not compatible with an increase 
in [3H]choline efflux contributing to the increase of K+-evoked release observed in the 
presence of the ChE inhibitors. [3H]Choline released would be susceptible to 
reuptake so that full potentiation by ChE inhibitors would only be evident in the 
presence of HC-3. The results in fact show (Figures 3.12b - 3.15b), that HC-3 in the 
presence of the ChE inhibitors did not increase the potentiation of release any further. 
It is therefore concluded that the increase in the S2/S1 release ratios, observed in the 
presence of the ChE inhibitors, is unlikely to be due to an increase in [3H]choline 
efflux. 
It would appear therefore that under the present experimental conditions, the ChE 
inhibitors may have some unknown activity stimulating ACh release. Previous reports 
suggesting that eserine and neostigmine have actions other than those of inhibition of 
ChE enzymes, seem to support this notion. Bell (1966), found that eserine (10 and 
100ptg/ml) produced an increase in tone of the innervated toad bladder, by releasing 
acetylcholine from cholinergic nerve endings. A similar mechanism of action for the 
eserine-induced spasm of guinea-pig trachealis muscle was proposed by Carlyle 
(1963). Neostigmine has been shown to stimulate sympathetic ganglia (Mason, 
1962a & b) and also to act in a similar way to eserine on the guinea-pig trachealis 
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muscle (Carlyle, 1963). Cox and Lomas (1972), investigated more fully the 
pharmacological actions of these two drugs, by studying the concentration-effect 
relations on the guinea-pig isolated ileum. It was concluded that the eserine and 
neostigmine-induced spasms of the ileum smooth muscle were concentration-related 
and due to an indirect action involving the release of ACh from cholinergic nerves. 
However the inhibition of ChE appeared not to be important for this action as 
experiments with dyflos, at a concentration that completely inhibited the ability of 
ileum homogenate to hydrolyse ACh, did not modify either the eserine or neostigmine 
dose-response plots. It was thus concluded, like this present chapter, that the higher 
levels of ACh obtained in release experiments might be related to a mechanism other 
than the efficient inhibition of ChE. It is interesting to note that this conclusion, 
separately arrived at, has practical implications. It must be borne in mind that ACh 
release measured in the presence of ChE-inhibitors differs from physiological release 
by the superimposition of at least two pharmacological mechanisms and would 
therefore be best treated with extreme caution. 
The inhibition of [3H]ACh release by high concentrations of tacrine 
As mentioned previously in this discussion, tacrine at concentrations above 50ýM 
showed an inhibition of [3H]ACh release - represented in its bell-shaped 
concentration-effect curve (Figure 3.3), which is quite unlike those of the other ChE- 
inhibitors (Figures 3.4 - 3.10). At a concentration of 100ýM, tacrine caused a 21% 
reduction of the S2/S1 ratio below control values (P<0.001). At 200ýt! Vl tacrine, the 
reduction was far greater, 66% below control values (P<0.0001). As concluded earlier 
in this discussion, inhibition of this magnitude cannot be ascribed to feedback 
inhibition caused by elevated concentrations of ACh even though previous authors 
have implicated muscarinic cholinoceptors in this role. However a direct action of 
tacrine itself on such receptors should be considered. 
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To cause such inhibition, tacrine would have to act presynaptically as a muscarinic 
agonist. The [3H]QNB-displacement curves (Figure 3.23) show tacrine to have 
appreciably stronger muscarinic receptor binding properties than the other ChE- 
inhibitors. However tacrine has been shown to inhibit the carbachol-stimulated 
hydrolysis of phosphatidylinositol (PI) in cortical slices (Freeman & Dawson, 1991). 
This suggests tacrine to be a muscarinic receptor antagonist rather than an agonist, 
even though there is evidence that PI hydrolysis is stimulated via muscarinic 
receptors other than those controlling ACh release (Hulme et al., 1990). It is possible 
that muscarinic receptor blocking properties of tacrine and such compounds may play 
a role in potentiating ACh release. Muscarinic actions of tacrine are discussed further 
in Chapter 5. However alternative mechanisms by which tacrine might inhibit ACh 
release are considered below and in Chapter 4. 
The interaction of tacrine with monoamines and 5-HT 
In addition to its inhibitory effect on AChE and its interaction with muscarinic 
cholinoceptors, tacrine has also been shown to influence monoamine (Drukarch et 
al., 1988) and GABA release (De Belleroche & Gardiner, 1988). Drukarch et al., 
(1988), have shown tacrine to release [3H]NA and [3H]5-HT from cortical slices and 
[3H]DA from striatal slices and similar observations have been made by Robinson et 
al., (1989). The results in this present chapter show that tacrine at 1 00ýLM and 200ýM 
concentrations, is also capable of producing direct release of [3H]DA, [3H]5-HT and 
[3H]NA from hippocampal prisms in the absence of depolarization by K+ (Figures 
3.18 - 3.20). Furthermore the effect of tacrine on basal [3H]5-HT release was 
significantly greater than the release evoked by 30mM K+ (Figures 3.18). In 
comparison, while edrophonium showed comparable [3H]NA releasing properties, 
neostigmine and eserine lacked effect on basal release (Figure 3.22). it was also 
observed that neostigmine and edrophonium caused release of [3H]5HT, while 
eserine had no effect (Figure 3.21). For these reasons, a number of release 
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experiments included the pretreatment of the hippocampal prisms with 300nM 
reserpine, in order to reduce as far as possible, the influence of monoamines on ACh 
release. It was shown that reserpinization of the prisms abolished the effect of tacrine 
on basal release and also greatly diminished the K+-evoked release of [3H]5-HT, 
[3H]NA and [3H]DA (Figures 3.18 - 3.20). 
A number of in vitro and in vivo studies have shown ACh release to be modulated by 
nerve terminal heteroreceptors for 5-HT, DA and NA. While most in vivo studies using 
microdialysis consistently demonstrate that the release of hippocampal ACh is 
enhanced by DA and 5-HT (Ohue et aL, 1992a & b), many in vitro studies have 
shown that 5-HT receptors mediate inhibition of ACh release in cortical and 
hippocampal tissue from rat and human brain (Maura & Raiteri, 1986; Barnes et al., 
1989; Maura et al., 1992). In the rat hippocampus, 5-HT receptors of the 5-HT1B 
subtype have been shown to inhibit the depolarization-evoked release of [3H]ACh 
(Maura & Raiteri, 1986). It is reported that tacrine however, does not display any 
affinity for adrenergic, doparninergic or serotonergic receptors at concentrations 
which release [3H]NA, [3H]DA or [3H]5-HT (Drukarch et al., 1988). 
Reserpinization of the prisms prior to release of [3H]ACh however, had no effect on 
either the S2/S1 ratios for control release (Figure 3.16a), or the tacrine-induced 
potentiation (30ýM) and inhibition (200ýM) (Figure 3.17) of [3H]ACh release. The 
concentration-effect curve for tacrine (Figure 3.17) is virtually identical to that in non- 
reserpinized slices (Figure 3.3). Potentiation by neostigmine remained at levels 
comparable with those in non-reserpinized slices (Figure 3.16b). It is therefore 
concluded that inhibition of [3H]ACh release by tacrine, is unlikely to be due to an 
interaction with the monoamines NA, DA and 5-HT. Similarly it is unlikely that 
potentiation of [3H]ACh release by ChE-inhibitors is due to an interaction with 5-HT, 
NA or DA, since neostigmine (100ýM) and tacrine at 30ýM were still able to increase 
the release of [3H]ACh in reserpinized slices as shown in Figure 3.16b. Moreover 
135 
eserine, which does not affect the basal release of [3H]5-HT or [3H]NA (Figures 3.21 
& 3.22) like tacrine or edrophonium, is just as effective at potentiating [3H]ACh 
release in untreated slices (Figures 3.1 - 3.10). 
The results presented in this chapter quite clearly show that the ChE inhibitors 
tacrine, eserine, neostigmine and edrophonium potentiate the release of K+-evoked 
[3H]ACh from hippocampal prisms. Furthermore it was also shown that tacrine unlike 
the other ChE-inhibitors, caused inhibition of [3H]ACh release at high concentrations. 
The mechanism of action which causes the potentiation and inhibition of K+-evoked 
[3H]ACh release is however unknown as yet and remains to be elucidated. As 
discussed above, the inhibition and potentiation of [3H]ACh release was not due to 
the release of monoamines or 5-HT by tacrine and the other ChE-inhibitors. It was 
also argued that the inhibition by tacrine was not due to muscarinic autoreceptor- 
mediated feedback inhibition by [3H]ACh. However tacrine has also been shown to 
interact with a number of other receptor systems such as muscarinic, nicotinic, 
phencyclidine (PCP), adenosine and histamine receptors (Nordberg et al., 1989). The 
aim of the following chapters therefore, was to compare the effects, on ACh release, 
of compounds known to have PCP, muscarinic or nicotinic actions with those of 
tacrine and the other ChE-inhibitors. 
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CHAPTER 4 




In the experiments described in Chapter 3 it was shown that the ChE-inhibitors 
tacrine, eserine, neostigmine and edrophonium all potentiate the K+-evoked release 
of [3H]ACh from hippocampal prisms. However it was also noted that at higher 
concentrations, tacrine, unlike the other ChE-inhibitors, caused a marked inhibition of 
release. As discussed in Chapter 3, tacrine has been shown to interact with 
muscarinic receptors as well as with a variety of other receptors. Previous studies 
investigating tacrine and the other ChE-inhibitors have suggested that they interact 
with the phencyclidine (PCP) site linked to the NMDA (N-methyl-D-aspartate) 
receptor channel complex. The aim of the work described in this chapter was to 
investigate the effects of PCIP and PCP-like compounds on [3H]ACh release and their 
interaction with the aforesaid ChE-inhibitors. 
Binding studies have demonstrated that tacrine and to a lesser degree eserine, 
neostigmine and edrophonium, all displace [3H]TCP ( N-[l-(2-thienyl)cyclohexyl]-3,4- 
[3H]piperidine), a radioligand specific for the PCP site, in rat brain homogenates 
(Albin et al., 1988). Clinical studies have also shown that tacrine reduces the duration 
of anaesthesia and emergence symptoms associated with dissociative anaesthetics 
such as PCP and ketarnine, suggesting an antagonistic effect of tacrine (Albin et al., 
1974). However observations made from in vitro studies using murine cortical 
cultures, suggest that the neuroprotective effects of tacrine against the NMDA- 
mediated toxicity, may possibly be due to a PCP-like action, resulting in the blockade 
of the NMDA channel (Davenport et al., 1988). The cholinesterase inhibitors eserine, 
neostigmine and edrophonium also showed partial neuroprotection at similar 
concentrations in the same study. Furthermore PCP, ketamine, MK-801 and also the 
I cy opiates' N-allylnormetazocine (SKF 10047 or NANM) and cyclazocine have all 
been found to share the ability of antagonizing the neuroexcitatory effects of NMDA 
on central neurons (Anis et aL, 1983; Davenport et al., 1988; Berry et al., 1984). It 
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has been suggested that tacrine may be exerting some of its clinical effects through a 
mixed agonist-antagonist interaction at the PCP site (Davenport et aL, 1988). 
It is now well known that the PCP site is part of the NIVIDA receptor complex and it 
has also been shown that PCP-type ligands antagonize the neuroexcitatory effects of 
NIVIDA on central neurons possibly by blocking the open NIVIDA channel (cited in 
Davenport et aL, 1988). However the neurochemical mechanisms of action of PCP 
are widespread and it has also been shown to interact with dopaminergic and 
cholinergic systems. PCP-induced stereotypy, turning behaviour and locomotor 
activity indicate that PCP may act by indirectly releasing dopamine (Leventer & 
Johnson, 1983). At a biochemical level PCIP has been shown to inhibit competitively, 
both butyryl and acetylChE (Leventer & Johnson, 1983). PCP has also been shown 
to antagonize the action of ACh at muscarinic receptors in the guinea pig ileum 
(Leventer & Johnson, 1983) and also to displace the nicotinic channel blocker 
[3H]perhydrohistrionicotoxin ([3H]Hl2-HTX) (Eidefrawi et al., 1981). Furthermore 
PCP has also been shown to affect ACh release from different areas of the brain. 
There is evidence that it inhibits the K+-evoked [3H]ACh release in the striatum 
(Leventer & Johnson, 1983) and others have reported that it has no effect (Junien et 
al., 1991) and also that it potentiates (Jackisch et al., 1987) depolarization-evoked 
[3H]ACh release in the hippocampus. 
Until recently, PCIP sites were thought to be identical to a binding sites, based on a 
number of findings. For example benzomorphans such as NANM, cyclazocine and 
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pentazocine, in addition their antagonist activity at the NMDA receptor complex, were 
also shown to induce psychotomimetic effects similar to PCP in humans (cited in 
Campbell et al., 1989; Haertzen, 1970). Further behavioural studies demonstrated 
that PCIP generalized to (+)NANM in drug discrimination tests (Holtzman, 1982; 
Shannon, 1982) and radioligand binding studies showed that the pharmacological 
specificity of [3H]PCP and [3H](+)NANM binding sites was similar (Mendelsohn et al., 
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1985). Hence the single receptor site for PCIP analogs and psychotomimetic 
benzomorphans was designated the 1(y/PCPreceptor. 
The existence of a binding sites was first proposed following the observation that 
opiate benzomorphans induced unique behavioural effects in the chronic spinal dog. 
Martin and coworkers reported that benzomorphans such as NANM, cyclazocine and 
pentazocine, induced a characteristic pattern of 'canine delirium' identified by 
stereotyped head movements, nystagmus, vocalization and restlessness which 
distinguished these compounds from morphine-like and ketocyclazocine-like opioids 
(Martin et aL, 1976; Gilbert & Martin, 1976). Moreover it was also observed that the 
effects of these drugs showed stereoselectivity that was the reverse of the classical 
opiate effects and were not abolished by the opiate antagonist naloxone (Brady et al., 
1982). Further studies indicated that the psychotornimetic effects elicited by the 
benzomorphans were similar to those induced by PCIP (Brady et al., 1982; Brent, 
1991; Vaupel, 1983). 
Evidence for the existence of separate PCP and a sites was provided by 
autoradiographic and ligand binding studies (Largent et al., 1984a). It was shown by 
comparison of the rank order potencies of several drugs for the inhibition of the 
binding of (+)[3H]NANM and [3H]TCP, that these sites were considerably different. 
Moreover the drug selectivity pattern of [3H]NANM was obse rved to differ from that of 
[3H]PCP showing that these drugs bind to different receptors. For example certain 
antipsychotics such as haloperidol were shown to displace [3H]NANM with high 
affinity whereas haloperidol was inactive against [3H]PCP binding; conversely PCP 
was shown to be weak against [3H]haloperidol binding (Walker et al., 1990). It was 
clear from these studies that [3H]NANM binds at two distinct sites; a haloperidol 
sensitive site known as the a site and a PCP site. 
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With the development of selective cr ligands such as (+)-3-(3-hydroxyphenyl)-N-(l - 
propyl)piperidine ((+)-3-PPP) (Largent et aL, 1984b) and 1,3-di-o-tolylguanidine 
(DTG) (Weber et aL, 1986) which have negligible affinity for the PCP binding site, 
identification of distinct (T binding sites was made possible in brain tissue thus 
distinguishing the a and the PCP binding site as distinct physical entities. Largent et 
al., (1986) described a cell line (NCB-20 hybrid neurotumor cells) which is labelled by 
(+)[3H]NANM and (+)[3H]3-PPP but not by [3H]PCP. More evidence has 
accumulated from drug discrimination tests in which PCIP failed completely Jo 
generalize to (+)-pentazocine (Steinfels et aL, 1988) and also from ontogenic studies 
showing divergent postnatal development of a and PCP binding sites (Majewska et 
aL, 1989). Thus it is now widely accepted that cy binding sites are distinct from PCIP 
receptors. The cy binding site is currently defined as a non opioid, binding site 
exhibiting a high affinity for haloperidol, DTG, (+)3-PPP and (+)NANM (Quirion et aL, 
1987). 
Autoradiographic studies of rat and guinea pig brain have shown that the distribution 
of a binding sites is distinct from any other known neurotransmitter receptor. 
Preferential localization has been observed, of (+)-[3H]3-PPP binding sites in the 
pyramidal cells of the hippocampus, hypothalamus, choroid plexus, the ganglia of the 
ponticular region and the purkinje cells of the cerebellum (Gundlach et al., 1986b). 
[3H]DTG binding sites are also concentrated in the limbic and sensory-motor 
structures (Weber et al., 1986). Areas in the forebrain include the diagonal band of 
Broca, the septum, the paraventricular nucleus of the hypothalamus, the anterodorsal 
thalarnic nucleus, the zona incerta and the reticulum of the thalamus. Sigma binding 
sites are also found in the midbrain (the dorsal raphe and the substantia nigra) and in 
the hind brain (the locus coeruleus) (Weber et al., 1986). In addition to its distribution 
in the brain, cy binding sites have also been found in endocrine organs such as the 
pituitary, adrenal, testis, ovary (Wolfe et al., 1989) and also in the rat heart (Dumont 
& Lemaire, 1991), guinea pig ileum (Roman et al., 1988) and vas deferens (Vaupel & 
141 
Su, 1987) and at high concentrations in the membrane fractions of the spleen, liver 
and on lymphocytes (Itzhak et al., 1990 & 1991). Furthermore the subcellular 
distribution of the cr binding sites appears to be different from typical neurotransmitter 
receptors -a high concentration of cy binding sites have been found in the plasma 
membrane and also in the mitochondrial and microsomal fractions of cell 
homogenates (Itzhak et aL, 1991). 
Sigma activity has been implicated in numerous studies of all types. Several 
bioassays have been employed in order to define a physiological function for these cy 
binding sites. Sigma modulation of smooth muscle contraction has been observed in 
the guinea pig ileum where a binding sites have been described in the longitudinal 
muscle/ myenteric plexus (LMPP) preparation (Campbell et al., 1989). DTG and its 
congeners inhibited contractions evoked by electrical stimulation or by 5-HT in a 
manner which correlated well with their binding affinities. This inhibition of evoked 
contractions was suggested to be due to the inhibition of ACh release and not a direct 
effect on muscarinic receptors in the LMMP preparation (Campbell et al., 1991). 
(+)NANM, however was shown to have the opposite effect of potentiating the 
stimulated contractions in the same preparation (Campbell et al., 1989) - the reason 
for this remains unclear. Electrophysiological studies have demonstrated an inhibition 
of KI currents by a ligands (VVu et aL, 1990). Data obtained from single cell voltage 
clamp studies performed on NCB-20 cells were shown to display an excellent 
correlation with the binding affinities observed in the same cells as well as those 
obtained previously in the isolated guinea pig vas cleferens assay (Vaupel & Su, 
1987), where (5 ligands have been shown to potentiate electrically induced 
contractions. 
Biochemical studies have shown cy ligands to have an inhibitory effect on carbachol- 
and noradrenaline-stimulated phosphaticlylinositol metabolism (Candura et al., 1990). 
Although some cy ligands have low affinity for muscarinic receptors, there is evidence 
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for the involvement of c; binding sites in i nositol phosphate turnover. Sigma ligands 
show reduced ability to inhibit the oxotremorine-M stimulated inositolphosphate 
response in three cyl-deficient cell lines, indicating the relevance of cyl sites in this 
inhibitory mechanism (Bowen et aL, 1991). Sigma ligands have also been shown to 
reverse the increases in cGMP mediated by the NMDA receptor complex (Rao et al., 
1991). 
Behavioural studies demonstrate that a binding sites also appear to play a role in the 
regulation of movement and posture. Microinjection of various a ligands into the red 
nucleus of rats have been shown to produce marked alterations in posture and tone 
(Walker et aL, 1990) resembling the motor alterations observed in humans following 
neuroleptic treatment. The potency of these a ligands in producing postural effects 
was highly correlated with their affinity for a receptors. Also microinjection of cr 
ligands in the substantia nigra was shown to produce contralateral circling, an effect 
eliminated by 6-hydroxydopamine lesions of nigral cells (Walker et al., 1990). DTG 
was shown to be the most potent in producing this effect. Benzomorphan a ligands 
have also been shown to stimulate dopamine synthesis in the rat corpus striatum 
(Booth & Baldessarini, 1991). These findings implicate modulation by (T binding sites 
of central dopaminergic function and is supported by the localization of cy binding sites 
in these regions of the brain (Weber et al., 1986). 
The role of cy ligands in memory processes has also been investigated. The 
interaction between NMDA receptors and a binding sites (discussed below) however, 
may be of considerable importance in such studies as it is known that NMDA 
antagonists have amnesic effects on learning and memory mechanisms. Studies 
demonstrating the effect of the selective a ligand J01784 have shown it to reverse 
the amnesic effects of scopolamine in the passive avoidance task in rats and it has 
been suggested that this response may be due to an interaction with the NMDA 
receptors (Earley et al., 1991). 
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Several lines of evidence suggest a functional modulation by a ligands, of the events 
mediated by the NMDA receptor complex. These include: 
* The neuroprotective action of cy ligands such as dextromethorphan, dextrorphan, 
BMY-14802, opipramol, ifenprodil and its structural analog SL-82-0715 (Rao et 
aL, 1991). 
Modulation of NMDA-induced activation of CA3 dorsal hippocampal pyramidal 
neurons by cy ligands (Monnet et al., 1991 a). 
* Reversal of the cy ligand-mediated neuroenclocrine and clopamine (DA) turnover 
effects by the competitive NMDA antagonist CPP [3-(2-carboxypiperazin-4-yl)- 
propyl-1 -phosphonic acid] (1yengar et aL, 1991). 
*Attenuation by (T ligands such as ifenprodil, SL-82.0715 and BMY-14802 of 
responses mediated by the cGMP-dependent NMDA/glycine/PCP/ion channel 
complex (Rao et al., 1991). 
* The inhibition of ischemia-induced glutamate release by a ligands (Rao et al., 
1991). 
9 The modulation by a ligands of NIVIDA-evoked [3H]noradrenaline release from 
hippocampal slices (Monnet et al., 1991b) and NMDA-induced DA release from 
the striatum (Rao et al., 1991). 
Thus the evidence provided so far seems to suggest that a major physiological role of 
cy binding sites might be to modulate the function of the NMDA receptor complex. For 
this reason the experimental work described in the present chapter included 
examination of potential NMDA receptor effects. 
Progress in understanding the function of these (Y sites has been hampered by the 
lack of selective ligands. Initial studies using the "prototypic" cy ligand (+)[3H]NANM 
showed that it has a high affinity for the haloperidol binding site while also displaying 
an affinity for the PCIP site. 3-PPP, which has a high affinity for the a sites also 
displays dopaminergic, actions in intact animals. However autoradiography studies 
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have demonstrated that the distribution of (+)3-PPP binding sites in mammalian brain 
is distinct from that of the dopamine receptors and very similar to the haloperidol- 
sensitive (+)NANM binding site (Gundlach et aL, 1986). The lack of generalization of 
(+)3-PPP to dopamine ligands in drug discrimination studies further substantiates its 
usefulness as a (T ligand (cited in lyengar et aL, 1991). 
Recent studies have indicated that DTG labels binding sites distinct from those 
labelled with (+)3-PPP suggesting the existence of heterogenous populations of a 
binding sites (Itzhak & Stein, 1990). There is growing evidence that 
(+)benzomorphans differentiate the recently identified u2 from the original al binding 
site (Hellewell & Bowen, 1990). Sigmal sites are thought to be those sites highly 
sensitive to (+)benzomorphans while the cT2 site, shows reversed stereoselectivity i. e 
(-)benzomorphans being more potent than (+)benzomorphans. DTG and haloperidol 
have comparable affinity for both sites whereas (+)3-PPP binds with higher affinity to 
the al site. Although c72 sites were initially characterized on PC12 cells and in rat 
liver, they are very similar to the sites described by Itzhak et al., (1991) in mouse 
brain, by Rothman et al., (1990) in guinea pig brain and Wu et aL, (1990) in NCB-20 
cells. It is still not absolutely certain whether the findings described above suggest the 
existence of a subtypes or different binding states. However pharmacological studies 
using electrically stimulated guinea pig ileum preparations support the existence of 
subtypes, as the differences observed cannot be explained as differences due to 
agonist/antagonist activity (Campbell et al., 1989; Coccini et al., 1991). Further 
evidence for the existence of a subtypes also comes from studies of the interaction 
between cy binding sites and the NMDA receptor complex where the observed effects 
appeared to be divided into groups characterized by benzomorphan and non 
benzomorphan cy ligands (1yengar et al., 1991). 
Although cy activity has been implicated in numerous pharmacological, biochemical 
and behavioural events, the physiological role of the a site is not well understood. 
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Also a variety of structural and pharmacological classes of drugs including 
benzomorphans, morphinans, antipsychotics (triflupromazine, chlorpromazine), 
phenylpiperazines, phenethylamines, antidepressants (imipramine), anthistarnines, 
anti-Parkinsonian agents, muscarinic antagonists (Hudkins & De Haven-Hudkins, 
1991), Ca2+ channels blockers (Rothman et aL, 1990) and monoamine oxidase 
inhibitors (Itzhak et al., 1991) have been shown to interact with the a site. Despite the 
ambiguity of the role of cy sites, their involvement in psychiatric disorders is supported 
by recent developments of atypical antipsychotics which have a high affinity for the a 
binding sites and may also lack the common side effects observed with such 
treatment. The high incidence of extrapyramidal side effects and tardive dyskinesia 
associated with most antipsychotics (D2 antagonists) in clinical use today has 
inspired the search for novel antipsychotics with high efficacy and without 
extrapyramidal side effects. Of these novel antipsychotic drugs, three have 
undergone clinical trials and shown beneficial effects in schizophrenic patients - they 
are rimcazole, remoxipricle and tiospirone (Largent et al., 1988). It is possible that a 
binding sites may also have some clinical relevence in other disease states. 
The effect of PCIP and (y ligands on K+-evoked [31-11ACh release is investigated in this 
chapter in relation to the effects observed with the ChE-inhibitors tacrine, eserine, 
neostigmine and edrophonium. 
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METHODS 
1. Release experiments 
Hippocampal prisms were prepared, preloaded with [3H]choline and superfused as 
described in Chapter 2- General Methods and Materials. 
2. Receptor binding assays 
a) [3H]QNB binding experiments 
Whole membrane preparations were made from freshly dissected hippocampi and 
radioligand displacement experiments were carried out as described as in Chapter 3. 
b) [3H](+)Pentazocine binding experiments 
Preparation of tissue 
The membrane preparations were prepared following the procedure described by 
DeHaven-Hudkins et al., (1993). Brain tissue was obtained from male, Sprague 
Dawley rats weighing 250-300g. The rats were stunned, cervically dislocated and 
decapitated. The brain was removed and dissected on ice for the hippocampus. The 
tissue was homogenized in 10 volumes (w/v) of 0.32M sucrose with a glass-teflon 
homogenizer at 600 r. p. m., 10 strokes. The homogenate was centrifuged at 900g for 
10 min at 4'C and the resulting supernatant was collected and centrifuged at 
22,000g for 20 min at 40C. The pellet was resuspended in 10 volumes of Tris-HCI 
buffer (50mM, pH 7.4) incubated at 37"C for 30 min and recentrifuged at 22,000g for 
20 min at 40C. Following this, the pellet was resuspended in Tris-HCI buffer and 
frozen in 5ml aliquots at -700C. 
Receptor binding assay 
A modified version of the procedure described by DeHaven-Hudkins et al., (1993) 
was used. Membrane aliquots were freshly thawed, resuspended in fresh Tris-HCI 
buffer and stored on ice until use. In binding competition studies, each assay tube 
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contained 100ýtl of a solution of [3H](+)pentazocine prepared to give a final 
concentration of 1OnM (7.33x105 DPM/ml). The [3H](+)pentazocine solution was 
prepared by adding 20ýd of [3H](+)pentazocine (31.6 ýiCi/nmol) to a6 ml volume of 
Tris-HCI (50mM, pH 7.4) containing 10ýM atropine to minimize muscarinic receptor 
interactions by the radioligand. 100ýtl samples of various concentrations of the drugs 
to be tested were added to 500ýtl of the tissue suspension and 300ýtl of Tris-HCI 
buffer to give a final assay volume of 1 ml. Non-specific binding was defined as 
residual binding in the presence of 1ýLM haloperidol. Following addition of the tissue, 
the asssay tubes were incubated at 370C in a shaking water bath for 21/2 h. The 
reaction was terminated by rapid filtration on Whatman GF/B glass fibre filters that 
were presoaked in a solution of 0.5% polyethylenei mine for at least 1h prior to use. 
Filters were washed thrice with 4ml volumes of cold Tris-HCI buffer. Following 
addition of NE260, the scintillation cocktail, samples were allowed to equilibrate for at 
least 24 h. The amount of bound radioactivity was determined by liquid scintillation 
spectrometry using a Beckman LS 233 liquid scintillation counter with an efficiency 




From Semat Technical UK Ltd, St. Albans, Hertfordshire, (Research Biochemicals 
Incorporated, USA): 
MK-801 (dizocilpine maleate), (+)NANM hydrochloride, (+)cyclazocine, (+)3PPP 
hydrochloride 
From Sigma Chemical Co. Ltd., Poole, Dorset, UK: 
Phencyclidine hydrochloride, (±)pentazocine hydrochloride, haloperidol, DTG (1,3- 
di(2-tolyl)guanidine), Tris-HCI, polyethyleneimine. 
Radiochemicals 
From New England Nuclear (NEN): 




1. The effect of noncompetitive NMDA receptor antagonists on K+-evoked 
[3H]ACh release. 
MK-801 
MK-801 at concentrations ranging from 1-50ptM did not affect K+-evoked [3H]ACh 
release as shown in Figure 4.1 a and Table 4.1 below. Neither did MK-801 (1OOgM) 
affect the potentiation of release caused by 100ýM neostigmine (Figure 4.1b) - 
control S2/S1 0.633 ± 0.034 (n=6); 100l-tM neostigmine S2/S1 1.385 ± 0.055 (n=8); 
100ýM neostigmine and 100ptM MK-801 S2/Sl 1.277 ± 0.091 (n=8); P>0.05. 
CONCENTRATION S2lSl RATIO 
MK801 CONTROL MK801 
lpm 0.842 ± 0.030 (n=13) 0.796 ± 0.032 (n=16) 
logm 0.842 ± 0.030 (n=13) 0.789 ± 0.043 (n=15) 
50ýlm 0.675 ± 0.025 (n=13) 0.786 ± 0.024 (n=16) 
TABLE 4.1 
The effect of MK-801 on K+-evoked [3H]ACh release. The test samples were superfused with 
MK801 10 min prior to and during the S2 stimulation. The S2/S1 values are represented as the mean ± 
SEM of the total number of replicates (n) observed from four experiments; see Methods (Chapter 2) for 
details. 
Phencyclidine (PCP) 
As shown in Figure 4.2 and Table 4.2 below, phencyclidine at concentrations of 1 
and 1 OýM had no effect on K+-evoked [3H]ACh release although at 1 00[tM it caused 
an increase of 17% (P<0.05). 
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CONCENTRATION S2/Sl RATIO 
PHENCYCLIDINE CONTROL PHENCYCLIDINE 
1AM 0.708 0.021 (N=4) 0.731 0.044 (N=4) 
lopm 0.738 0.017 (n=16) 0.796 0.023 (n=16) 
loopm 0.760 0.028 (n=14) 0.857 0.034* (n=16) 
TABLE 4.2 
The effect of PCP on K+-evoked [3H]ACh release. The test samples were superfused with PCP 10 
min prior to and during the S2 stimulation. The S2/S1 values are represented as the mean ± SEM of 
means (N) or the mean ± SEM of the total number of replicate samples (n) observed from four 
experiments depending on the analysis of variance; see Methods (Chapter 2) for details. Significant 
differences with respect to the control are denoted by * P<0.05. 
2. The effects of the benzomorphan a ligands 
a) The effects of the a ligand (±)pentazocine on: 
K+-evoked[3H]ACh release 
As shown in Figure 4.3, (±)pentazocine does not alter K+-evoked [3H]ACh release at 
concentrations 10 and 50ýM; control S2/S1 0.681 ± 0.018 n=17; 10ýLM pentazocine 
S2/Sl 0.724 ± 0.041 
P>0.05. 
n=18; 50ýM pentazocine S2/Sl 0.613 ± 0.043 n=19; 
Potentiation of KI-evoked release of PHIACh by ChE-inhibitors 
(±)Pentazocine at 50ýLM concentrations significantly attenuates the potentiation 
caused by the ChE-inhibitors tacrine, eserine, neostigmine and edrophonium (Table 
4.3, Figures 4.4 & 4.5). Concentrations of 1 OýM however do not affect the 
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100ýt! Vl neostigmine 
F>ýý 1 00ýt! Vl neostigmine +1 00ýt! Vl MK-801 
Figure 4.1 The S2/S1 ratios for K+-evoked release of [31-11ACh from rat hippocampal prisms - the 
effect of MK-801. 
a) MK-801; 1-50pM concentrations 
b) MK-801 in combination with 100ýM neostigmine 
The prisms were stimulated twice (S1 and S2) for 2 min and MK-801 or MK-801 and neostigmine was 
added to the superfusing medium 10 min prior to and during the S2 stimulation. The values represent 
the S2/S1 ratios as the mean ± SEM of the total number of replicate samples (n) observed from 4 (a) 


















Control PCP concentration (ýW) 
Figure 4.2 The S2/S1 ratios for K+-evoked release of [3HIACh from rat hippocampal prisms - the 
effect of phencyclidine. 
The prisms were stimulated twice (S1 and S2) for 2 min and phencyclidine was added to the 
superfusing medium 10 min prior to and during the S2 stimulation. Each point represents the S2/S1 
ratio as the mean ± SEM of means (N) or the mean ± SEM of the total number of replicate samples (n) 
observed from 4 experiments; see Table 4.2 for details. The control represents the mean ± SEM of 
means obtained from all the experiments. Significant differences in the S2/S1 ratio compared to the 
control group are denoted by * P<0.05. 
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Control 










Figure 4.3 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of (±)pentazocine. 
The prisms were stimulated twice (S1 and S2) for 2 min and (±)pentazocine was added to the 
superfusing medium 10 min prior to and during the S2 stimulation. Each column represents the S2/S1 
ratio as the mean ± SEM of the total number of replicate samples (n) observed from five experiments; 


























30ýtM tacrine + lOpM (±)pentazocine 
30ýtM tacrine + 50ýtM (±)pentazocine 
gl@ 1 00piM eserine 
1 00ýiM eserine +1 OýiM (±)pentazocine 
1 00ýiM eserine + 50ýiM (±)pentazocine 
Figure 4.4 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of (±)pentazocine on the potentiation of [3H]ACh release caused by the ChE-inhibitors-. 
a) 30pM tacrine 
b) 100pM eserine. 
Each column represents the S2/S1 ratio as the mean ± SEM of the total number of replicate samples 
(n) observed from four experiments; see Table 4.3 for details. Significant differences in the S2/S1 ratio 



























100ýN neostigmine + 10ýtM (±)pentazocine 
1 00ýtM neostigmine + 30piM (±)pentazocine 
100ýM neostigmine + 50ýLM (±)pentazocine 
100ýW edrophonium 
1 00ýM edrophonium +1 OýtM (±)pentazocine 
1 00ýtM edrophonium + 50ýtM (±)pentazocine 
Figure 4.5 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of (±)pentazocine on the potentiation of [3H]ACh release caused by the ChE-inhibitors'. 
a) 100pM neostigmine 
b) 100pM edrophonium. 
Each column represents the S2/S1 ratio as the mean ± SEM of means (N) or the mean ± SEM of the 
total number of replicate samples (n) observed from four experiments; see Table 4.3 for details. 
Significant differences in the S2/S1 ratio compared to the ChE-inhibitors alone are denoted by * P<0.01 
and ** P<0.001 - 
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b) The effect of the a ligand (+)cyclazocine on: 
K+-evoked [3H]A Ch release 
As shown in Figure 4.6 and Table 4.4 below, (+)cyclazocine does not affect K+- 
evoked [3H]ACh release at 10 and 30ýLM concentrations, although at 50ptM, an 
inhibition of 22% (P<0.05) was observed. 
CONCENTRATION S2/Sl RATIO 
(+)CYCLAZOCINE CONTROL (+)CYCLAZOCINE 
lopm 0.669 0.043 (N=5) 0.569 0.054 (N=5) 
30pM 0.673 0.024 (n=12) 0.669 0.040 (n=14) 
501.1m 0.669 0.043 (N=5) 0.525 0.037* (N=5) 
TABLE 4.4 
The effect of (+)cyclazocine on K+-evoked [3H]ACh release. The test samples were superfused with 
(+)cyclazocine 10 min prior to and during the S2 stimulation. The S2/S1 values are represented as the 
mean ± SEM of means (N) or the mean ± SEM of the total number of replicate samples (n) observed 
from 4 to 5 experiments, depending on the analysis of variance; see Methods (Chapter 2) for details. 
Significant differences with respect to the controls are denoted by * P<0-001 - 
Potentiation of K+-evoked release of 13H]ACh by ChE-inhibitors 
(+)Cyclazocine at concentrations of 10ýM and above significantly attenuates the 
potentiation induced by the ChE-inhibitors tacrine, eserine, neostigmine and 
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0 10 20 30 40 50 
(+)Cyclazocine concentration (ýLM) 
Figure 4.6 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of (+)cyclazocine. 
The prisms were stimulated twice (S1 and S2) for 2 min and (+)cyclazocine was added to the 
superfusing medium 10 min prior to and during the S2 stimulation. Each point represents the S2/S1 
ratio as the mean ± SEM of means (N) or the mean ± SEM of the total number of replicate samples (n) 
observed from 4-5 experiments; see Table 4.4 for details. The control represents the mean ± SEM of 
the means obtained from all the experiments. Significant differences in the S2/S1 ratio compared to the 






















M 300 tacrine 
= 30ýW tacrine + 100 (+)cyclazocine 
p7; ý] 30ptM tacrine + 30ýW (+)cyclazocine 
M1 00ýtM eserine 
F/71 1 00ýtM eserine + 2pM (+)cyclazocine 
F>7>ýj 100pM eserine + 10ýLM (+)cyclazocine 
Figure 4.7 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of (+)cyclazocine on the potentiation of [3H]ACh release caused by the ChE-inhibitors: 
a) 30pM tacrine 
b) 100ýM eserine. 
Each column represents the S2/S1 ratio as the mean ± SEM of means (N) or the mean ± SEM of the 
total number of replicate samples (n) observed from four experiments; see Table 4.5 for details. 
Significant differences in the S2/S1 ratio compared to the ChE-inhibitors alone are denoted by 

























100ýt! Vl neostigmine + 2pM (+)cyclazocine 
100ýV neostigmine + 30pM (+)cyclazocine 
100ýt! Vl neostigmine + 50pM (+)cyclazocine 
@JE 1 00ýtM edrophonium 
=1 00ýiM edrophonium +1 OýN (+)cyclazocine 
EI] 1 00ýiM edrophonium + 30ýLM (+)cyclazocine 
Figure 4.8 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of (+)cyclazocine on the potentiation of [3H]ACh release induced by the ChE-inhibitors. 
a) 100pM neostigmine 
b) 100pM edrophonium. 
Each column represents the S2/S1 ratio as the mean ± SEM of means (N) or the mean ± SEM of the 
total number of replicate samples (n) observed from four experiments; see Table 4.5 for details. 
Significant differences in the S2/S1 ratio compared to the ChE-inhibitors alone are denoted by 
* P<0.001 and ** P<0.0001. 
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c) The effects of the a ligand (+)NANM on: 
K+-evoked [3H]A Ch release 
As shown in Figure 4.9 and Table 4.6 below, (+)NANM at concentrations of 0.5,10 
and 30ýLM showed no effect on KI-evoked [3H]ACh release; P>0.05. 
CONCENTRATION S2/Sl RATIO 
(+)NANM CONCENTRATION (+)NANM 
0.5pm 0.769 ± 0.019 (n=6) 0.770 ± 0.040 (n=8) 
loýtm 0.703 ± 0.037 (n=6) 0.655 ± 0.048 (n=8) 
30pM 0.703 ± 0.037 (n=6) 0.769 ± 0.077 (n=8) 
TABLE 4.6 
The effect of (+)NANM on K+-evoked [3H]ACh release. The test samples were superfused with 
(+)NANM 10 min prior to and during the S2 stimulation. The S2/S1 values are represented as the mean 
± SEM of the total number of replicate samples (n) observed, from two experiments; see Methods 
(Chapter 2) for details. 
Potentiation of K+-evoked release of [3H]A Ch by neostigmine 
(+)NANM at 30ýM concentrations had no effect on the neostigmine-induced 
potentiation of [3H]ACh release (Figure 4.10a); control S2/S1 0.669 ± 0.027 n=14; 
100ýLM neostigmine S2/Sl 1.245 ± 0.061 n=16; 100ptM neostigmine and 30ptM 
(+)NANM S2/Sl 1.237 ± 0.061 n=16; P>0.05. 
K+-evoked release of [3H]ACh in combination with naloxone 
Naloxone (10ýM) had no effect on KI-evoked [3H]ACh release either alone or in the 
presence of 10ýM (+)NANM (Figure 4.10b); control S2/S1 0.792 ± 0.048 n=7; 
10ýtM naloxone S2/Sl 0.661 ± 0.059 n=8; 10ýM naloxone and 10ýLM (+)NANM 














1 10 100 
(+)NANM concentration (ýtM) 
Figure 4.9 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of (+)NANM. 
The prisms were stimulated twice (S1 and S2) for 2 min and (+)NANM was added to the superfusing 
medium 10 min prior to and during the S2 stimulation. Each point represents the S2/S1 ratio as the 
- see Table 4.6 mean ± SEM of the total number of replicate samples (n) observed from two experimentsl 

























1 00ýt! Vl neostigmine +30ýW (+)NANM 
Control 
10ýW naloxone 
1 OpM naloxone +1 OýW (+)NANM 
Figure 4.10 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of (+)NANM in combination with: 
a) 1OOpM neostigmine 
b) 10ýW naloxone 
Each column represents the S21S1 ratio as the mean ± SEM of the total number of replicate samples 
(n) observed from 2-4 experiments; see Results for details. 
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d) The effect of the a ligands (+)cyclazocine, (+)NANM and (±)pentazocine on 
[3H]QNB binding to whole membrane preparations from rat hippocampus. 
Figure 4.11 shows the results of radioligand binding studies using the muscarinic 
ligand [3H]QNB. The cy ligands (+)cyclazocine, (+)NANM and (±)pentazocine inhibit 
[3H]QNB binding in a dose-dependent manner - (±)pentazocine is clearly the 

















Concentration of displacing ligand (ýLM) 
Figure 4.11 Displacement of [3H]QNB binding in rat hippocampal membrane preparations by the CY 
benzomorphans (±)pentazocine, (+)cyclazocine and (+)NANM. 
Each point represents the % inhibition as the mean ± SEM obtained from 2 experiments, each done in 
quadruplicate. 
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3. The effects of non benzomorphan cy ligands 
a) The effects of the cr ligand haloperidol on: 
Potentiation of K+-evoked release of [3H]ACh by ChE-inhibitors 
As shown in Figure 4.12 and Table 4.8,30ýM concentrations of haloperidol produce 
marked reduction (P<0.001) in the potentiation caused by the ChE-inhibitors tacrine, 
eserine, neostigmine and edrophonium to control release. 
KI-evoked[3H]ACh release 
Haloperidol acting alone also produces marked inhibition of 33 and 53% (P<0.001), 
at 10 and 30gM concentrations respectively (Figures 4.13 & 4.14 and Table 4.7), 
while at 100ýM concentrations, [3H]ACh release is completely abolished (Figures 
4.13a &b&4.14). Figures 4.13a &b show the time course of the K+-stimulated 
release of radiolabel and the effects of haloperidol at the given concentrations. The 
mean ± SEM S2/Sl ratios corresponding to the data presented in Figure 4.13a &b 
are 0.665 ± 0.025,0.274 ± 0.013 and 0.059 ± 0.005 for the controls, 30 and 100ýt! Vl 
haloperidol respectively. 
CONCENTRATION S2/Sl RATIO 
HALOPERIDOL, CONTROL HALOPERIDOL 
lopm 0.673 0.024 (n=13) 0.477±0.037* (n=15) 
30pM 0.724 0.040 (N=4) 0.326 ± 0.034* (N=4) 
I oopm 0.724 0.040 (N=4) 0.072±0.011** (N=4) 
TABLE 4.7 
The effect of haloperidol on K+-evoked [3H]ACh release. The test samples were superfused with 
haloperidol 10 min prior to and during the S2 stimulation. The S2/S1 values are represented as the 
mean ± SEM of means (N) or the means ± SEM of the total number of replicate samples (n) observed 
from four experiments, depending on the analysis of variance; see Methods (Chapter 2) for details. 
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The effects of DI and D2 dopamine antagonists on the neostigmine-induced 
potentiation of [3H]ACh release 
Sulpiride 
Sulpiride, a D2 antagonist had no effect at 30ýM concentrations on either the 
neostigmine-induced potentiation of [3H]ACh release (control S2/S1 0.707 ± 0.041 
n=5; 100ýM neostigmine S2/Sl 1.209 ± 0.058 n=8; 100ýM neostigmine and 30ýM 
sulpiride S2/Sl 1.293 ± 0.071 n=7; P>0.05; Figure 4.15b) or on K+-evoked [3H]ACh 
release (control S2/S1 0.709 ± 0.021 n=7; 30gM sulpiride S2/S1 0.800 ± 0.05 n=8; 
100ýtM sulpiride S2/Sl 0.720 ± 0.035 n=8; P>0.05; Figure 4.15a). 
SCH 23390 
The D1 antagonist SCH 23390 at 30ýM concentrations did not alter the effect of 
neostigmine on K+-evoked [3H]ACh release (Figure 4.15c); control S2/S1 0.678 ± 
0.040 (n=6); 100ýtM neostigmine S2/Sl 1.267 ± 0.057 (n=8); 100ýLM neostigmine 
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Figure 4.13 the release of radiolabel from hippocampal prisms evoked by 30mM K+ - the effect of 
haloperidol. 
The prisms were preloaded with [3H]choline (see Chapter 2 for experimental details) and stimulated 
twice (S1 and S2) for 2 min. Haloperidol was added to the superfusing medium 10 min prior to and 
during the S2 stimulation in the test group. Each point represents release as the mean ± SEM of 
replicate samples (per group) observed from one typical experiment and expressed as: 
a) CPM 










Haloperidol concentration (ýV) 
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Figure 4.14 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of haloperidol. 
The prisms were stimulated twice (S1 and S2) for 2 min and haloperidol was added to the superfusing 
medium 10 min prior to and during the S2 stimulation. Each point represents the S2/S1 ratio as the 
mean ± SEM of means (N) or the mean ± SEM of the total number of replicate samples (n) observed 
from 4 experiments; see Table 4.7 for details. The control represents the mean ± SEM of means 
obtained from all the experiments. Significant differences in the S2/S1 ratio compared to the control 
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b) The effect of the a ligand (+)3PPP on: 
K+-evoked [3H]A Ch release 
Figure 4.16a shows that (+)3PPP at concentrations 10 and 50gM had no effect on 
K+-evoked [3H]ACh release; control S2/S1 0.686 ± 0.034 n=13; 1OgM (+)3PPP 
0.724 ± 0.037 n=l 5; 50gM (+)3PPP 0.734 ± 0.043 n=l 5; P>0.05. 
Neostigmine-induced potentiation of K+-evoked[3H]ACh release 
As shown in Figure 4.16b, (+)3PPP had no effect on the neostigmine-induced 
potentiation of K+-evoked [3H]ACh release at the above tested concentrations of 10 
and 50ýM; 100ýLM neostigmine S2/Sl 1.312 ± 0.120 N=4; 100ýtM neostigmine and 
10ýM (+)3PPP S2/Sl 1.511 ± 0.084 N=4; 100ýM neostigmine and 50ýM (+)3PPP 
S2/S 1 1.451 ± 0.119 N=4; P>0.05. 
c) The effect of the a ligand DTG on: 
K+-evoked [3H]A Ch release 
DTG caused a significant inhibition of KI-evoked [3H]ACh release at the 
concentrations tested. At concentrations of 30[tM and 100ptM release was inhibited 
by 16% (P<0.05) and 39% (P<0.001) of the control values; control S2/S1 0.682 ± 
0.030 n=12; 30ýM DTG S2/Sl 0.572 ± 0.036 n=14; 100ýtM DTG S2/Sl 0.415 ± 
0.040 n=15 (Figure 4.17). 
4. The effect of the ChE-inhibitors on PH]pentazocine binding to whole 
membrane preparations from rat hippocampus. 
Figure 4.18 shows the interaction of the ChE-inhibitors tacrine, eserine, neostigmine 
and edrophonium with cy binding sites labelled by the cy radioligand [3H]pentazocine. 
The ChE-inhibitors showed a concentration-dependent inhibition of [3H]pentazocine 
binding - tacrine displayed the highest affinity for the a 
binding sites with an IC50 Of 
approximately 10ýM. Eserine, neostigmine and edrophonium are weak inhibitors of 
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[3H]pentazocine binding displaying IC50S greater than 100ýM. HC-3 at 100ptM 
concentrations also inhibited the binding of [3H]pentazocine by 16 ± 6%. 
(+)Cyclazocine and (±)pentazocine at 50ýM concentrations caused complete 























1 OýW (+)3PPP 
50ýW (+)3PPP 
100ýW neostigmine 
1 00ýtM neostigmine +1 OpM (+)3PPP 
1 00ýLM neostigmine + 50ýtM (+)3PPP 
Figure 4.16 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of (+)3-PPP. 
a) (+)3-PPP; 10 and 50pM concentrations 
b) (+)3-PPP in combination with 100pM neostigmine 
Each column represents the S2/S1 ratio as the mean ± SEM of means (N) or the mean ± SEM of the 











Figure 4.17 The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the 
effect of DTG. 
Each column represents the S2/S1 ratio as the mean ± SEM of the total number of replicate samples 
(n) observed from four experiments; see Results for details. Significant differences in the S2/S1 ratio 
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Figure 4.18 Displacement of [3H](+)pentazocine binding in rat hippocampal membrane preparations 
by the ChE-inhibitors tacrine, eserine, neostigmine and edrophonium . 




The results described in the previous chapter led to the conclusion that inhibition of 
ACh release by tacrine is unlikely to be the result of muscarinic receptor activation. 
As discussed, feedback inhibition by extracellular ACh seemed unlikely, although a 
role for muscarinic receptors in the potentiation of release, common to the ChE- 
inhibitors studied remains to be assessed (Chapter 5). Amongst other possibilities it 
had been previously reported that tacrine and the other ChE-inhibitors exhibit binding 
at PCP sites. 
The displacement of [3H]TCP binding by tacrine as well as the other cholinesterase 
inhibitors eserine, neostigmine and edrophonium, (Albin et al., 1988) led to the 
possibility that an interaction with the PCIP site might be responsible for the [3H]ACh 
release-enhancing effect. Albin et al., (1988) reported that tacrine displaces [3H]TCP 
with an IC50 of 26ptM, eserine and edrophonium with an IC50 of 100piM and 
neostigmine with an IC50 greater than 100ptM. Interaction of ChE-inhibitors at the 
PCP site was further supported by the observation that tacrine and the cholinesterase 
inhibitors eserine, neostigmine and edrophonium also provide neuroprotection 
against the NIVIDA-mediated toxicity in murine cortical cultures (Davenport et al., 
1988). Furthermore in both studies tacrine was shown to be far more effective than 
the other cholinesterase inhibitors, as was the case in the present [3H]ACh-release 
experiments, in which the maximum effect of tacrine observed at 30ýM 
concentrations, was comparable to the maximum effect of eserine, edrophonium and 
neostigmine at 1 00ýM concentrations (Chapter 3). 
[3H]TCP, an analogue of PCP, and MK-801 both bind to the cation channel of the 
NMDA receptor channel complex in the rat brain and have been shown to share 
many common binding properties (Fagg, 1987). The effects were therefore 
investigated of these noncompetitive NMDA receptor antagonists MK-801 and PCP, 
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on the K+-evoked release of [3H]ACh. MK-801 at concentrations up to 50ý11V! had no 
effect on evoked-[3H]ACh release from the hippocampal prism preparation (Figure 
4.1a) and as Figure 4.1b shows, 100ýM concentrations, also had no effect on the 
neostigmine-induced potentiation of [3H]ACh release. 
PCIP however increased [3H]ACh release significantly (P<0.05), at a concentration of 
1 00ptM (Figure 4.2). This is in agreement with the observation of Jackisch et al. 
(1986), that electrically-stimulated release of [3H]ACh from rabbit hippocampal slices 
was significantly increased by PCIP (concentrations not reported in this abstract 
publication). Junien et al., (1991) however were unable to show an increase in 
[3H]ACh release from hippocampal slices with PCP although the maximum 
concentration tested in this latter study was only 30ýtM. 
It may therefore be concluded from these results that the effect of PCP on [3H]ACh 
release is rather unlikely to be an action mediated via the PCP site inasmuch as MK- 
801 did not give a similar effect. However PCIP is also known to have appreciable (Y- 
binding compared to that of MK-801 (Walker et al., 1990). The characteristics and 
functional role of PCP and a sites in the brain have been under extensive 
investigation for several years. Ligand binding studies and behavioural studies have 
shown the effects of PCP ligands to overlap with those of cy ligands (Mendelsohn et 
aL, 1985; Mc Cann et al., 1989), although other studies have provided evidence for 
the existence of distinct PCP and (y sites (Largent et al., 1984a). These studies 
together with the preliminary results described above (Figures 4.1a &b&4.2) 
prompted an investigation of the action of a ligands on [3H]ACh release from 
hippocampal prisms. As described in the Introduction to this chapter, the existence of 
subtypes of cy binding sites (cyl and a2) has been based primarily on the 
stereoselectivity of the a benzomorphans. For this reason the effect of cyl-selective 
(+)benzom orphans was investigated in comparison with other non selective, non- 
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benzomorphan ligands such as haloperidol, (+)3PPP and DTG, which do not 
discriminate between al and u2 binding sites. 
(+)Benzomorphan a-ligands 
Although (+)NANM has been referred to in the literature as the "prototypic cy ligand", it 
is also known to label PCIP sites (Mendelsohn et al., 1985) and is therefore not strictly 
selective for cy binding sites. (+)Cyclazocine also has an affinity for the a and PCIP 
binding site comparable to that of (+)NANM (Mendelsohn et al., 1985; Walker et al., 
1990). (+)Pentazocine however, appears to have a greater affinity for a binding sites 
as judged by its displacement of [3H](+)3-PPP and [3H]DTG (Largent et al., 1984a; 
Walker et a/., 1990) and a negligible affinity for the PCP site (Largent et al., 1984a). 
The effects were therefore investigated of these benzomorphan cr ligands 
(±)pentazocine, (+)cyclazocine and (+)NANM on KI-evoked [3H]ACh release. 
(±)Pentazocine (10 and 50ýM) was shown to have no effect on KI-evoked [3H]ACh 
release (Figure 4.3) although at 50ýM concentrations it was shown to attenuate the 
potentiation of the evoked release of [3H]ACh caused by the ChE inhibitors tacrine, 
esenne, neostigmine and edrophonium (Figures 4.4 & 4.5). Interestingly however the 
S2/S1 ratio was not reduced to control values except in the case of eserine (Figure 
4.4b). It is suggested at this stage, that the residual increase over and above control 
S2/S1 values is likely to be a reflection of the [3H]ACh accumulated as a result of 
AChE inhibition and equivalent to the HC-3 effect described in Chapter 3. However 
this is reconsidered in Chapter 6. 
(+)Cyclazocine was shown to have a similar effect to that of (±)pentazocine, at 
concentrations greater than 10ýM (Figures 4.7 & 4.8). It is evident from the results 
shown in Figure 4.8a that maximium inhibition occurs at 30ýM concentrations, as 
50ýM concentrations caused no further inhibition. Furthermore the S2/S1 ratio for 
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potentiation of release by neostigmine remained significantly greater than the control 
S2/Sl ratio in the presence of both 30 and 50ýN concentrations of (+)cyclazocine. 
(+)Cyclazocine alone however, had no effect on evoked release at 1 OýLM and 30ptM 
concentrations although at 50ýM concentrations it caused a significant reduction of 
22% (P<0.05, Figure 4.6). Despite this inhibition at higher concentrations, it seems 
clear that (+)cyclazocine, attenuates the potentiation of release caused by the ChE- 
inhibitors at a concentration (30ptM) which alone, has no effect on KI-evoked release 
(see Chapter 6). 
In contrast to the above findings with (±)pentazocine and (+)cyclazocine, (+)NANM 
the "prototypic cr ligand" has been reported to increase the release of ACh in the CNS 
in vivo and in vitro. In vivo, microdialysis has demonstrated that (+)NANM increases 
extracellular ACh levels in the presence of eserine in rat frontal cortex (Matsuno et 
al., 1992). (+)NANM also enhances electrically evoked [3H]ACh release in rabbit 
hippocampal slices (Jackisch et aL, 1987) as well as KI-evoked release in cortical 
and thalamic slices, in the presence of eserine or carbachol (Siniscalchi et aL, 1987). 
Moreover Junien et al., (1991) reported that (+)NANM or J01784, a novel cy ligand, 
increased KI-evoked release of [3H]ACh from rat hippocampal slices in the presence 
of HC-3 (10ýM). 
However in the present experiments (Figure 4.9), (+)NANM had no effect on K+- 
evoked release even though HC-3 was added to conform to the procedure of Junien 
et al., (1991). Neither did it affect the neostigmine-induced potentiation of [3H]ACh 
release as shown in Figure 4.10a. However the levorotatory (-) isomer of NANM has 
been previously shown to haveKopioid agonist properties (Quirion et al., 1987) and 
opioid receptors are known to be involved in the inhibition of ACh release in the brain 
(Lapchak et al., 1988). The possibility was considered therefore, that in the present 
experiments, potentiation of [3H]ACh release by the a activity of (+)NANM (as 
observed in the aforesaid studies) might have been opposed by some opioid activity. 
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However as Figure 4.10b shows, naloxone did not alter the effect of (+)NANM on K+- 
evoked release and neither did it alone affect control KI-evoked release. 
It is not clear therefore why the present results with (+)NANM are at variance with 
those previously reported, nor is it clear why the effects with (±)pentazocine and 
(+)cyclazocine (Figures 4.4,4.5,4.7 & 4.8) differ from those with (+)NANM (Figure 
4.10a). However it has also been previously reported that (+)NANM has a muscarinic 
antagonist effect which blocks negative feedback inhibition by ACh (Siniscalchi et aL) 
1987). The role of muscarinic autoreceptors is considered further in the following 
chapter. 
Relevant to the present discussion, the displacement of [3H]QNB, by the three cy 
ligands was compared (Figure 4.11). (+)NANM was clearly not more effective in the 
displacement of [3H]QNB than was (+)cyclazocine, and indeed (±)pentazocine, was 
markedly more effective than both (+)NANM and (+)cyclazocine. (+)Pentazocine and 
(+)NANM have both been shown to be muscarinic antagonists as is evident by their 
ability to inhibit carbachol-induced phosphoinositicle turnover OC50 32 & 213ptM 
respectively) (Candura et al., 1990). They also inhibit carbachol-induced contractions 
in the guinea pig ileum preparations and oxotremorine-induced analgesia in mice 
(Vargas & Pechnick, 1991). It may seem unlikely therefore, that muscarinic receptor 
antagonism would explain the distinction observed between (+)NANM on the one 
hand and (+)cyclazocine and (±)pentazocine, on the other, in the present 
experiments. This is reconsidered in Chapters 5 and 6. 
It might be tentatively concluded at this stage that potentiation of [3H]ACh release by 
the ChE-inhibitors involves their action at a receptors and that this is attenuated by 
(+)cyclazocine and (±)pentazocine. The fact that PCIP itself causes potentiation 
(Figure 4.2) may be thought to support this idea although it is known to have other 
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properties (see next chapter). The results discussed and presented so far however, 
fail to explain the lack of effect of (+)NANM on K+-evoked release. 
Non-benzomorphan cy ligands 
One of the pharmacological characteristics of the cT binding site is its high affinity for 
haloperidol, a non-benzornorphan, which has been suggested to act as an antagonist 
at this site. Recently Junien et al. (1991) demonstrated that the potentiation of K+- 
evoked [3H]ACh release from rat hippocampal slices by (+)NANM or JO 1784 was 
antagonized by haloperidol (0.3pLM). This compound was therefore tested in the 
present series of experiments; on the potentiation of [3H]ACh release caused by the 
ChE-inhibitors and also on of K+-evoked release of [3H]ACh. Haloperidol at a 
concentration of 1 ýM was ineffective (results not- shown), however at 30ýM 
concentrations, the potentiation caused by each of the four ChE-inhibitors was 
abolished - i. e the S2/S1 ratios were reverted to control values (Figure 4.12, Table 
4.8). This effect appeared to be a functional antagonism since haloperidol alone, also 
inhibited KI-evoked release by 33% (P<0.001) and 53% (P<0.001) at concentrations 
of 10 and 30ýM respectively, while at 100ýM haloperidol, the S2 stimulation was 
completely abolished (Figures 4.13 & 4.14, Table 4.7). 
In addition to its high affinity for cy binding sites, haloperidol has also been shown to 
bind with high affinity to receptors for dopamine, noradrenaline (ccl), 5HT and very 
weakly to muscarinic binding sites (cited in Monnet et al., 1991 a) while showing no 
affinity for the PCIP sites (Largent et al., 1984a; Quirion et al., 1987). In order to 
determine whether the inhibition of [3H]ACh release caused by haloperidol was due 
to dopamine/ACh interactions, the D1 and D2 antagonists SCH 23390 and sulpiride 
were tested and found to have no effect on the neostigmine-induced potentiation of 
[3H]ACh release (Figures 4.15b & 4.15c). Furthermore sulpiride, which has minimal 
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affinity for the (T site (Rao et aL, 1991) was also shown to have no effect on the K+- 
evoked release of [3H]ACh (Figure 4.15a). 
The effects of the non-benzomorphan, ligands (+)3-PPP and DTG were also 
investigated (Figures 4.16 & 4.17). These a ligands display a high affinity for the a 
binding site and are frequently used in ligand binding studies, although DTG does not 
differentiate between the subtypes. (+)3-PPP which is known to have a slightly higher 
affinity for the cyl binding sites (KID ý5 and 440nM for al and (Y2 respectively) (Wa I ker 
et al., 1990), had no effect on [3H]ACh release either K+-evoked or neostigmine- 
potentiated (Figures 4.16a & 4.16b). DTG however, was shown to inhibit K+-evoked 
[3H]ACh release in a concentration-dependent manner similar to haloperidol as 
shown in Figures 4.14 & 4.17. Concentrations of 30 and 100ýM DTG gave inhibitions 
of 16% (P<0.05) and 39% (P<0.001) respectively (Figure 4.17). Similar effects in the 
rat hippocampus have also been also reported by Junien et al., (1991). 
DTG and its congeners have also been shown to have similar effects in the 
periphery, where they are reported to inhibit [3H]ACh release and also 5-HT-induced 
and electrical ly-ind uced contractions in isolated guinea pig ileum (Campbell et al., 
1989). The potency of these ligands in inhibiting guinea-pig ileum contractions was 
shown to be highly correlated with their binding affinity to the a binding sites. Although 
DTG has been shown to have weak muscarinic antagonist activity (Hudkins & De 
Haven-Hudkins, 1991; Vargas & Pechnick, 1991), a ligands lacking affinity to the 
muscarinic receptors were also found to inhibit the contractions as well as [3H]ACh 
release from this preparation. Furthermore DTG congeners structurally related to 
DTG but lacking affinity for the a binding sites were found not to alter [3H]ACh 
release. The inhibition of [3H]ACh release by these ligands was therefore ascribed to 
an action at the cy binding sites (Campbell et al., 1989). 
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The observation that tacrine (Chapter 3) and the non-benzomorphan ligands 
haloperidol and DTG, strongly inhibit K+-evoked [3H]ACh release may be of 
significance. It is possible that the tacrine-induced inhibition of [3H]ACh release is 
similarly mediated by a binding sites. Thus the overall picture emerging appears to 
involve a activity in both the potentiation of [3H]ACh release by ChE-inhibitors and 
paradoxically, also in the inhibition of KI-evoked release. 
Furthermore it is interesting to observe that the ChE-inhibitors tacrine, eserine, 
neostigmine and edrophonium, as shown in Figure 4.18, displace the al-selective 
radioligand [3H](+)pentazocine from hippocampal membrane preparations. 
Nevertheless although tacrine displaced [3H](+)pentazocine with a IC50 Of 
approximately 10ýM, eserine, neostigmine and edrophonium, showed considerably 
weaker affinity for the cy binding sites with IC50 values greater than 100ýM. The 
results from these radioligand binding studies therefore make it difficult to suggest 
that the potentiation of K+-evoked [3H]ACh release by the ChE-inhibitors eserine, 
neostigmine and edrophonium is due to an interaction with cy binding sites, although it 
is clear from the results presented in this chapter, that this potentiation is attenuated 
by the a ligands (±)pentazocine and (+)cyclazocine. 
Since the ligands (+)NANM, (+)cyclazocine and (±)pentazocine which are known to 
be predominantly al -selective, have no effect on K+-evoked [3H]ACh release in the 
present studies, it is tempting to speculate that the inhibition of [31-11ACh release 
observed with the non-benzomorphan, non-selective a ligands haloperidol and DTG 
is due to an action at the a2 binding sites. It is therefore suggested that the inhibition 
of [3H]ACh release observed with concentrations of 100 and 200ýM tacrine, might 
also be mediated by a mechanism similar to that responsible for the inhibition of 
[3H]ACh release by haloperidol and DTG. However it is noted that the concentrations 
of haloperidol and DTG required to produce inhibition are in the micromolar range 
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compared to the nanomolar IC50s observed in radioligand binding studies (see 
Chapter 6). 
In addition to its actions at the a and muscarinic binding sites, the cy benzomorphans 
cyclazocine, NANM and pentazocine have also been shown to act non competitively 
at the nicotinic receptors. King and Aronstam (1983), showed that the above 
mentioned benzornorphans inhibited the binding of [3H]perhydrohistrionicotoxin 
([3H]Hl2-HTX) to ion channel sites in torpedo ACh receptor complexes with IC50 
values of approximately 5ýM. Interestingly, previous studies by various workers have 
also shown that the ChE-inhibitors tacrine, eserine and neostigmine also interact with 
nicotinic receptors (De Sarno et aL, 1989; Fiekers, 1985; Nilsson et al., 1987; Shaw 
et aL, 1985; Sherby et al., 1985). It is possible therefore that the potentiation of K+- 
evoked [3H]ACh release is due to an interaction at the nicotinic receptor and this will 
therefore be further investigated in the following chapter. 
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CHAPTER5 




It was observed from the results described in Chapter 4 that the benzomorphan cy 
ligands (+)cyclazocine and (±)pentazocine blocked the potentiation of [31-IJACh 
release caused by the ChE-inhibitors tacrine, eserine, neostigmine and 
edrophonium. However the binding affinities of these ChE-inhibitors for the cy binding 
sites labelled with [3H](+)pentazocine were unimpressive (Figure 4.18). Thus it was 
concluded that the potentiation of [3H]ACh release by the ChE-inhibitors was unlikely 
to be due to an interaction with the a binding sites. However as mentioned 
previously, these benzomorphan a ligands as well as (+)NANM have all been shown 
to act noncompetitively at the nicotinic receptors. The binding of 
[3H]perhydrohistrionicotoxin to nicotinic ion channel sites was inhibited by these 
benzomorphans with IC50 values of approximately 5[tM (King & Aronstam, 1983). 
Furthermore several workers have also shown that the ChE-inhibitors themselves 
interact with nicotinic receptors. Here in this chapter, the role of nicotinic and 
muscarinic receptors in the modulation of [3H]ACh release is considered. 
One of the mechanisms regulating ACh release in the CNS is by presynaptic auto 
and heteroreceptors. A great deal of interest has been focused on the 
characterization and pharmacological manipulation of these presynap ic 
autoreceptors by cholinergic agents, which may possibly improve cholinergic 
transmission if these receptors differ pharmacologically from the postsynaptic ones. 
It is now well documented, that ACh release from cholinergic axon terminals in the 
CNS and in the periphery are under presynaptic feedback control through muscarinic 
autoreceptors. Auto receptor-m ed i ated feedback, a process controlling the synaptic 
release of transmitters was first described by Langer (1977) wherein endogenous 
ligands inhibited their own release by activating presynaptic "autoreceptors". The 
inhibition of depolarization-dependent ACh release by ACh itself was however, 
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observed long before (Mitchell, 1963; Szerb, 1964; Polak and Meeuws, 1966) and a 
large body of evidence has since been documented supporting the autoreceptor 
mediated regulation of ACh release in the periphery and CNS. Muscarinic ACh 
autoreceptors mediating inhibition of ACh release from central cholinergic neurons 
have been investigated in rat cortical brain slices and synaptosomes (Hadhazy and 
Szerb, 1977; Rospars et aL, 1977; Raiteri et aL, 1984; Meyer and Otero, 1985) and 
also in rat hippocampal nerve endings (Nordstrom and Bartfai, 1980; March et 
aL, 1981; Raiteri et a/., 1984). It is commonly observed that muscarinic agonists 
decrease ACh release and a property common to these ACh release-inhibiting 
autoreceptors is their sensitivity to atropine. 
ACh release has also been shown to be modulated by heteroreceptors such as 
those for 5-HT, noradrenaline, dopamine, adenosine and opioid receptors. However 
in each brain area the cholinergic nerve endings are equipped with different sets of 
presynaptic receptors making possible a differential regional modulation. For 
instance Marchi et al., 1983, demonstrated that the activation of striatal muscarinic 
autoreceptors is less effective in reducing ACh release in the striatum than in the 
cortex and hippocampus. Similarly adenosine inhibition of ACh release is more 
effective in the hippocampus than in the cerebral cortex (Pedata et al., 1986). 
Furthermore the heteroreceptors modulating ACh release have also been shown to 
vary in subtype in the different regions of the brain. For example, 5-HT 
heteroreceptors mediating the inhibition of ACh release in the hippocampus have 
been shown to belong to the 5-HT1B subtype in the hippocampus (Maura & Raiteri, 
1986), 5-HT3 in the cortex (Barnes et al., 1989) and 5-HT2 in the striatum (cited in 
Maura & Raiteri, 1986). The inhibition of ACh release by NA involving U2 
heteroreceptors has been reported only in the cortex (Vizi, 1980; Beani et al., 1986) 
as far as is known and likewise, the potentiation of evoked DA release by muscarinic 
heteroreceptors is best known in the striatum (Schoffelmeer et al., 1986; Ono et al., 
1988; Raiteri et al., 1984) and the cortex (Marchi & Raiteri, 1985a). 
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There have been many studies attempting to correlate the heterogeneity of 
muscarinic receptors with neurochemical function in the CNS. In many studies, 
muscarinic receptors subtypes in the brain have been investigated by using 
neurotransmitter release as a functional parameter and by comparing the effects of 
agonists and antagonists. Recent studies dealing with the ACh release-i n hi biting 
autoreceptors have led to their characterization and the evidence suggests that they 
are of the M2 muscarinic receptor subclass in the striatum (Weiler, 1989; James & 
Cubeddu, 1987; Schoffelmeer et al., 1986), cortex (Marchi & Raiteri, 1985a) and 
hippocampus (Marchi & Raiteri, 1985a; Pohorecki et aL, 1988; Ono et aL, 1988). 
Furthermore there is increasing evidence that muscarinic receptors are located also 
on clopaminergic nerve terminals (Raiteri et al., 1982; Schoffelmeer et al., 1986) and 
it has been shown that the activation of these heteroreceptors which potentiate 
evoked release of DA in the cerebral cortex (Marchi & Raiteri, 1985a; Marchi & 
Raiteri, 1985b) and striatum (Raiteri et al., 1984; Schoffelmeer et al., 1986; Ono et 
al., 1988), belong to the M1 subtype. 
Evidence supporting the existence of nicotinic receptors on cholinergic nerve 
endings (Yoshida & Imura, 1979; Romano & Goldstein, 1980; Sc6artz et al., 1982) 
as well the ability of nicotine to promote transmitter release led to the idea and the 
possibility of a direct presynaptic action of nicotine. Nicotine has been shown to 
evoke release of neurotransmitter and also to potentiate release evoked by nerve 
impulses or by other depolarizing stimuli such as high K+ concentrations (Westfall, 
1974; Beani et al., 1985). 
It was found that nicotinic receptor stimulation enhances the release of ACh (Beani 
et al., 1989; Chiou et al., 1970; Wilkie et al., 1993) and aspartate (Beani et al., 1989) 
from the cortex, NA and DA from the hypothalamus and the striaturn (Goodman, 
1974; Sandor et al., 1991). It appears that the best characterized presynaptic action 
of nicotine concerns the enhancement of ACh release from the hippocampus (Beani 
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et a/., 1989; Wilkie et aL, 1993; Araujo et al., 1988; Moss & Wonnacoft, 1985; 
Wonnacott et al., 1987) and DA release from the striatum. The nicotinic facilitation of 
DA release in vivo from striatal nerve terminals has been previously reported (cited 
in Marchi et a/., 1983), as has DA release from slice (Giorguieff et al., 1976; 
Goodman 1974) and synaptosomal preparations (Clarke et al., 1994; Giorguieff- 
Chesselet et aL, 1979; Rapier et aL, 1984; Wonnacott, 1991). Nicotine-evoked 
release of [3H]ACh from hippocampal synaptosomes has also been well 
documented by Wonnacott et al., (Moss & Wonnacott, 1985; Wonnacott et al., 1989; 
Wilkie et aL, 1993). Furthermore, nicotine-evoked [3H]DA release from rat striatal 
synaptosomes has been shown to be blocked by the ChE-inhibitors tacrine, eserine 
and neostigmine (Clarke et al., 1994). 
It has been suggested by Wonnacott et al., (1989) that these striatal presynaptic 
nicotinic receptors are similar to those found on hippocampal synaptosomes, which 
are involved in the facilitation of ACh release. It is reported that these striatal and 
hippocampal presynaptic receptors (which modulate DA and ACh release) are 
blocked by DHPE, but are insensitive to (x-bungaratoxin (Wonnacott et al., 1989; 
Wonnacott, 1991). Araujo et aL, (1988) have also shown that the nicotinic agonist 
methylcarbamylcholine (MCC) enhanced [3H]ACh release from rat hippocampal and 
cortical slices but not from striatal slices. This effect of MCC to increase ACh release 
was found to be antagonized by the nicotinic antagonists DHPE and d-tubocurarine 
but not by cc-bungarotoxin . 
The hypothesis that nicotinic receptors increase the release of ACh (at the 
neuromuscular junction) was first suggested by Beani et al., in 1964 and has since 
been reviewed and demonstrated in vivo (Armitage et al., 1969; Erickson et al., 
1973; Beani et al., 1989) and in vitro (Beani et al., 1989; Rowell & Winkler, 1984; 
Beani et al., 1985; Moss & Wonnacott, 1985; Wilkie et al., 1993; Meyer et al., 1987; 
Araujo et al., 1988; Loiacono & Mitchelson, 1990) in the CNS and the periphery 
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(Wessler et aL, 1986; Bowman et al., 1988). Beani et al. (1985) showed that nicotine 
as well as the nicotinic agonist cytisine facilitated the electrically stimulated release 
of [3H]ACh from cortical slices of the guinea pig brain and was blocked by d- 
tubocurarine. In the periphery also, Wessler et aL, (1986) was able to demonstrate a 
positive feedback mechanism mediated by presynaptic nicotinic receptors on the 
motor nerve terminals (rat phrenic nerve). They showed that the nicotinic agonist 
DMPP (dimethylphenylpiperazinium) enhanced the electrically stimulated release of 
[3H]ACh in a concentration-dependent manner which was antagonized by d- 
tubocurarine. 
Evidence for the existence of several subtypes of nicotinic receptors has been 
accumulated from pharmacological, electrophysiological and immunohistochemical 
studies. Differences in single channel conductances and sensitivity to snake 
neurotoxins such as (x bungarotoxin and neuronal bungarotoxin suggest that there 
are physiological, pharmacological and structural differences between nicotinic 
receptors across species, tissues and even within tissues. Immunohistochemical and 
immunochernical analyses also support nicotinic receptor heterogeneity and are 
beginning to reveal relationships between nicotinic receptor-like antigens, specific 
radioligand binding sites and specific nicotinic receptor subunits (Lukas & Bencherif, 
1992). The application of recombinant DNA techniques in the characterization and 
cloning of nicotinic receptor subunit-encoding genes and mRNA have been of 
significant importance in the understanding of the diversity of nicotinic receptors. 
It has also been reported by many workers that neostigmine, eserine and other ChE 
inhibitors, at higher concentrations have various effects that are unrelated to AChE 
inhibition. These include: 
* an interaction with nicotinic ACh receptor; the binding of neostigmine and eserine 
to these receptors has been demonstrated by their competitve inhibition of 
specific [3H]ACh binding in the electric organ of the Torpedo and the 
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competitive inhibition of the 1251-cc-bungarotoxin binding to the aplysia receptors 
(Sherby et aL, 1985). Binding studies have also revealed these ChE inhibitors to 
interact directly with the nicotinic receptor channel in different ways also causing 
desensitization (which is measured as increased potency of the agonist to inhibit 
binding of the radioligand e. g 1251-(x-bungarotoxin to the receptor sites) (Sherby 
et al., 1985; Bloch & Stallcup, 1979). Furthermore eserine has been shown to be 
a potent blocker of the receptor's activated channel conformation (Sherby et al., 
1985). 
0 an agonist as well as an antagonist effect on the nicotinic ACh receptor: 
Electrophysiological studies have demonstrated that neostigmine and eserine 
have agonist activity similar to ACh (Shaw et al., 1985; Harvey & Dryden, 1974) 
and carbachol (Bloch & Stallcup, 1979). However neostigmine is also known to 
block ACh receptors in the voltage clamped twitch fibres of the costocutaneous 
muscles of the garter snake (Fiekers, 1985). Furthermore neostigmine, eserine 
and tacrine have been shown to produce a concentration-dependent blockade of 
nicotine-evoked [3H]DA from rat striatal synaptosomes (Clarke et al., 1994) 
0 direct and indirect presynaptic effects affecting the release of ACh; It was found 
by Chang and Hong (1986) using intracellular recording techniques with glass 
microelectrodes, that train stimulation (50-200 Hz) of the phrenic nerve of intact 
or cut mouse diaphragm induced an accumulative depolarisation of the end plate 
and triggered after a few pulses, an "all or none" regenerative depolarisation 
when AChE was inhibited by neostigmine. It was suggested that the ACh 
accumulated in the synaptic cleft acts on the nerve terminal cholinoceptor 
causing a depolarisation which, at a threshold depolarisation produced a 
regenerating release of ACh. D-Tubocurarine was shown to block the 
regenerating depolarisation (Chang & Hong, 1986). 
The ChE-inhibitors tacrine, eserine, neostigmine and edrophonium which are also 
known to have muscarinic and nicotinic properties, have been shown in the previous 
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chapters to potentiate the K+-evoked release of [3H]ACh from rat hippocampal 
prisms. It has also been observed that the ChE-inhibitors tacrine and eserine 
enhanced evoked-[3H]ACh release from postmortem Alzheimer brain tissue in a 
manner which was blocked by d-tubocurarine and DHPE (Nordberg et al., 1989). 
Facilitation of synaptic transmission by muscarinic and nicotinic agents therefore, 
seems a rational approach and has been considered as a possible therapeutic 
approach for the treatment of Alzheimer's disease. The modulation of hippocampal 
ACh release by the interaction of cholinergic agents with muscarinic and nicotinic 
receptors and the possibilty of the ChE-inhibitors having a direct action on 




1. Release experiments 
Preparation of tissue 
Hippocampal prisms were prepared, preloaded with [3H]choline and superfused as 
described in Chapter 2- General Methods and Materials 
MATERIALS 
Chemicals 
From Semat Technical UK Ltd, St. Albans, Hertfordshire, (Research Biochemicals 
Incorporated, USA): 
DHPE hydrobromide, (+)cyclazocine and (+)NANM hydrochloride 
From Sigma Chemical Co. Ltd., Poole, Dorset, UK: 
Oxotremorine sesquifumarate salt, carbachol chloride, nicotine salicylate salt, DMPP 
iodide, mecamylamine hydrochloride, d-tubocurarine chloride, hexamethonium 
bromide and (±)pentazocine hydrochloride 




1. The effects of the muscarinic antagonist atropine on: 
The potentiation of [3H]ACh release caused by the ChE inhibitors 
Atropine at 10ýM concentrations produced a significant enhancement of 19,19,28 
and 16% respectively of the potentiation of [3H]ACh release caused by the ChE 
inhibitors tacrine (30ýM), eserine (100ptM), neostigmine (100ptM) and edroPhonium 
(100ptM), see Table 5.2 and Figure 5.1. 
The inhibition of [3H]ACh release caused by tacrine 
Tacrine at 100 and 200ýM concentrations caused a 24% (P<0.001) and 62% 
(P<0.0001) inhibition of [3H]ACh release. At 100gM concentrations of tacrine 
however, this inhibition was reversed by 10ýM atropine. Atropine had no effect on 
the inhibition of release caused by 200ýM tacrine, see Table 5.1 below and Figure 
5.2. 
CONCENTRATION S2/Sl RATIO 
TACRINE CONTROL TACRINE TACRINE+ATROPINE 
loopm 0.675±0.019 (n=15) 0.516 ± 0.027*(n=15) 0.622 0.025 (n=l 5) 
200jiM 0.704 ± 0.012 (N=3) 0.266 ± 0.039**(N=3) 0.247 0.039 (N=3) 
TABLE 5.1 
The effect of atropine on the tacrine-induced inhibition of K+-evoked [3H]ACh release. The test 
samples were superfused with tacrine or tacrine and atropine 10 min prior to and during the S2 
stimulation. The S2/S1 values are represented as the mean ± SEM of means (N) or the means ± SEM 
of the total number of replicate samples (n) observed from 3 to 4 experiments, depending on the 
analysis of variance; see Methods (Chapter 2) for details. Significant differences compared to the 
S2/S1 ratio of the ChE-inhibitor alone are denoted by *P<0.001 and ** P<0.0001. 
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The oxotremorine-induced inhibition of [3H]ACh release 
As shown in Figure 5.3a oxotremorine at 100ýM concentrations, caused a 22% 
inhibition of [3H]ACh release - control S2/S1 0.686 ± 0.054 N=3; 1 OOPtM 
oxotremorine S2/S1 0.534 ± 0.033 N=3 (P<0.001). This inhibition was antagonized 
by 10ýM atropine to S2/S1 values comparable to those of control - 100ptM 
oxotremorine and 1OgM atropine S2/S1 0.748 ± 0.024 N=3 (P>0.05). 
K+-evoked release of [3H]A Ch 
Atropine at 1OptM concentrations had no effect on KI-evoked [3H]ACh release - 
Figure 5.3b. Control S2/S1 0.705 ± 0.030 n=15; 10ýiM atropine S2/S1 0.670 ± 0.025 
n=16 (P>0.05). 
2. The effects of (+)NANM on: 
The carbachol-induced inhibition of [3H]ACh release 
As shown in Figure 5.4a, (+)NANM at 30ýM concentrations was found to antagonize 
the inhibition of [3H]ACh release caused by carbachol (50ýM); control S2/S1 0.639 ± 
0.019 n=13; 50gM carbachol S2/Sl 0.529 ± 0.032, n=16 (P<0.05); 50ýM carbachol 
and 30ýM (+)NANM S2/Sl 0.628 ± 0.026, n=14. 
The neostigmine-induced potentiation of [3H]ACh release in the presence of 
atropine to 
(+)NANM at 30ýLM concentrations was foundloppose the potentiation of [3H]ACh 
release caused by neostigmine (1 00ýLM) and atropine (1 OýM) together; 1 00ýM 
neostigmine and 10ýM atropine S2/Sl 1.238 ± 0.071, n=16; 100ýM neostigmine 
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100ptM tacrine + IlOpM atropine 
Control 
200ýtM tacrine 
200ýV tacrine + 10ýW atropine 
Figure 5.2 
The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the effect of atropine 
on: 
a) 100pM tacrine 
b) 200pM tacrine 
Each column represents the S2/SI ratio as the mean ± SEM of means (N) or the mean ± SEM of the 
total number of replicate samples (n) obtained from three to four experiments; see Table 5.1 for details. 



























1 OktM atropine 
The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the effect of atropine 
on: 
a) oxotremorine-induced inhibition of [3H]ACh release 
b) K+-evoked [3H]ACh release 
Each column represents the S2/S1 ratio as the mean ± SEM of means (N) or the mean ± SEM of the 
total number of replicate samples (n) obtained from 3 to 4 experiments; see Results for details. 
























50ýM carbachol + 30ýW(+)NANM 
1 00ýtM neostigmine +1 OýtM atropine 
1 00ýtM neostigmine +1 OýLM atropine + 30ýtM (+)NANM 
The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the effect of 
(+)NANM on: 
a) carbachol-induced inhibition of [3H]ACh release 
b) neostigmine and atropine-induced potentiation of [3H]ACh release 
Each column represents the S2/S1 ratio as the mean ± SEM of the total number of replicate samples 
(n) obtained from four experiments; see Results for details. Significant differences compared to the 
control S2/S1 ratio are denoted by * P<0.05. 
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3. The effect of nicotinic agonists on K+-evoked release of [3H]ACh 
Nicotine 
Nicotine had no effect on KI-evoked [3H]ACh release at concentrations ranging from 
0.1-10ýM; see Table 5.3 below and Figure 5.5a. 
CONCENTRATION S2/S2 RATIO 
NICOTINE CONTROL NICOTINE 
0.1 PM 0.730 0.018 (N=4) 0.815 0.071 (N=4) 
I pm 0.692 0.023 (n=13) 0.742 0.036 (n=14) 
I OPLM 0.687±0.021 (n=13) 0.691 0.037 (n=15) 
TABLE 5.3 
The effect of nicotine on K+-evoked [3H]ACh reiease. The test samples were superfused with 
nicotine only in the S2 stimulation. The S2/S1 values are represented as the mean ± SEM of means (N) 
or the mean ± SEM of the total number of replicate samples (n) observed from four experiments, 
depending on the analysis of variance; see Methods (Chapter 2) for details. 
DMPP 
As shown in Table 5.4 below and Figure 5.5b, DMPP at concentrations ranging from 
0.11-10ýM had no effect on K+-evoked [3H]ACh release. 
CONCENTRATION S2/S2 RATIO 
DMPP CONTROL DMPP 
0.1pm 0.725±0.026 (n=13) 0.761± 0.037 (n=16) 
IPM 0.644 0.023 (n=14) 0.684 ± 0.033 (n=16) 
I ollm 0.694 0.062 (N=4) 0.762 ± 0.072 (N=4) 
TABLE 5.4 
The effect of DMPP on K+-evoked [3H]ACh release. The test samples were superfused with DMPP 
only in the S2 stimulation. The S2/S1 values are represented as the mean ± SEM of means (N) or the 
mean ± SEM of the total number of replicate samples (n) observed from four experiments, depending 








































0.1 1 1,0 
Control DMPP concentration ([iM) 
The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippocampal prisms - the effect of nicotinic 
agonists: 
a) nicotine (0.1-lOpM) 
b) DMPP (0.1-lOpM) 
The prisms were stimulated twice (S1 and S2) for 2 min and the nicotinic agonists were added only 
during the S2 stimulation. Each point represents the S2/S1 ratio as the mean ± SEM of means (N) or 
the mean ± SEM of the total number of replicate samples (n) observed from 4 experiments; see Tables 
5.3 and 5.4 for details. The control represents the mean ± SEM of means obtained from all the 
experiments. 
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4. The effect of the non-competitive nicotinic antagonist mecamylamine on the 
ChE-inhibitor-induced potentiation of [3H]ACh release 
As shown in Table 5.5 and Figures 5.6a, 5.7a and 5.8a, the non-competive 
antagonist mecamylarnine had no effect on the ChE-inhibitor-induced potentiation of 
[3H]ACh release, at 30 and 1 OOgM concentrations (P>O. 05). 
5. The effect of the competitive nicotinic antagonist DHPE on the ChE-inhibitor- 
induced potentiation of [3H]A Ch release 
DHPE had no effect at 30 and 100ýM concentrations on the potentiation of [3H]ACh 
release caused by tacrine (30ýM) eserine (100ýM) and neostigmine (100ptM) - see 
Table 5.6 and Figures 5.6b, 5.7b and 5.8b. 
6. The effect of nicotinic antagonists on K+-evoked[3H]ACh release 
DHPE and mecamylamine 
Figure 5.9a shows the effect of the competitive antagonist DHPE (100ýM) and the 
noncompetitive antagonist mecamylamine (1 00ýM) on K+-evoked [3H]ACh release. 
DHPE caused a 43% increase in release (P<0.001) - control S2/S1 0.727 ± 0.033 
n=12; 100ýM DHPE S2/S1 1.042 ± 0.042 n=14. The release of [3H]ACh is unaltered 
in the presence of mecamylamine - control S2/S1 0.727 ± 0.033 n=12; 100ýM 
mecamylamine S2/Sl 0.653 ± 0.034 n=l 5 (P>0.05). 
D-tubocurarine and hexamethonium 
The effects of two other nicotinic antagonists d-tubocurarine and hexamethonium are 
shown in Figure 5.9b. At 100ý" concentrations the non-competitive antagonist 
hexamethonium had no effect on K+-evoked [H]ACh release (control S2/S1 0.742 ± 
0.037 n=12; 100ýtM hexamethonium S2/Sl 0.794 ± 0.038 n=14; P>0.05) whereas 
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the competitive antagonist d-tubocurarine (100ýM) showed a significant increase of 
12% (P<0.05); control S2/S1 0.742 ± 0.037 n=12; JOOptM d-tubocurarine S2/S1 
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30ýtM tacrine + 30ktM mecamylamine 
30ýLM tacrine + 100ýW mecamylamine 
30jiM tacrine 
30pM tacrine + 30pM DHPE 
30pLM tacrine + 100PIM DHPE 
The S2/S1 ratios of K+-evoked release of [3H]ACh from rat hippocampal prisms - the effect of tacrine with 
the nicotinic antagonists 
a) mecamylamine 
b) DHOE 
Each column represents the S2/S1 ratio as the mean ± SEM of means (N) or the mean ± SEM of the total 













1 OOpM eserine 
1 OOpM eserine + 30ptM mecamylamine 
1 00ýV eserine +1 00ýW mecamylamine 
@10m 1 00ýtM eserine SEEM 
=1 00ýV eserine + 30ptM DHPE 











The S2/S1 ratios of K+-evoked release of [3H]ACh from rat hippocampal prisms - the effect of eserine with 
the nicotinic antagonists 
a) mecamylamine 
b) DHPE 
Each column represents the S2/S1 ratio as the mean ± SEM of the total number of replicate samples (n) 

























1 00ýtM neostigmine 
1 00ýLM neostigmine + 30ptM mecamylamine 
1 00ýV neostigmine +1 00ýW mecamylamine 
1 OOpM neostigmine 
1 00piM neostigmine + 30pLM DHPE 
1 001-tM neostigmine +1 OOpM DHPE 
The S2/S1 ratios of K'-evoked release of [3H]ACh from rat hippocampal prisms - the effect of neostigmine 
with the nicotinic antagonists 
a) mecamylamine 
b) DHPE 
Each column represents the S2/S1 ratio as the mean ± SEM of means (N) or the mean ± SEM of the total 
























100ýt! Vl mecamylamine 
M Controi 
F-71 100ýiM d-tubocurarine 
F7ýl 100ýM hexamethonium 
The S2/S1 ratios of K+-evoked release of [3H]ACh from rat hippocampal prisms - the effect of nicotinic 
antagonists. 
a) DHOE and mecamylamine 
b) d-tubocurarine and hexamethonium 
Each column represents the S2/S1 ratio as the mean ± SEM of the total number of replicate samples (n) 
obtained from 4 experiments; see Results for details. Significant differences compared to the control S2/S1 
ratio are denoted by * P, 0.05 and ***P<0.001. 
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5. The effects of the competitive nicotinic antagonist DHPE: 
K+-evoked PHIA Ch release 
DHPE showed a concentration-dependent effect on K+-evoked [3H]ACh release at a 
concentration range of 10-100ýM - Table 5.7, Figure 5.10. A 43% increase in K+- 
evoked [3H]ACh release was seen at 100ýM concentrations (P<0.001). 
CONCENTRATION S2/Sl RATIO 
DHPE CONTROL DHPE 
logm 0.782±0.016 (n=13) 0.786 ± 0.026 (n=14) 
30jiM 0.782±0.016 (n=13) 0.839 ± 0.050 (n= 12) 
I oogm 0.727 ± 0.033 (n=12) 1.042 ± 0.042* (n=14) 
TABLE 5.7 
The effect of DHOE on K+-evoked [3H]ACh release. The test samples were superfused with DHPE 10 
min prior to and during the S2 stimulation. The S2/S1 values are represented as the mean ± SEM of the 
total number of replicate samples (n) observed from four experiments, depending on the analysis of 
variance; see Methods (Chapter 2) for details. Significant differences with respect to the controls are 
denoted by* P<0.001. 
With the benzomorphan (y ligands (±)pentazocine, (+)cyclazocine and (+)NANM 
The increase in K+-evoked [3H]ACh release caused by 100ýM concentrations of DHPE 
was significantly reduced by the benzomorphan a ligands (±)pentazocine (50ýM), and 
(+)cyclazocine (30ýLM) but not by (+)NANM (50ýM) (Table 5.8, Figure 5.11). 
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BENZOMORPHAN S2/Sl RATIO 
a LIGAND DHOE 
- 
DHOE +cT LIGAND 
PENTAZOCINE (5OpM) 0.929 0042 (N=6) 0.589 0.050* (N=6) 
(+)CYCLAZOCINE (30liM) 0.955 0.059 (n=12) 0.693 037* (n= 11) 
(+)NANM (5OpM) 0.878 0.054 (N=3) 0.911 0.018 (N=3) 
TABLE 5.8 
The effect of the benzomorphan a ligands on the DHOE-induced potentiation of K+-evoked [3H]ACh 
release. The test samples were superfused with DHOE or DHPE and one of the benzomorphans 
(±)pentazocine, (+)cyclazocine or ((+)NANM, 10 min prior to and during the S2 stimulation. The S2/S1 
values are represented as the mean ± SEM of means (N) or the mean ± SEM of the total number of 
replicate samples (n) observed from 3 to 6 experiments, depending on the analysis of variance; see 




















DHPE concentration (ýtM) 
Figure 5.10 
The S2/S1 ratios for K+-evoked release of [3H]ACh from rat hippcampal prisms - the effect of the 
competitive nicotinic antagonist DHPE (10-1 OOgM)- 
The prisms were stimulated twice (S1 and S2) for 2 min and DHPE was added to the superfusing medium 
10 min prior to and during the S2 stimulation. Each point represents the S21S1 ratio as the mean ± SEM of 
the total number of replicate samples (n) observed from 4 experiments; see Table 5.7 for details. The 
control represents the mean ± SEM of means obtained from all the experiments. Significant differences in 
the S2/S1 ratio compared to the control group are denoted by *P<0.001. 
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[EM 1 00ýtM DHPE 
1 00ýtM DHPE + 50ýLM (±)pentazocine 
1 00ýW DHPE + 30ýtM (+)cyclazocine 












The S2/S1 ratios of K+-evoked release of [3H]ACh from rat hippocampal prisms - the effect of the non- 
competitive nicotinic antagonist DHOE with the benzomorphan a ligands (±)pentazocine, (+)cyclazocine or 
(+)NANM. 
Each column represents the S2/S1 ratio as the mean ± SEM of means (N) or the mean ± SEM of the total 
number of replicates (n) obtained from 3-6 experiments; see Table 5.8 for details. The control represents 
the mean ± SEM of means obtained from all the experiments (N=6). Significant differences compared to 
100pM DHOE S2/S1 ratio are denoted by * P<0.001. 
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DISCUSSION 
The possible role of muscarinic receptors in the effects of tacrine and HC-3 on 
[3H]ACh release, was considered in Chapter 3. Displacement experiments showed 
that while tacrine was a potent inhibitor of [3H]QNB specific binding, the other ChE- 
inhibitors eserine, neostigmine and edrophonium and HC-3 were far less effective 
(Figure 3.23). Evidence also exists that tacrine and the ChE-inhibitors eserine and 
neostigmine bind at the nicotinic receptor binding site (De Sarno et aL, 1989; Nilsson 
et aL, 1987) as well as at the ion channel (Sherby et al., 1985). Moreover the 
benzomorphan a ligands (±)pentazocine, (+)cyclazocine and (+)NANM, which were 
shown in the previous chapter to oppose the potentiation of [3H]ACh release caused 
by the ChE-inhibitors, also displace [3H]QNB specific binding (Figure 4.11) and are 
also known to interact with the nicotinic ion channel (King & Aronstam, 1983, 
Eldefrawi et aL, 1982). The aim of this chapter therefore, was to study these 
muscarinic and nicotinic interactions and their role in the modulation of [3H]ACh 
release. 
Muscarinic interactions 
In Figure 5.3b it is shown that atropine itself did not increase KI-evoked release of 
[3H]ACh although reports exist that it does so in various brain areas such as the 
cerebral cortex (Pittel et aL, 1990), hippocampus (Nordstrom & Bartfai, 1980; 
Pohorecki et aL, 1988) and striatum (Hadhazy & Szerb, 1977, Weiler et aL, 1984). 
However it has also been reported by Marchi et a/. (1981) using rat hippocampal 
synaptosomes and by Szerb and Somogyi (1973) using rat cortical slices, to have no 
effect on evoked release. One of the reasons for the apparent lack of effect may be 
due to the different methodologies used - for example the use of slices or 
synaptosomes, K+ or electrical stimulation. Furthermore James and Cubeddu (1984) 
demonstrated that the ability of atropine to increase ACh release was directly 
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proportional to the intensity of the stimulation. They suggested that although the 
release of ACh evoked by high rates of stimulation was subject to autoreceptor 
inhibition, ACh released by low rates, was not. It was reasoned that at higher 
stimulation rates, the concentration of ACh in the synapse would build up until it 
exceeded the threshold concentration at which the feedback inhibition mediated by 
presynaptic receptors would be activated. Antagonists would therefore have more 
substantial effects at higher stimulation rates, at which the feedback system is more 
effective. It is possible therefore, that the lack of effect of atropine in the present 
experiments might be due to inadequate activation of the autoreceptors during the 2 
min pulse of 30mM K1. 
Consistent with the above interpretation, atropine in combination with each of the 
ChE-inhibitors was found to enhance the potentiation of [3H]ACh release caused by 
these ChE-inhibitors (Figure 5.1). Similar results were first described by Maclntosh 
and Oborin in 1953, where they reported that atropine, in the presence of a ChE- 
inhibitor, enhanced the release of ACh from the intact cerebral cortex of the cat 
(cited in Pohorecki et aL, 1988). Since then there have been many supporting 
observations by other investigators (Molenaar & Polak, 1970; Polak, 1971; Szerb & 
Somogyi, 1973). It appears that in the presence of ChE-inhibitors, the action of the 
unhydrolyzed [3H]ACh would result in the stimulation of the muscarinic 
autoreceptors, thus limiting the potentiation caused by the ChE-inhibitors. Muscarinic 
antagonists such as atropine would relieve this autoinhibition giving rise to a further 
enhancement of [3H]ACh release as seen in Figure 5.1. 
The existence of presynaptic cholinoceptors that inhibit ACh release has been amply 
demonstrated using rat brain slices (Szerb & Somogyi, 1973; Hadhazy & Szerb, 
1977; Pohorecki et aL, 1988) and synaptosomes (Marchi & Raiteri, 1985a; Marchi et 
al.,, 1981; Meyer & Otero, 1985; Pittel et al., 1990), either by superfusion (Marchi et 
al., 1981) or fixed volume incubation (Nordstrom & Bartfai, 1980). In the present 
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work, it was shown that 1 OýM atropine effectively reversed the oxotremorine-induced 
inhibition of [3H]ACh release (Figure 5.3a). Similarly (+)NANM which was 
demonstrated in Chapter 4 to displace [3H]QNB specific binding (Figure 4.11) is 
known to be a muscarinic antagonist and was shown to antagonize inhibition of 
[3H]ACh release by carbachol (Figure 5.4a). These results support the involvement 
of muscarinic receptors in the autoinhibition of [3H]ACh release and also the 
reliability of this preparation in the measurement of [3H]ACh release. 
Interestingly however, the ChE-inhibitors themselves displace [3H]QNB binding in 
the order tacrine> eserine = neostigmine = edrophonium (Figure 3.23). Furthermore 
tacrine has also been reported to be a muscarinic antagonist (see Chapter 3). Thus 
the possibilty has to be considered that the ChE-inhibitors, as well as potentiating 
ACh release by inhibiting acetylcholinesterase, might also simultaneously relieve 
negative feedback inhibition and further enhance potentiation of release 
("autoenhancement"). According to the [3H]QNB diplacement data in Figure 3.23 the 
ChE-inhibitors eserine, neostigmine and edrophonium cause a 40-80% inhibition of 
[3H]QNB binding at concentrations of 100ýM, while tacrine causes a displacement of 
>90% at 30ptM concentrations. Thus it is conceivable that atropine, at saturating 
concentrations (10ýM) is completing the blockade of negative feedback promoted by 
eserine, neostigmine and edrophonium. However 30ýM tacrine alone would be 
efficient at relieving autoinhibition caused by its own potentiating effect. It is therefore 
difficult to see how atropine can cause a further enhancement of release comparable 
to that obtained in the presence of the other ChE-inhibitors. A similar difficulty arises 
from the observation that atropine relieves the inhibition of [3H]ACh release 
observed at 100ýM tacrine (Figure 5.2a). 
It must however be mentioned at this point that the concentration of the ChE- 
inhibitors tested here, were those that were individually, maximally effective at 
potentiating [3H]ACh release but not maximally effective at displacing [3H]QNB 
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(compare Figures 3.3 3.5.3.7 & 3.9 and Figure 3.23). Moreover eserine, which failed 
to show a con centration-dependent effect on [3H]ACh release at the concentrations 
tested, clearly shows a con ce ntration-dependent displacement of [3H]QNB. Thus the 
functional effects of the ChE-inhibitors are clearly at variance with the binding data 
observed in Figure 3.23. It might be suggested that this phenomenon is due to the 
presence of 'spare receptors'. However it has been shown that muscarinic 
autoreceptors on hippocampal cholinergic nerve terminals do not exhibit such a 
'spare receptor' population (Vickroy et aL, 1993). Moreoever, the radioligand 
[3H]QNB is not selective for muscarinic autoreceptors alone, and so its binding and 
displacement would reflect the entire muscarinic receptor population - pre and post 
synaptic. 
It is possible therefore, that the [3H]QNB binding data is more relevant to muscarinic 
receptors other than those controlling [3H]ACh release. It has been shown that the 
affinity of the antagonists atropine, N-methyl-scopolamine and QNB for the 
presynaptic muscarinic receptors is 10-20 times less than that for postsynaptic 
receptors (Szerb, 1978). The KID for QNB reversal of oxotremorine-induced inhibition 
of [3H]ACh release from hippocampal slices was reported to be approximately 8nM, 
whereas the KID for [3H]QNB binding to hippocampal membranes after 
septohippocampal lesioning was approximately 0.4nM. Thus, in the present 
experiments which used 0.9nM [3H]QNB, only 10% (approximately) of the receptors 
controlling ACh release are likely to be radiolabelled in contrast to 70% of the other 
receptors. 
Recent detailed studies on rat hippocampal autoreceptors concluded that the 
presynaptic sites belong to the M2 (Richards, 1990) and M4 (McKinney et al., 1993) 
class of muscarinic receptors. Further studies using mRNA analysis and 
immunoprecipitation by receptor specific antibodies have shown, that these 
receptors represent a minor component of [3H]NMS binding in the hippocampus - as 
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little as 10-20% (Vilaro et al., 1993; Ladinsky, 1993). It would therefore appear, that 
the present [3H]QNB binding data is not a reliable indicator of the presynaptic action 
of tacrine or the classical ChE-inhibitors eserine, neostigmine and edrophonium. An 
interpretation therefore of the present data is that the ChE-inhibitors tacrine, eserine, 
neostigmine and edrophonium cause little or no blockade of presynaptic muscarinic 
autoreceptors. Atropine, the more potent muscarinic antagonist is therefore able to 
exert full enhancement of release in the presence of tacrine or the other ChE- 
inhibitors. That tacrine is ineffective as a muscarinic autoreceptor antagonist is 
further supported by the observation that at 1 OýM concentrations it did not reverse 
the oxotremorine (1ýLM)-induced inhibition of [3H]ACh release from cortical slices 
(Potter et aL, 1989) 
As quoted in Chapter 3, the notion that tacrine is a muscarinic receptor antagonist 
comes from the observation of its inhibition of carbachol-stimulated PI hydrolysis. 
However it is known that muscarinic autoreceptors are linked to cAMP (Hulme et al., 
1990). Furthermore tacrine is reported to be an appreciable inhibitor of the binding of 
the M2-selective ligand [3H]AF-DX1 16 OC50 1.5gM) to whole membrane 
preparations from rat forebrain (Nielson et aL, 1989). Since the above evidence 
(Potter et al., 1989) suggests that tacrine is not an autoreceptor antagonist, the 
implication is that it must be an agonist. 
According to the IC50 value (1.5ýM) reported, tacrine at 30gM concentrations would 
be expected to completely (-95%) occupy the M2 binding sites and therefore to 
exert maximum autoinhibition. This is supported by the observation that 10ýM 
atropine, which relieves autoinhibition, enhances [3H]ACh release by 19 and 21% in 
the presence of 30 and 100liM tacrine. Thus the very pronounced concentration- 
related decline in [3H]ACh release observed at 30-200ýLM concentrations of tacrine 
suggests that a mechanism additional to muscarinic autoinhibition must be 
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responsible. This lends further support for the role of cr binding sites in the inhibition 
of [3H]ACh release (Chapter 4) and will be discussed further in Chapter 6. 
It is important to note that despite the maximum autoinhibition caused by the agonist 
action of 30ýM tacrine, the overall effect at this concentration is that of potentiation 
of [3H]ACh release. Thus, as discussed previously (Chapter 3), it is clear that tacrine 
and the other ChE-inhibitors possess an additional property which is responsible for 
the marked potentiation of [3H]ACh release. It is known that these ChE-inhibitors 
also interact with nicotinic receptors and this will be considered presently. 
(±)Pentazocine, (+)cyclazocine and (+)NANM also show muscarinic receptor-binding 
affinities, comparable to the ChE-inhibitors as seen from the [3H]QNB binding data 
(Figure 4.11) and are known to have muscarinic antagonist actions (Discussion, 
Chapter 4). However as shown in Chapter 4, (±)pentazocine and (+)cyclazocine 
actually reduce the potentiation caused by the ChE-inhibitors, rather than enhance it, 
while (+)NANM has no effect (Figures 4.4 - 4.5,4.7 - 4.8 & 4.10a). Therefore some 
other mechanism of action must predominate in their overall effect on [3H]ACh 
release. As discussed in the next chapter, these cy benzomorphans also exhibit 
nicotinic receptor binding, which may well be relevant. 
Nicotinic interactions 
As discussed above, the data presented support the existence of muscarinic 
autoreceptors mediating negative feedback in the control of ACh release. It therefore 
seemed reasonable to explore the possibility of nicotinic receptors mediating positive 
feedback. Evidence favouring the existence of nicotinic autoreceptors has been 
mentioned in the Introduction to this chapter. 
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Neither nicotine nor the nicotinic agonist DMPP at concentrations 0-1-10ýM affected 
K+-evoked release from hippocampal prisms (Figures 5.5a & 5.5b). As nicotine is 
known to cause desensitization (Beani et aL, 1985; Wessler et aL, 1986; Wilkie et aL, 
1993) it is possible that the reason for the observed lack of effect is that the nicotinic 
receptors are inactivated in this way, even though exposure was restricted to the 2 
min period of the S2 stimulation. These results agree with previous reports in which it 
was shown that nicotine had no effect on KI-evoked (Lapchak et aL, 1989) and 
electrically stimulated [3H]ACh release (Pohorecki et al., 1989). However Beani et 
aL, (1985) reported that nicotine (18nM-l8OnM) and the nicotinic agonist cytisine 
(0.5-50ýM), enhanced electrically stimulated release of [3H]ACh from cortical slices 
prepared from guinea pig brain. Furthermore Wonnacott et aL (1989) also showed 
that nicotine evoked a dose-dependent release of [3H]ACh from hippocampal 
synaptosomes, which was blocked by the nicotinic antagonists dihydro-p-erythroidine 
(DHPE) and histrionicotoxin. 
Since the reported effects of nicotine on [3H]ACh release have been somewhat 
diverse, the possibility was considered that positive feedback might be exerted by 
the build up of unhydrolyzed ACh, caused by the inhibition of acety1cholinesterase. 
The competitive nicotinic antagonist DHPE and the non-competitive nicotinic channel 
blocker mecamylamine which have both been shown to block nicotinic responses in 
the rat hippocampus (Ropert & Krnjevic, 1982; Lukas and Bencherif 1992) were 
tested against the potentiation of [3H]ACh release caused by the ChE-inhibitors. 
Neither DHPE nor mecamylamine had any effect on the potentiation of [3H]ACh 
release induced by the ChE-inhibitors (Figures 5.6 - 5.8). Interestingly however, 
DHPE alone, markedly increased control KI-evoked release of [3H]ACh. A similar 
effect was observed with d-tubocurarine, but to a lesser extent (Figure 5.9a & 5.9b). 
The nicotinic channel blockers mecamylamine and hexamethonium had no effect 
alone on K'-evoked [3H]ACh release (Figure 5.9a & 5.9b). 
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PAGE 224a, NOTE ADDED AFTER VIVA 
Taking into account the statistical uncertainty associated with each of the data points in Figure 
5.10, there is only limited support for the possibilty that the DHPE effect saturates with 
increasing concentration. An interpretation therefore might be that the effect is not mediated 
by nicotinic receptors. This view is supported by the large concentrations of DHPE required to 
cause a significant effect (however see page 235a-c). It has been reported that 
mecamylamine in high concentrations causes the release of DA (Mills & Wonnacott, 1984) 
possibly by a carrier-mediated mechanism analogous to that by which tyramine causes the 
release of NA. It may seem feasible therefore that DHPE is having a similar effect in releasing 
ACh in the present experiments. However if DHPE on the one hand and the ChE-inhibitors on 
the other act at independent sites it is difficult to see why DHPE did not cause additional 
release over and above that caused by the ChE-inhibitors (Figures 5.6b-5.8b). To explain this 
it would have to be additionally speculated that the ChE-inhibitors block the ACh-releasing 
action of DHPE, possibly by blocking carriers essential to its action. 
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It is noteworthy that although DHPE alone causes a marked increase, it has no effect 
over and above that of the ChE-inhibitors (Figures 5.6b - 5.8b). Furthermore, this 
increase in [3H]ACh release observed with DHPE, was found to be opposed by 
(+)cyclazocine or (±)pentazocine but not by (+)NANM (Figure 5.11), in a similar 
manner to that seen with the ChE-inhibitors (Figures 4.4 - 4.5,4.7 - 4.8 & 4.10). 
Thus it would appear that the ChE-inhibitors exert their effects via a similar 
mechanism to that of DHPE. It is suggested that this common mechanism may be 
nicotinic receptor blockade. Previous reports that tacrine, eserine, neostigmine and 
DHPE produce a concentration-dependent blockade of nicotine-evoked [3H]DA 
release from rat striatal synaptosomes (Clarke et al., 1994; Wonnacott et aL, 1989; 
Wonnacott, 1991) strongly support this suggestion. 
These results would then suggest that DHPE and the ChE-inhibitors may be acting to 
relieve negative feedback in some way. DHPE has in fact been reported to block 
muscarinic receptor-mediated responses (Ropert and Krnjevic, 1982; Bird & 
Aghajanian, 1976), although in the present experiments this is unlikely to be the case 
since atropine, the classical muscarinic antagonist, had no effect on K+-evoked 
release (Figure 5.3b). Furthermore there are no reports that DHPE has ChE- 
inhibiting properties and so it is very unlikely that the increase in [3H]ACh release is 
due to combined effects of muscarinic receptor blockade and autoreceptor 
activation. It is concluded therefore, that nicotinic receptor blockade is very likely to 
be responsible for its potentiating effects, implying that nicotinic receptors exert 
negative feedback on ACh release. This feedback is exerted at control levels of 
evoked release in the present experiments. 
A point worth noting is that while DHPE and d-tubocurarine alone, increase K+- 
evoked [3H]ACh release, the nicotinic channel blockers mecamylamine and 
hexamethoniurn have no effect (Figure 5-9). At first glance these differences might 
be ascribed to the differences between receptor binding site block and channel 
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block. However d-tubocurarine is also known to be a channel blocker (cited in 
Lebeda et al., 1982). Moreover it will be recalled that PCP, which is also a non 
competitive blocker (NCB) rather than a channel blocker (1-6na & Changeux, 1993), 
was shown in Chapter 4 to increase [3H]ACh release (see Figure 4.2). 
It might seem reasonable to speculate at this stage that the effects observed with 
various antagonists, result from their specificities for the nicotinic receptor complex 
controlling [3H]ACh release. As mentioned in the Introduction to this Chapter, 
heterogeneity of neuronal nicotinic receptors has been inferred not only from 
pharmacological studies, but also from electrophysiological and 
immunohistochemical studies. However it is not immediately clear how nicotinic 
receptors when activated, might inhibit ACh release - so that blockade by DHPE 
would, as observed, promote release. Since nicotinic receptors are intrinsic 
components of cation channels that cause membrane depolarization, they would be 
expected to bring cholinergic nerve terminals closer to the threshold at which release 
occurs - i. e to promote release. 
However it is well known that in ganglia and at the neuromuscular junction, nicotinic 
receptor activation leads to failure of subsequent electrophysiological events. For 
example suxamethonium, a nicotinic agonist, causes failure of muscle action 
potentials. This is considered to be the result initially, of Na+ channel inactivation 
caused by persistent end plate depolarization. There may also be a second phase 
block caused by nicotinic receptor desensitization. 
Similarly it can be speculated that in control KI-evoked release, elevated 
extracellular concentrations of ACh might cause sufficient additional depolarization to 
cause inactivation of some of the voltage-operated Ca2+ channels for example, 
involved in release. Indeed it has been suggested that N-type Ca2+ channels, which 
are known to have relatively fast inactivation kinetics (Scott et al., 1991) may 
be 
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inactivated even in the rising phase of K+-evoked depolarization (Momiyama and 
Takahashi, 1994). Moreover N-type Ca2+ channels are also known to be involved in 
the release of ACh (Fossier et aL, 1994). It might therefore be expected that nicotinic 
receptor blockade by the ChE-inhibitors or DHPE would prevent the additional 
depolarization caused by ACh via the nicotinic receptors, thus relieving inactivation 
of these Ca2+ channels. This would then enable these Ca2+ channels to be more 
responsive to K+-depolarization resulting in an increase in [3H]ACh release. 
According to this hypothesis, nicotine or DMPP might be seen as further inactivating 
Ca2+ channels, via additional receptor activation while also introducing a more 
marked receptor desensitization. This could well be the reason for the observed lack 
of effect of nicotine or DMPP on [3H]ACh release (Figures 5.5a & 5.5b). 
The present results are different to those of Wonnacott et al., (1989), where 
hippocampal synaptososmes were used (also Wilkie et aL, 1993). It was observed 
that in the absence of depolarizing concentrations of KI, nicotine evoked the release 
of [3H]ACh. Furthermore, DHPE blocked these effects (Wilkie et aL, 1993, 
Wonnacott et aL, 1989), in marked contrast to the potentiation of release observed 
with DHPE in the present experiments using 30mM KI. The difference could well 
arise from the different depolarizing conditions. As mentioned above, inactivation of 
some significant fraction of Ca2+ channels may accompany K+ depolarization so 
that additional depolarization by pharmacological concentrations of nicotine or DMPP 
may cause further inactivation and a failure of release. In the absence of 
depolarizing concentrations of KI, depolarization by nicotinic agonists may be 
sufficient to evoke [3H]ACh release without extensive Ca2+ channel inactivation and 
receptor desensitization. DHPE would thus block agonist-evoked release of [3H]ACh 
but promote K+-evoked release, as observed in the present experiments. Support for 
this suggestion derives from the observations of Araujo et al., (1988). MCC or 
nicotine alone evoked the release of [3H]ACh from hippocampal slices but gave no 
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additional release in the presence of depolarizing concentrations of K+. DHPE or d- 
tubocurarine again, blocked the agonist-evoked release. 
Antagonism of nicotine-evoked release from synaptosomes by DHPE (Wonnacott et 
al., 1989; Wilkie et aL, 1993), indicates that the site of action of the antagonist is the 
nicotinic autoreceptor located on cholinergic nerve terminals. In these experiments, 
receptor activation by nicotine is the primary signal by which depolarization and thus 
release, is brought about. Antagonism of receptor activation by DHPE, must 
therefore inhibit agonist-evoked release by overcoming the source of depolarization. 
However where depolarization is primarily independent of receptor activation, as in 
the presence of 30mM K1, blockade by DHPE will not inhibit release. Indeed as 
discussed above, if autoreceptor activation by released ACh contributes to voltage- 
operated Ca2+ channel inactivation, then blockade by DHPE could well result in 
increase of KI-evoked release of [3H]ACh. 
Physiologically, release in vivo is evoked by nerve action potential, which activates 
vo Itag e-ope rated Ca2+ channels in the active zones of the nerve terminal (Smith & 
Augustine, 1988). However Ca2+ channel activation by ACh release would 
presumably be too brief to lead to significant inactivation of Ca2+ channels. It seems 
unlikely therefore, that DHPE would normally potentiate release in vivo in the manner 
demonstrated in the present experiments. However it is possible that the increased 
synaptic concentrations of ACh, caused by the ChE-inhibitors would contribute to 
and prolong nerve terminal depolarization, and thus lead to some Ca2+ channel 
inactivation. Under these circumstances, autoreceptor blockade by the ChE- 
inhibitors themselves, could well contribute to the potentiation of ACh release in vivo. 
Interestingly Nordberg et al., (1985) reported that eserine or tacrine potentiated K+- 
evoked release of [3H]ACh from post mortem Alzheimer brain tissue. Relevant here, 
DHPE, mecamylamine or d-tubocurarine blocked this potentiation in marked contrast 
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to the effects reported in the present chapter. A similar result was obtained with 
mecamylamine in hippocampal slices from rats treated with the cholinotoxin AF64A 
(ECMA) (Potter & Nitta, 1993). However it must be borne in mind that evoked 
release of [3H]ACh from post mortern and biopsy Alzheimer tissue is significantly 
reduced, compared to control tissue (Nilsson et al., 1987; Nordberg et aL, 1989; 
Giacobini, 1990; see Chapters 1& 3) and may not therefore contribute significantly 
to Ca2+ channel inactivation. 
Be this as it may, the data presented in this chapter can be explained by the 
existence of both nicotinic and muscarinic receptors on the cholinergic nerve 
terminals. It appears that activation of both these types of receptors by release of 
ACh leads to inhibition of release. Nicotinic receptors are activated by control K+- 
evoked release and muscarinic receptors are activated only during potentiation of 
release. Nicotinic receptors appear to underlie potentiation by the ChE-inhibitors and 
DHPE. Muscarinic receptors limit this potentiation and underlie the enhancement of 






It was suggested in the previous chapter that the ChE-inhibitors and DHPE probably 
exert their effect on KI-evoked ACh release by interacting with nicotinic receptors 
located on the nerve terminal. It appears as though these nicotinic receptors exert a 
negative feedback effect which is blocked by the drugs mentioned. The hypothesis 
was developed that the mechanism underlying the negative feedback effect is that of 
inactivation of Ca2+ channels involved in release. Thus blockade of the nicotinic 
receptors by DHPE or ChE-inhibitors allows Ca2+ channels to reactivate and to 
respond to K+-depolarization, so that [3H]ACh release is potentiated. 
Nevertheless the effects of (+)cyclazocine and (±)pentazocine remain unexplained. 
These compounds which are better known as cy benzomorphans, oppose the 
potentiation caused by the ChE-inhibitors, but have no effect by themselves on K+- 
evoked (control) release (see Chapter 4). However cyclazocine, pentazocine and 
NANM are also known to interact with nicotinic receptors and have been shown to 
displace [3H]perhydrohistrionicotoxin (IC50-5ptM for all three benzomorphans) (King 
& Aronstam, 1983) and [3H]PCP from nicotinic channel sites (Ki values of 1.2 and 
0.9ýM for cyclazocine and NANIVI respectively) (Eldefrawi et aL, 1982). It is quite 
possible therefore, that nicotinic receptor blockade contributes to the observed 
effects of (+)cyclazocine and (±)pentazocine on [3H]ACh release. However since 
(+)cyclazocine and (±)pentazocine inhibit only potentiated release, while DHPE 
potentiates only KI-evoked release, some other mechanism of action would appear 
to intervene. 
It will be recalled that in Chapter 4, inhibition of control K+-evoked [3H]ACh release 
by haloperidol, DTG and tacrine was ascribed to an action at a binding sites. It is 
plausible therefore that the observed effects of (+)cyclazocine and (±)pentazocine 
are the net result of cy-mediated inhibitory action and the nicotinic autoreceptor 
action which causes potentiation of [3H]ACh release. Since these two effects oppose 
each other, (+)cyclazocine and (±)pentazocine would have little or no effect on control 
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KI-evoked [3H]ACh release, while DHPE lacking a activity would cause potentiation, 
as observed (Figures 4.3,4.6,5.9a & 5.10). Furthermore, if the nicotinic 
autoreceptors are already occupied by the ChE-inhibitors such as tacrine, eserine, 
neostigmine, edrophonium or by DHPE, the inhibitory a activity of (+)cyclazocine or 
(±)pentazocine would then be unmasked as observed in Figures 4.4 - 4.5 & 4.7 - 4.8. 
Since haloperidol and DTG markedly inhibited control K+-evoked [3H]ACh release 
(Figures 4.14 & 4.17) it is not unreasonable to expect (+)cyclazocine or 
(±)pentazocine to show significant inhibitory effects under the same conditions, 
despite an opposing effect at the nicotinic autoreceptors. There is evidence of the a 
inhibitory action predominating, in the effect of (+)cyclazocine on control KI-evoked 
release, which was significantly inhibited at higher concentrations of (+)cyclazocine 
(Figure 4.6). Similarly, the effect of (±)pentazocine on the potentiation caused by 
eserine (Figure 4.4b) and DHPE (Figure 5.11), reduced the S2/S1 ratio to levels 
below control. 
Interestingly tacrine at low concentrations potentiates K+-evoked release but causes 
inhibition at greater concentrations (Figure 3.3). It would appear therefore that the 
anti ch ol i nesterase and nicotinic autoreceptor blocking properties initially predominate 
and that the cy inhibitory activity becomes evident only at greater concentrations. As 
was demonstrated, the [3H]pentazocine displacement curves showed that although 
weak, tacrine was effective at displacing this a ligand whereas the classical ChE- 
inhibitors showed negligible a binding (Figure 4.18). The lack of an inhibitory phase 
at higher concentrations of the classical ChE-inhibitors (in contrast to tacrine) 
supports this suggestion. 
The lack of effect of (+)NANM however, on potentiated [3H]ACh release, remains 
unexplained. It was observed that this "prototypic a ligand" did not inhibit the 
neostigmine-potentiated [3H]ACh release in a similar manner to that exhibited by 
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(+)cyclazocine and (±)pentazocine (Figure 4.10a). Although (+)NANM and 
(+)cyclazocine have similar affinity for a binding sites (Walker et al 1990), 30PtM 
(+)NANM had no significant effect on potentiated [3H]ACh release, while 30gM 
(+)cyclazocine caused marked inhibition (Figures 4.10a & 4.8). 
However, from a number of reports it appears that (+)NANM also has muscarinic 
receptor blocking properties (see Introduction and Discussion in Chapter 4). Indeed it 
was shown in Chapter 5, Figure 5.4a, that (+)NANM reverses the carbachol-induced 
inhibition of [3H]ACh release indicating an appreciable muscarinic autoreceptor 
blockade. Thus it may be assumed that (+)NANM would have an atropine-like 
enhancing effect on potentiation over and above that caused by the nicotinic action 
of neostigmine (or the other ChE-inhibitors). Furthermore this additional atropine-like 
enhancement would oppose the inhibitory cy effect of (+)NANM so that overall, 
release would remain similar to the ChE-inhibitor-potentiated levels. This is in fact 
what was observed (Figure 4.1 Oa) and further supported by the finding that in the 
presence of atropine, neostigmine-potentiated [3H]ACh release was clearly inhibited 
by (+)NANM (Figure 5.4b). It seems that the independent block of the muscarinic 
autoreceptors by atropine unmasks the inhibitory a effect of (+)NANM. In 
comparison, any muscarinic autoreceptor blocking properties of (+)cyclazocine or 
(±)pentazocine would appear to be weaker so that the a inhibitory effect is 
unopposed. Thus as observed, inhibition by (+)cyclazocine or (±)pentazocine of the 
potentiation caused by neostigmine, the classical ChE-inhibitors or DHPE is clearly 
significant compared to the effect of (+)NANM. 
Although an additional muscarinic autoreceptor action might explain the lack of effect 
of (+)NANM on potentiated release, it cannot explain the lack of effect on control K+- 
evoked release since atropine itself had no effect on controls (Figure 5.3a). (+)NANM 
would therefore appear to also act on nicotinic autoreceptors. Indeed as mentioned 
in Chapter 5 (introduction), NANM has been shown to have non competitive actions 
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on nicotinic receptors (King & Aronstam 1983). Like (+)cyclazocine or (±)pentazocine 
therefore, the nicotinic autoreceptor-mediated potentiation opposes a-mediated 
inhibition, leaving control K+-evoked release unchanged. 
In Chapter 4 it was shown that the cy ligand (+)3PPP behaved very much like 
(+)NANM in that it had no effect on control K+-evoked release or on neostigmine- 
potentiated [3H]ACh release (Figures 4.16a & b). According to the above argument 
these results could be explained if (+)3PPP were also a muscarinic and nicotinic 
autoreceptor blocker. Interestingly it has been reported that (+)3PPP inhibits 
carbachol-induced contractions of the guinea pig ileum (Vargas & Pechnick, 1991) 
although there is no evidence in the literature to suggest muscarinic or nicotinic 
autoreceptor action. On the basis that muscarinic and nicotinic autoreceptor effects 
oppose cy binding site-mediated inhibition, the marked inhibition of [3H]ACh release 
by DTG or haloperidol would imply that neither of these drugs have significant 
muscarinic nor nicotinic autoreceptor-mediated effects. Indeed it is well reported that 
haloperidol and DTG are very weak antagonists of this type (Hudkins & DeHaven- 
Hudkins, 1991; Vargas & Pechnick, 1991). 
Relevant to this discussion is the nature of the a effects possessed by the various 
drugs discussed above. In Chapter 4 it was concluded that the potentiation of 
[3H]ACh release could not be related to a al effect since the ChE-inhibitors had 
negligible [3H]pentazocine displacing effects. On the basis of the direct inhibitory 
effects of haloperidol and DTG, it was tentatively suggested that a2 activity might be 
responsible for this effect. However the recognition that (+)cyclazocine and 
(±)pentazocine and (+)NANM (and possibly (+)3PPP) also have inhibitory effects 
(albeit masked by presynaptic cholinoceptor activity) would suggest that the inhibition 
is mediated by al binding activity. These agents are known to be selective for al 
binding sites whereas DTG and haloperidol are known to be less selective with 
appreciable al as well as cr2 activity. However as commented in Chapter 4, there is a 
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marked discrepancy between the micromolar concentrations of a ligands causing 
inhibition of [3H[ACh release observed in this study and the reported nanomolar IC50 
and KID values for displacement of al or cr2 ligands. 
Nevertheless a third low affinity a binding in the micromolar concentration range has 
recently been described (Wu et aL, 1991). It is possible therefore that this binding 
underlies the inhibitory effects seen in the present studies of [3H]ACh release. This 
low affinity cr binding site was identified with the modulation of tonic K+ currents (in 
NCB20 cells). Significantly tacrine, demonstrated in the present work to be a cy 
ligand, and haloperidol, which both inhibit [3H]ACh release strongly (Figures 3.3 & 
4.14) also modulate K+ channels (see Chapter 3) (Morio et al., 1994; Marsh et aL, 
1990; Halliwell & Grove 1989). It is suggested therefore that a binding sites may be 
part of a signal transcluction pathway linked to K+ channels. 
A final aspect of this study that must be mentioned is that the experimental work 
concentrated entirely on the young, adult (200-300g) rat brain, whereas drug therapy 
would have to be more geared towards the partially degenerated, aging brain in 
order to be clinically successful. As Nordberg et aL, (1989) demonstrated, the effect 
of eserine and tacrine were quite different when compared in control and Alzheimer 
brain tissue (see Chapter 3, introduction). A further line of investigation and perhaps 
more relevant to the treatment of Alzheimers might be [3H]ACh release from the 
AF64A lesioned rat. Indeed preliminary work of this kind has recently been reported 
(Potter& Nitta, 1993). 
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It may be possible to evaluate diffusion barriers of this kind by studying the equilibration of 
inert markers like mannitol or inulin into, and their elution from, prisms of different sizes. 
Diffusion barriers may well explain why the classical ChE-inhibitors, DHPE and the a ligands 
had to be used throughout this work at concentrations greater than pharmacologically 
accepted values. In vivo microdialysis studies would shed more light on the relevance of 
effective concentrations of tacrine and the other drugs. Indeed studies of this type have shown 
that tacrine does not release monoamines at therapeutic doses (Baldwin et al., 1991 
referenced in this thesis). 
b) Relevance of the drug actions studied in this thesis to clinical situations: 
According to Nielson's binding data (Nielson et al., 1989, referenced in this thesis) clinical 
concentrations of tacrine (0.2-0.6ýW) would cause only 13-32% occupation of M2 
autoreceptors. Thus at clinically relevant concentrations, tacrine is unlikely to exert strong 
muscarinic autoreceptor effects of the kind discussed here (Chapter 5). 
In view of the possible diffusion barriers discussed above, the nicotinic receptor-mediated 
potentiation of ACh release by the ChE-inhibitors and by DHPE, observed in the present work 
(Chapter 5) might well occur at much lower concentrations than suggested by the effective 
superfusion concentrations. As discussed (page 228) increased synaptic concentrations of 
ACh, caused by inhibition of ChE, might well contribute to and prolong nerve terminal 
depolarization, thus leading to some Ca 2+ channel inactivation. Under these circumstances 
autoreceptor blockade by clinical concentrations of the ChE-inhibitors; might contribute to the 
potentiation of ACh release in vivo. 
A similar arguement based on diffusion barriers can be made about the relevance of the 
a effects discussed in Chapter 4. Sigma-mediated inhibition of ACh release by tacrine at 
superfusion concentrations greater than 30ýW might well translate into concentrations in vivo 
close to the clinical range. 
PAGE 235a, b, c NOTE ADDED AFTER VIVA 
Relevance of the present work to the treatment of Alzheimer's disease 
a) Concentrations effective in the tissue superfusates: 
In the present study it was only possible to demonstrate that tacrine had effects on [3 H]ACh 
release at concentrations of IlOgM and above. Although these concentrations are in accord 
with those reported by other workers using similar techniques they contrast with 
concentrations achievable clinically. These are in the range 0.2-0.6ýt! Vl in plasma. The IC50 for 
ChE inhibition by tacrine however, is approximately 0.24ýLM (Atack et al., 1989, this thesis 
page 126). It is possible therefore that if clinical concentrations could be closer to those in the 
present study a greater inhibition of the enzyme and possibly a more pronounced therapeutic 
effect would be achieved. There would appear to be a clinical need for an alternative to tacrine 
that can be used at concentrations greater than the IC50 without causing serious side effects. 
However it may be that prism-superfusion techniques require exaggerated drug 
concentrations to cause an observable effect on [3 H]ACh release. Thus there may be marked 
diffusion barriers between superfusing drug solutions and the intercellular space within the 
tissue, even though the prism size used is well within the range in which the penetration of 
oxygen is adequate (this thesis page 78). 
Incubation for 20 min with concentrations of oxotremorine ranging from 0.01-0.1ýLM inhibited 
ACh release in a dose-dependent manner from 0.5mm hippocampal prisms stimulated with 
35mM K' for 5 min (Benishin, 1990, referenced in this thesis). In this present study 12 min 
incubation with 100ltM oxotremorine was required to cause similar inhibition (Fig. 5.3b) using 
2 min stimulations with 30mM K+. It seems therefore that there may be marked concentration 
/ time dependent diffusions involved in K'-evoked release from tissue prisms and its 
susceptibility to superfusing drugs. 
In considering the relevance of the present results to Alzheimer therapy it should be 
remembered that the effects were obtained using fresh brain samples from young adult rats. 
In samples from Alzheimer patients levels of ACh release are known to be reduced so that 
presynaptic feedback could well be be less prominent. Thus although the inhibition of ChE and 
the (T effects discussed here remain relevant the nicotinic effects may not be so. The use of 
lesioned animals therefore would further this line of research. 
The effect of tacrine and the other ChE-inhibitors, as well as DHPE, on [3H]ACh release from 
rats partially lesioned with ECMA, and measured using in vivo microdialysis and in vitro 
methods would be a useful direction to take. Indeed a preliminary experiment of this kind was 
recently reported (Potter & Nitta, 1993, referenced in this thesis). The use of transgenic mice 
(Chapter 1) will also be crucial in determining the effect of plaques on ACh release in 
Alzheimer's disease and suggests a more relevant model with which to test the drug effects 
described in this thesis. 
Taken together it is clear that the measurement of brain ACh release is important in 
determining the overall efficacy of cholinomimetics such as tacrine and the other ChE- 
inhibitors. However it is now clear that the relevance of the concentrations as well as the 
physiological and pathological conditions must also be recognized when developing the "ideal" 
screening system for cholinornimetic efficacy. Cholinomimetics may also be in the form of 
muscarinic autoreceptor antagonists which enhance ACh release in the presence of ChE- 
inhibitors as demonstrated in this study (Chapter 5). As mentioned previously in the 
Introduction (Chapter 1) nicotinic compounds have not been extensively tested although 
recent research into allosteric modulation of the nicotinic receptor has begun to renew interest 
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